"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOU_RIUNITIANCONA",2000,68,7.1764705882353,2.80882352941176,0.558823529411765,0.367647058823529,0.558823529411765,1.35507246376812,1.12121212121212,1.19047619047619,1.12121212121212,0.397058823529412,2,37,11,5,13,0.54,0.16,0.07,0.19,66.31,1.46277064845582,NA,0.205882352941176,0.676470588235294,0.364,0.291,0.313,0.288,"MICHELE BRIGNOLE;GIUSEPPE REMUZZI;C. MENOZZI;BRUNO GRIDELLI;MARCO SPADA;A. SEGALIN;M. COLLEDAN;A. LUCIANETTI;A. MAMOLI;ANDREA REMUZZI;GIOVANNI LIGUORI;L. CASTO;ALESSANDRO RAMBALDI;B. CENSORI;L. CAVERNI;M. CAMERLINGO;SALVATORE SIRACUSANO;ANTONIO RAVIELE;PAOLA DI BENEDETTO;ROBERTO POZZI MUCELLI","6;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2","MICHELE BRIGNOLE;ANTONIO MAZZA;GIUSEPPE REMUZZI;CARMINE ZOCCALI;C. MENOZZI;BRUNO GRIDELLI;MARCO SPADA;A. SEGALIN;M. COLLEDAN;A. LUCIANETTI;ANDREA REMUZZI;GIOVANNI LIGUORI;GIANCARLO TIRELLI;M RUSSOLO;FRANCESCA MALLAMACI;A. MAMOLI;L. CASTO;B. CENSORI;M. CAMERLINGO;L. DALLA PALMA","1.62;1;0.97;0.62;0.62;0.6;0.6;0.6;0.6;0.6;0.56;0.54;0.53;0.53;0.5;0.42;0.42;0.42;0.42;0.42","MICHELE BRIGNOLE;GIUSEPPE REMUZZI;C. MENOZZI;BRUNO GRIDELLI;MARCO SPADA;A. SEGALIN;M. COLLEDAN;A. LUCIANETTI;A. MAMOLI;ANDREA REMUZZI;L. CASTO;ALESSANDRO RAMBALDI;B. CENSORI;L. CAVERNI;M. CAMERLINGO;ANTONIO RAVIELE;PAOLA DI BENEDETTO;ROBERTO POZZI MUCELLI;GIANPIETRO DOTTI;RICHARD SUTTON","6;6;5;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2","MICHELE BRIGNOLE;ANTONIO MAZZA;GIUSEPPE REMUZZI;CARMINE ZOCCALI;C. MENOZZI;BRUNO GRIDELLI;MARCO SPADA;A. SEGALIN;M. COLLEDAN;A. LUCIANETTI;ANDREA REMUZZI;GIANCARLO TIRELLI;M RUSSOLO;A. MAMOLI;L. CASTO;B. CENSORI;M. CAMERLINGO;L. DALLA PALMA;CLAUDIO FARINA;R TIRABOSCHI","1.62;1;0.97;0.62;0.62;0.6;0.6;0.6;0.6;0.6;0.56;0.53;0.53;0.42;0.42;0.42;0.42;0.42;0.4;0.39","MICHELE BRIGNOLE;C. MENOZZI;ANTONIO RAVIELE;PAOLÓ ALBONI;RICHARD SUTTON;ALESSANDRO RAMBALDI;GIUSEPPE REMUZZI;MANUELA LAZZARI;FRANCESCO TEDESCO;GIAN-MARIA BORLERI;JOSÉE GOLAY;LUISELLA ZAFFARONI;MARTINO INTRONA;SERGIO BERNASCONI;THOMAS VACCARI;ANDRÉS MOYÁ;PAOLO GIANI;ALICE COLUCCI;DANIELE PRATI;DARIO CONTE","1202;781;681;681;681;664;618;597;576;576;576;576;576;576;576;402;402;387;387;387","MICHELE BRIGNOLE;ALESSANDRO RAMBALDI;GIUSEPPE REMUZZI;MANUELA LAZZARI;FRANCESCO TEDESCO;GIAN-MARIA BORLERI;JOSÉE GOLAY;LUISELLA ZAFFARONI;MARTINO INTRONA;SERGIO BERNASCONI;THOMAS VACCARI;ANDRÉS MOYÁ;ANTONIO RAVIELE;C. MENOZZI;PAOLO GIANI;PAOLÓ ALBONI;RICHARD SUTTON;E. MINOLA;ANNALISA PERNA;PIERO RUGGENENTI","1202;664;618;597;576;576;576;576;576;576;576;402;402;402;402;402;402;387;270;270","GIUSEPPE REMUZZI;MICHELE BRIGNOLE;A. LUCIANETTI;A. SEGALIN;BRUNO GRIDELLI;M. COLLEDAN;MARCO SPADA;ALESSANDRO RAMBALDI;AM PEDRONCELLI;ANNALISA PERNA;ARIALDO VERNOCCHI;ARIELA BENIGNI;B. CENSORI;CARMINE ZOCCALI;ELIANA GOTTI;GIANPIETRO DOTTI;L. DALLA PALMA;L. DALLA-PALMA;M RUSSOLO;MANUELA LAZZARI","6;6;4;4;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;ENGINEERING;PHYSICS;MATHEMATICS;CHEMISTRY;COMPUTER SCIENCE;PSYCHOLOGY;BUSINESS;MATERIALS SCIENCE;POLITICAL SCIENCE;SOCIOLOGY","65;14;7;7;5;3;3;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;RADIOLOGY;GASTROENTEROLOGY;PATHOLOGY;IMMUNOLOGY;ANESTHESIA;GENETICS;ENDOCRINOLOGY;PSYCHIATRY;BIOCHEMISTRY;OPTICS;MECHANICAL ENGINEERING;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;UROLOGY;VIROLOGY;ANATOMY;AUDIOLOGY;CANCER RESEARCH;GENERAL SURGERY;MICROBIOLOGY;NUCLEAR MEDICINE","46;23;15;14;11;11;10;9;8;7;7;6;6;5;4;4;4;4;3;3;3;3;3;3","BLOOD PRESSURE;GENE;INCIDENCE (GEOMETRY);TRANSPLANTATION;KIDNEY;ALTERNATIVE MEDICINE;CANCER;HEART FAILURE;LYMPHOMA;NEUROLOGY;SYNCOPE (PHONOLOGY);THROMBOSIS;ANTIBODY;ATRIAL FIBRILLATION;COHORT;CORONARY ARTERY DISEASE;DIABETES MELLITUS;KIDNEY DISEASE;MAGNETIC RESONANCE IMAGING;MYOCARDIAL INFARCTION;POPULATION;PROSPECTIVE COHORT STUDY;RENAL FUNCTION;STENOSIS;STROKE (ENGINE);VIRUS","8;6;6;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","NEURORADIOLOGY;ANGIOTENSIN-CONVERTING ENZYME;LIVER TRANSPLANTATION;NEPHROPATHY;VASOVAGAL SYNCOPE;ALBUMINURIA;ALLELE;ANTIBACTERIAL AGENT;CUMULATIVE INCIDENCE;EJECTION FRACTION;EPSTEIN–BARR VIRUS;GENOTYPE;GROWTH HORMONE;HEART RATE;KIDNEY TRANSPLANTATION;NEUROPSYCHOLOGY;OCTREOTIDE;ORGAN TRANSPLANTATION;ORTHOSTATIC VITAL SIGNS;PARAPLEGIA;PROTEINURIA;RAMIPRIL;VENOUS THROMBOSIS;VIRAL DISEASE;WAITING LIST","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ACE INHIBITOR;ACROMEGALY;BRADYCARDIA;HERPESVIRIDAE;ACUTE LYMPHOCYTIC LEUKEMIA;ALENDRONIC ACID;ALLELE FREQUENCY;ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY;ARTICULAR CARTILAGE;BILIARY TRACT CANCER;BONE DENSITY CONSERVATION AGENTS;BUSULFAN;CD59;COLON CARCINOMA;COLONOSCOPY;COMPUTED RADIOGRAPHY;CUTANEOUS MASTOCYTOSIS;CYTOGENETICS;E-SELECTIN;FLAVIVIRIDAE;FLUORESCENCE IN SITU HYBRIDIZATION;HAPLOTYPE;HEMICOLECTOMY;HEPACIVIRUS;KARYOTYPE;KIDNEY TRANSPLANT;LEFT ATRIAL MYXOMA;LISINOPRIL;LOSS OF HETEROZYGOSITY;METERED-DOSE INHALER;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;NEUROPSYCHOLOGICAL TEST;ORTHOSTATIC INTOLERANCE;OSTEOPENIA;P-SELECTIN;PLATELET ADHESIVENESS;RIGHT HEMICOLECTOMY;SECOND-HARMONIC IMAGING MICROSCOPY;TILT TABLE TEST;TROVAFLOXACIN;TUMOR SUPPRESSOR GENE;VANCOMYCIN","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ADOLESCENT;ITALY;FOLLOW-UP STUDIES;SYNCOPE, VASOVAGAL;KIDNEY FAILURE, CHRONIC;PROTEINURIA;;KIDNEY DISEASES;OCTREOTIDE;PROSPECTIVE STUDIES;SOMATOSTATIN;THROMBOSIS;AGED, 80 AND OVER;CHILD","58;40;38;31;26;25;11;11;10;10;9;9;8;8;8;8;8;8;7;7","DIAGNOSIS AND MANAGEMENT OF SYNCOPE;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CHOLANGIOCARCINOMA;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND TREATMENT OF DIVERTICULITIS","4;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LIVER TRANSPLANTATION;NEURALLY MEDIATED SYNCOPE;NEURORADIOLOGY;LIVING DONOR LIVER TRANSPLANTATION;STROKE (ENGINE);SYNCOPE;VASOVAGAL SYNCOPE;ALBUMINURIA;COAGULATION;CUMULATIVE INCIDENCE;INTERVENTIONAL RADIOLOGY;LANREOTIDE;PARAPLEGIA;RAMIPRIL;SUPINE POSITION;TRANSCRANIAL DOPPLER;WAITING LIST;;ACE2;ACOUSTIC NEUROMA","4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1","SPLIT LIVER;LIVER TRANSPLANTATION;CENTRE EXPERIENCE;CHRONIC PROTEINURIC;LIBERAL POLICY;LONGTERM FOLLOWUP;PEDIATRIC LIVER;PROTEINURIC NEPHROPATHIES;SINGLE CENTRE;TRANSPLANT RECIPIENTS;VASOVAGAL SYNCOPE;ACCURATE MOLECULAR;ACE GENOTYPE;ACE INHIBITORS;ACOUSTIC NEUROMA;ACTIVATES NF-KB;ACUTE DIVERTICULITIS;ACUTE FLANK;ADENOSINE SENSITIVE;ADHESION STUDIES;ALLOGENEIC STEM;ALTERNATIVE SPLIT;ANALYSIS INVOLVING;ANTI-CD MONOCLONAL;ANTIBIOTIC PROPHYLAXIS;ANTIBODY RITUXIMAB;ANTIPHOSPHOLIPID SYNDROME;ANTIRETROVIRAL REGIMEN;ANTITHROMBIN III;AORTIC ISTHMUS","4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TILT TESTING;CARDIOLOGIA OSPEDALI;DI CARDIOLOGIA;DIVISIONE DI;EBV DNA;NONDIABETIC PROTEINURIC;OSPEDALI RIUNITI;SOT RECIPIENTS;LANREOTIDE SR;LEUKEMIA RELAPSE;PROTEINURIC NEPHROPATHIES;SKIN CANCER;SYMPTOMATIC EBV;SYNCOPAL EPISODES;ATP TEST;BLOOD PRESSURE;CLINICAL PHYSIOLOGY;CNR CLINICAL;DE MARIA;DI LENARDA;DISEASE PROGRESSION;DNA LEVELS;EBV INFECTIONS;ID GENOTYPE;INSTITUTE MILAN;MILAN ITALYSEARCH;MLMIN NA;MOLECULAR CHARACTERIZATION;PHYSIOLOGY INSTITUTE;POSITIVE RESPONSE","7;6;6;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,5,1750,1.47,0,0,51.5,0,0,0,0,1,0,0,1,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;LUNG;LUNG CANCER;ORPHAN DRUG;PATIENT SAFETY;PREVENTION;RARE DISEASES","2;2;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","1;1","2.4 SURVEILLANCE AND DISTRIBUTION;6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","1;1;1","LUNG CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIANCONA",2001,53,6.64150943396226,2.86792452830189,0.528301886792453,0.377358490566038,0.547169811320755,1.31034482758621,1.07692307692308,1,1.11538461538462,0.169811320754717,4,25,8,6,14,0.47,0.15,0.11,0.26,63.36,1.38662994990742,NA,0.113207547169811,0.716981132075472,0.415,0.258,0.336,0.298,"GIUSEPPE REMUZZI;ALESSANDRO RAMBALDI;MARINO ZORZON;ROBERTO POZZI MUCELLI;GIUSEPPE CAZZATO;MICHELE BRIGNOLE;ROBERTO DE MASI;A. MAMOLI;CLAUDIO FARINA;TIZIANO BARBUI;ROBERT ZIVADINOV;DAVIDE NASUELLI;BRUNO FABRIS;L. MONTI BRAGADIN;RENZO CARRETTA;AURELIO SONZOGNI;BRUNO GRIDELLI;FABIO FISCHETTI;ADELE BORGHI;JOSÉE GOLAY","5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","DALLA PALMA L;GIUSEPPE REMUZZI;MICHELE SENNI;S SERGIO;A COSENZI;ROBERTO POZZI MUCELLI;ALESSANDRO RAMBALDI;ADELE BORGHI;FRANCESCO PAOLO ANNECCHINO;GABRIELLA AGNOLETTI;A. MAMOLI;ALESSANDRA COSTALUNGA;ANTONELLO GAVAZZI;FABIO POZZI MUCELLI;M. FISICARO;MARINO ZORZON;PIERO RUGGENENTI;ARRIGO SCHIEPPATI;GIULIANO TORRE;GIUSEPPE CAZZATO","1.25;1.18;1;1;1;0.69;0.61;0.58;0.58;0.58;0.51;0.5;0.5;0.5;0.5;0.48;0.46;0.46;0.46;0.45","GIUSEPPE REMUZZI;ALESSANDRO RAMBALDI;MARINO ZORZON;GIUSEPPE CAZZATO;MICHELE BRIGNOLE;ROBERTO DE MASI;A. MAMOLI;CLAUDIO FARINA;TIZIANO BARBUI;ROBERT ZIVADINOV;DAVIDE NASUELLI;BRUNO FABRIS;L. MONTI BRAGADIN;RENZO CARRETTA;AURELIO SONZOGNI;BRUNO GRIDELLI;FABIO FISCHETTI;ADELE BORGHI;JOSÉE GOLAY;MORENO BARDELLI","5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","DALLA PALMA L;GIUSEPPE REMUZZI;MICHELE SENNI;S SERGIO;A COSENZI;ALESSANDRO RAMBALDI;ADELE BORGHI;FRANCESCO PAOLO ANNECCHINO;GABRIELLA AGNOLETTI;A. MAMOLI;ALESSANDRA COSTALUNGA;FABIO POZZI MUCELLI;MARINO ZORZON;PIERO RUGGENENTI;ARRIGO SCHIEPPATI;GIULIANO TORRE;GIUSEPPE CAZZATO;AURELIO SONZOGNI;TIZIANO BARBUI;MICHELE BRIGNOLE","1.25;1.18;1;1;1;0.61;0.58;0.58;0.58;0.51;0.5;0.5;0.48;0.46;0.46;0.46;0.45;0.42;0.39;0.39","C. MENOZZI;MICHELE BRIGNOLE;NICOLA BOTTONI;ALESSANDRO RAMBALDI;JOSÉE GOLAY;MARTINO INTRONA;GIUSEPPE CAZZATO;MARINO ZORZON;DAVIDE NASUELLI;ROBERT ZIVADINOV;ROBERTO DE MASI;TIZIANO BARBUI;ALBERTO SOLANO;ANTONIO RAVIELE;ATTILIO DEL ROSSO;MAURIZIO DINELLI;PAOLÓ ALBONI;GIANMARIA BORLERI;MANUELA LAZZARI;SERGIO BERNASCONI","747;747;747;710;624;624;527;514;484;484;484;475;435;435;435;435;435;419;419;419","MICHELE BRIGNOLE;ALESSANDRO RAMBALDI;GIUSEPPE CAZZATO;DAVIDE NASUELLI;MARINO ZORZON;ROBERT ZIVADINOV;ROBERTO DE MASI;TIZIANO BARBUI;ALBERTO SOLANO;GIANMARIA BORLERI;JOSÉE GOLAY;MANUELA LAZZARI;MARTINO INTRONA;SERGIO BERNASCONI;VALERIA FACCHINETTI;C. MENOZZI;FRANCISCO PÉREZ ERRAZQUIN;NICOLA BOTTONI;GIUSEPPE REMUZZI;ALESSIO BRATINA","747;710;527;484;484;484;484;475;435;419;419;419;419;419;419;312;312;312;256;247","ALESSANDRO RAMBALDI;GIUSEPPE CAZZATO;TIZIANO BARBUI;CLAUDIO FARINA;DAVIDE NASUELLI;GIUSEPPE REMUZZI;MARINO ZORZON;ROBERT ZIVADINOV;ROBERTO DE MASI;ARRIGO SCHIEPPATI;BRUNO FABRIS;BRUNO GRIDELLI;DALLA PALMA L;F. FIAMMENGO;FABIO FISCHETTI;GABRIELLA AGNOLETTI;L. MONTI BRAGADIN;LORENZO PASCAZIO;MICHELE BRIGNOLE;MORENO BARDELLI","5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ECONOMICS;ENGINEERING;COMPUTER SCIENCE;MATERIALS SCIENCE;POLITICAL SCIENCE;PSYCHOLOGY;BUSINESS;MATHEMATICS","48;13;4;3;3;3;2;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;RADIOLOGY;IMMUNOLOGY;PSYCHIATRY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;ANESTHESIA;ENDOCRINOLOGY;ANATOMY;BIOCHEMISTRY;ONCOLOGY;PEDIATRICS;PHARMACOLOGY;UROLOGY;ARTIFICIAL INTELLIGENCE;CANCER RESEARCH;DERMATOLOGY;GENERAL SURGERY;LAW;MECHANICAL ENGINEERING;MICROBIOLOGY;MOLECULAR BIOLOGY;OPTICS;PHYSICAL THERAPY;VIROLOGY","38;15;12;12;11;10;9;8;7;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","DISEASE;NEUROLOGY;CHEMOTHERAPY;BLOOD PRESSURE;GENE;TRANSPLANTATION;ANTIBODY;CANCER;NEUROSURGERY;ATRIAL FIBRILLATION;BACTERIA;DIABETES MELLITUS;HEART FAILURE;KIDNEY;LESION;LEUKEMIA;LYMPHOMA;MAGNETIC RESONANCE IMAGING;MULTIPLE SCLEROSIS;URINARY SYSTEM","10;8;7;6;6;6;4;4;4;3;3;3;3;3;3;3;3;3;3;3","NEURORADIOLOGY;CYCLOPHOSPHAMIDE;HEART RATE;RITUXIMAB;AUTOIMMUNE HEPATITIS;CD20;CHRONIC LYMPHOCYTIC LEUKEMIA;CISPLATIN;CYTOTOXIC T CELL;HUMAN LEUKOCYTE ANTIGEN;LIVER TRANSPLANTATION;NEPHROPATHY;NOCARDIA;PHENOTYPE;WARFARIN;ALEMTUZUMAB;ALLERGEN;ALLERGIC CONTACT DERMATITIS;ALPHA INTERFERON;AMIKACIN;AMYOTROPHIC LATERAL SCLEROSIS;ANGIOTENSIN-CONVERTING ENZYME;ANTERIOR COMMUNICATING ARTERY;ANTIBIOTIC RESISTANCE;ANTIPHOSPHOLIPID SYNDROME;AORTIC ARCH;ATOPY;AUTOANTIBODY;AUTOIMMUNE DISEASE;AZATHIOPRINE;BASAL (MEDICINE);BLADDER CANCER;BRAIN BIOPSY;BREAST CANCER;BRONCHOALVEOLAR LAVAGE;BUNDLE BRANCH BLOCK;CAROTID BIFURCATION;CAROTID ENDARTERECTOMY;CARVEDILOL;CATHETER ABLATION;CD19;CD34;CHRONIC RENAL DISEASE;CICLOSPORIN;CIPROFLOXACIN;CLINICALLY ISOLATED SYNDROME;CMAX;COGNITIVE IMPAIRMENT;COLOR DOPPLER;COMMON CAROTID ARTERY;COMPLEMENT SYSTEM;CONTACT DERMATITIS;CYTOTOXICITY;DACARBAZINE;DESCENDING AORTA;DIABETIC NEPHROPATHY;END STAGE RENAL DISEASE;EXON;EXPANDED DISABILITY STATUS SCALE;FABRY DISEASE;FOLLICULAR LYMPHOMA;GEMCITABINE;GENE EXPRESSION;GENOTYPE;GLOMERULONEPHRITIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATITIS C VIRUS;HETERODUPLEX;HYBRIDIZATION PROBE;HYDRONEPHROSIS;IMPLANTABLE LOOP RECORDER;INTRAVENOUS UROGRAPHY;ISCHEMIC STROKE;KIDNEY TRANSPLANTATION;LEFT PULMONARY ARTERY;LEFT VENTRICULAR HYPERTROPHY;LUPUS ANTICOAGULANT;LYMPHOBLASTIC LEUKEMIA;MAJOR HISTOCOMPATIBILITY COMPLEX;MANTLE CELL LYMPHOMA;MIDDLE CEREBRAL ARTERY;MOLECULAR MIMICRY;MONOCLONAL ANTIBODY;MUTATION;MYCOBACTERIUM;MYCOBACTERIUM TUBERCULOSIS;NEUROPSYCHOLOGY;OCCUPATIONAL MEDICINE;OPHTHALMIC ARTERY;ORGAN TRANSPLANTATION;OVARIAN CANCER;PARKINSON'S DISEASE;PERIPHERAL NEUROPATHY;POLYMERASE CHAIN REACTION;POSTERIOR COMMUNICATING ARTERY;PRIMARY HYPEROXALURIA;PRIMARY SCLEROSING CHOLANGITIS;PROTEINURIA;PSEUDOMONAS AERUGINOSA;PULMONARY VASCULATURE;RAMIPRIL;RELAPSING REMITTING;RENAL COLIC;RENAL PELVIS;RESPIRATORY DISEASE;RIGHT PULMONARY ARTERY;SINUS RHYTHM;SPIROMETRY;STREPTOZOTOCIN;SUPEROXIDE DISMUTASE;T CELL;TACROLIMUS;TECHNETIUM (99MTC) SESTAMIBI;TECHNETIUM TC 99M SESTAMIBI;THERAPEUTIC INDEX;THROMBOPLASTIN;TOLERABILITY;TROUGH CONCENTRATION;UNIVARIATE ANALYSIS;UPPER URINARY TRACT;VENOUS PRESSURE","6;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NOCARDIOSIS;ACE INHIBITOR;ACUTE LYMPHOCYTIC LEUKEMIA;BAROREFLEX;CAROTID STENTING;CD40;CD59;CD86;CENTRAL VENOUS PRESSURE;DEBULKING;DEEP BRAIN STIMULATION;DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;DEOXYCYTIDINE;DISMUTASE;DNA MICROARRAY;DYSKINESIA;ELECTROPHYSIOLOGY STUDY;EXHALED NITRIC OXIDE;FABRY'S DISEASE;FLUDARABINE;GLOMERULAR HYPERFILTRATION;HAND DERMATITIS;HISTOCOMPATIBILITY;HLA-A;IMIPENEM;INTERFERON ALFA;INTERRUPTED AORTIC ARCH;IRRITANT CONTACT DERMATITIS;MAMMOGRAPHY;METHACHOLINE;MICROARRAY ANALYSIS TECHNIQUES;MONOCLONAL;MULTIPLEX POLYMERASE CHAIN REACTION;MYCOBACTERIUM CHELONAE;MYCOBACTERIUM KANSASII;MYCOBACTERIUM MARINUM;MYCOBACTERIUM TUBERCULOSIS COMPLEX;NONTUBERCULOUS MYCOBACTERIA;OCCUPATIONAL DERMATITIS;ORAL ANTICOAGULANT;PIPERACILLIN;POLYMORPHISM (COMPUTER SCIENCE);POSTERIOR CEREBRAL ARTERY;PRESYNCOPE;PROLYMPHOCYTIC LEUKEMIA;RENAL GLOMERULUS;SOD1;SOLID ORGAN;TRANSITIONAL CELL CARCINOMA;TROUGH LEVEL;VINCRISTINE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;AGED;MULTIPLE SCLEROSIS;NOCARDIA INFECTIONS;;ANTIBODIES, MONOCLONAL;ANTINEOPLASTIC AGENTS;CISPLATIN;COGNITION DISORDERS;HEPATITIS, AUTOIMMUNE;SYNCOPE;CHILD;HEART DEFECTS, CONGENITAL;HEART FAILURE;IMMUNOSUPPRESSIVE AGENTS;ITALY","44;29;25;18;17;12;9;9;8;8;8;7;7;7;7;6;6;6;6;6","DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;ASTHMA;CLINICAL AND MOLECULAR ASPECTS OF NOCARDIOSIS;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;DIAGNOSIS AND MANAGEMENT OF SYNCOPE;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEMATOPOIETIC STEM CELL BIOLOGY;;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANALYSIS OF CARDIAC AND RESPIRATORY SOUNDS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;COMPUTER GRAPHICS AND VISUALIZATION TECHNIQUES;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;ECONOMICS OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT","3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","NEURORADIOLOGY;ATRIOVENTRICULAR BLOCK;AUTOIMMUNE HEPATITIS;CAROTID ARTERY STENOSIS;GLOMERULAR FILTRATION RATE;HYPERTENSION;INTERVENTIONAL RADIOLOGY;LIVER DISEASE;NEURALLY MEDIATED SYNCOPE;NOCARDIA SPP.;RITUXIMAB;STROKE (ENGINE);ACUTE LYMPHOCYTIC LEUKEMIA;ADOPTIVE CELL TRANSFER;AIRWAY AFFERENT NERVES;ALLERGIC DERMATITIS;ALPHA 1-ANTITRYPSIN DEFICIENCY;AMIKACIN;ANTERIOR COMMUNICATING ARTERY;ANTIPHOSPHOLIPID SYNDROME","6;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MULTIPLE SCLEROSIS;AUTOIMMUNE HEPATITIS;CAROTID ARTERY;HEART DISEASE;LEFT VENTRICULAR;RENAL DISEASE;ACE INHIBITORS;ACUTE ETHANOL;ACUTE GUTTATE;ACUTE LYMPHOBLASTIC;ACUTE STROKE;ADULT ALLOGENEIC;ADVANCED PARKINSONS;ADVENTITIAL CYSTIC;AGXT GENE;ALLOGENEIC BONE;ALVEOLAR MACROPHAGES;ANTI-CD ANTIBODY;ANTI-TRYPSIN DEFICIENCY;ANTIBODY RITUXIMAB;ANTICOAGULANT RESULTS;ANTICOAGULANT TREATMENT;ANTIPHOSPHOLIPID SYNDROME;AORTIC ARCH;ARRHYTHMIA RISK;ARTERY CLINICAL;ARTERY DIAMETER;ARTERY WALL;ASSOCIATIVE MEMORY;AUTOLOGOUS GRAFTING","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AAT DEFICIENCY;ACE INHIBITION;PROTEIN EXCRETION;URINARY PROTEIN;CD CELLSKG;DIABETIC RATS;HEPATIC VENOUS;INNO LIPA;LIPA MYCOBACTERIA;PPB NA;PULMONARY FISTULAS;RANGE CD;ANTICOAGULANT TREATMENT;BASAL GFR;CD CD;CD CELLS;CD LEVELS;COMPLEMENT-DEPENDENT CYTOTOXICITY;CREATININE CLEARANCE;DNA PROBE;FLUORESCENCE INTENSITY;GLOMERULAR FILTRATION;GLOMERULAR HYPERFILTRATION;HUMAN RECOMBINANT;INCREASED URINARY;MAC MYCOBACTERIUM;ORAL ANTICOAGULANT;ORAL ANTICOAGULANTS;PATIENTS INVESTIGATED;RENAL INSUFFICIENCY","5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,7.33,353.5,3.64,0,0,59.5,0,0,1,0,2,0,1,0,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Germany;Italy","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES","4;3;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;ORPHAN DRUG;PATIENT SAFETY;RARE DISEASES;CARDIOVASCULAR;CHILDHOOD LEUKEMIA;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY;PEDIATRIC;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;STEM CELL RESEARCH;UROLOGIC DISEASES","4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","3;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS","3;1","BLADDER CANCER;BLOOD CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA","1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","3;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIANCONA",2002,85,8.72941176470588,2.54117647058824,0.470588235294118,0.294117647058824,0.482352941176471,1.37414965986395,1.14705882352941,1.15,1.14285714285714,0.2,2,37,9,14,19,0.44,0.11,0.16,0.22,91.54,1.65929519855551,NA,0.305882352941176,0.717647058823529,0.422,0.303,0.318,0.298,"ROBERTO LABIANCA;CLAUDIO ARICI;TIZIANO BARBUI;GIUSEPPE REMUZZI;GIANCARLO TIRELLI;PAOLO FERRAZZI;M RUSSOLO;VITTORIO GIACOMARRA;MICHELE BRIGNOLE;BRUNO GRIDELLI;R. FIOCCHI;A. RIMONDINI;C. MENOZZI;LEDIA PAPANIKOLLA;ALESSANDRO RAMBALDI;PETER REISS;PIERA VIERO;RENATO BASSAN;MATTIA GLAUBER;THÉRÈSE STAUB","6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2","FRANCESCO BERTONI;P. DONATEO;GIANCARLO TIRELLI;M RUSSOLO;VITTORIO GIACOMARRA;GIUSEPPE REMUZZI;LUIGI NALDI;TIZIANO BARBUI;ROBERTO LABIANCA;MICHELE BRIGNOLE;C. MENOZZI;A. RIMONDINI;LEDIA PAPANIKOLLA;ANDREA PERKAN;GIANFRANCO SINAGRA;DI LENARDA A;ALEXANDRE CAMPANELLI;BRUNO PINAMONTI;GIUSEPPE CACCIATORE;ALDO MORRA","1;1;0.79;0.79;0.79;0.76;0.75;0.74;0.72;0.72;0.72;0.68;0.64;0.53;0.53;0.53;0.5;0.5;0.5;0.48","ROBERTO LABIANCA;CLAUDIO ARICI;TIZIANO BARBUI;GIUSEPPE REMUZZI;GIANCARLO TIRELLI;PAOLO FERRAZZI;M RUSSOLO;VITTORIO GIACOMARRA;MICHELE BRIGNOLE;BRUNO GRIDELLI;R. FIOCCHI;A. RIMONDINI;LEDIA PAPANIKOLLA;ALESSANDRO RAMBALDI;PIERA VIERO;RENATO BASSAN;PAOLA TORRE;ROBERTO POZZI MUCELLI;ANDREA PERKAN;GIANFRANCO SINAGRA","6;5;5;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2","FRANCESCO BERTONI;P. DONATEO;GIANCARLO TIRELLI;M RUSSOLO;VITTORIO GIACOMARRA;GIUSEPPE REMUZZI;LUIGI NALDI;TIZIANO BARBUI;ROBERTO LABIANCA;MICHELE BRIGNOLE;A. RIMONDINI;LEDIA PAPANIKOLLA;ANDREA PERKAN;GIANFRANCO SINAGRA;BRUNO PINAMONTI;ALDO MORRA;PIERO RUGGENENTI;PAOLO FERRAZZI;STEFANIA MOSCONI;MICHELE BERTOLOTTO","1;1;0.79;0.79;0.79;0.76;0.75;0.74;0.72;0.72;0.68;0.64;0.53;0.53;0.5;0.48;0.48;0.46;0.45;0.4","GIULIO GUAGLIUMI;ANTONIO COLOMBO;ERNESTO BAN HAYASHI;FERENC MOLNÁR;GERHARD SCHÜLER;J. EDUARDO SOUSA;JEAN FAJADET;MARCO PERIN;MARIE‐CLAUDE MORICE;PATRICK W. SERRUYS;PAUL BARRAGAN;ROBERT FALOTICO;ANTONELLO GAVAZZI;ALAIN COHEN‐SOLAL;FERENC FOLLÁTH;HUGO MADEIRA;ISTVÁN PRÉDA;J KOREWICKI;J WIDIMSKÝ;J. EASTAUGH","4017;4011;4011;4011;4011;4011;4011;4011;4011;4011;4011;4011;869;538;538;538;538;538;538;538","GIULIO GUAGLIUMI;ANTONELLO GAVAZZI;BRUNO GRIDELLI;GIUSEPPE REMUZZI;R. FIOCCHI;ROBERTO LABIANCA;ANTONIA MORETTA;DANIELA MONTAGNA;FABRIZIO GINEVRI;FAUSTO BALDANTI;FRANCO LOCATELLI;G. ROSSI;GIUSEPPE GERNA;MARIO VIGANÒ;MASSIMO LABIRIO;MILENA FURIONE;PAOLO GROSSI;PATRIZIA COMOLI;RITA MACCARIO;SABRINA BASSO","4017;869;417;322;322;284;256;256;256;256;256;256;256;256;256;256;256;256;256;256","ROBERTO LABIANCA;CLAUDIO ARICI;GIANCARLO TIRELLI;GIUSEPPE REMUZZI;M RUSSOLO;PAOLO FERRAZZI;VITTORIO GIACOMARRA;BRUNO GRIDELLI;FREDY SUTER;LEDIA PAPANIKOLLA;PIERO RUGGENENTI;TIZIANO BARBUI;MICHELE BRIGNOLE;R. FIOCCHI;ALDO MORRA;ALESSANDRO RAMBALDI;AMANDO GAMBA;ANTONELLO GAVAZZI;ANTONIO BAVA;FILIPPO MAMPRIN","5;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;PHYSICS;COMPUTER SCIENCE;PHILOSOPHY;PSYCHOLOGY;ECONOMICS;MATERIALS SCIENCE;MATHEMATICS;SOCIOLOGY;POLITICAL SCIENCE","82;21;5;4;4;3;3;3;2;2;2;2;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;CARDIOLOGY;IMMUNOLOGY;RADIOLOGY;GASTROENTEROLOGY;ONCOLOGY;ENDOCRINOLOGY;GENETICS;INTENSIVE CARE MEDICINE;PSYCHIATRY;BIOCHEMISTRY;ANESTHESIA;CANCER RESEARCH;PEDIATRICS;ANATOMY;DERMATOLOGY;ARTIFICIAL INTELLIGENCE;ENVIRONMENTAL HEALTH;MEDICAL PHYSICS;MICROBIOLOGY;NUCLEAR MEDICINE;OPTICS;VIROLOGY","66;22;18;17;17;14;11;10;9;9;9;8;7;5;5;5;4;4;3;3;3;3;3;3;3","CANCER;BLOOD PRESSURE;GENE;HEART FAILURE;ALTERNATIVE MEDICINE;DISEASE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);ANTIBODY;CHEMOTHERAPY;DIABETES MELLITUS;KIDNEY;REGIMEN;TRANSPLANTATION;BIOPSY;CLINICAL TRIAL;CONFIDENCE INTERVAL;GOLD STANDARD (TEST);MELANOMA;MYOCARDIAL INFARCTION;OBSERVATIONAL STUDY;ODDS RATIO;POPULATION;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;STENT;SYNCOPE (PHONOLOGY)","18;10;10;8;6;6;6;5;5;5;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;COLORECTAL CANCER;VIRAL LOAD;HEART RATE;METASTASIS;CARDIOMYOPATHY;DILATED CARDIOMYOPATHY;EJECTION FRACTION;ADENOCARCINOMA;ALLELE;CALCINEURIN;CD8;DIABETIC RETINOPATHY;GENOTYPE;LIVER TRANSPLANTATION;LOCUS (GENETICS);MUTATION;NECK DISSECTION;OCCULT;POLYMERASE CHAIN REACTION;RETINOIC ACID;RETINOPATHY;TACROLIMUS;THROMBOTIC MICROANGIOPATHY;TYPE 2 DIABETES","6;6;6;5;5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;MAMMOGRAPHY;TAMOXIFEN;ADAMTS13;ADENOSQUAMOUS CARCINOMA;AFFERENT ARTERIOLES;ATYPICAL HEMOLYTIC UREMIC SYNDROME;BASILIXIMAB;BRADYCARDIA;CARDIAC RESYNCHRONIZATION THERAPY;CHRONOTROPIC;CLINICAL DEMENTIA RATING;COLONOSCOPY;CORONARY RESTENOSIS;CTL*;CYCLE ERGOMETER;DEBULKING;DIAGNOSIS OF MALARIA;DONEPEZIL;FACTOR H;FOLINIC ACID;GENE MUTATION;GERIATRIC DEPRESSION SCALE;GLOMERULAR HYPERFILTRATION;HAEMOLYTIC-URAEMIC SYNDROME;HAPLOTYPE;HEART RATE VARIABILITY;HYPERINSULINEMIA;HYPERTRIGLYCERIDEMIA;IDARUBICIN;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRINOTECAN;LAMIVUDINE;LMNA;MARGINAL ZONE;MELANOCYTIC NEVUS;MICROANGIOPATHIC HEMOLYTIC ANEMIA;MICROMETASTASIS;MOLECULAR EPIDEMIOLOGY;MOLECULAR MEDICINE;MUCOSA-ASSOCIATED LYMPHOID TISSUE;MULTILOCUS SEQUENCE TYPING;NUCLEAR PROTEIN;ONCOGENE;PARASITEMIA;PNEUMOCOCCAL INFECTIONS;PRIMARY TUMOR;RADIOIMMUNOTHERAPY;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;RESTRICTIVE CARDIOMYOPATHY;RETINALDEHYDE;REVERSE TRANSCRIPTASE;SCEDOSPORIUM APIOSPERMUM;SENTINEL LYMPH NODE;SINGLE-NUCLEOTIDE POLYMORPHISM;TILT TABLE TEST;TRETINOIN;UPPER MOTOR NEURON;VASCULAR DEMENTIA;XERODERMA PIGMENTOSUM","5;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;AGED;HIV INFECTIONS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PROSPECTIVE STUDIES;COLORECTAL NEOPLASMS;HEART FAILURE;OROPHARYNGEAL NEOPLASMS;BREAST NEOPLASMS;RETROSPECTIVE STUDIES;ADOLESCENT;AGED, 80 AND OVER;ANTI-HIV AGENTS;ITALY;SYNCOPE;LYMPHATIC METASTASIS","75;50;48;36;35;32;20;16;15;14;12;12;11;11;10;10;10;10;10;9","DIAGNOSIS AND MANAGEMENT OF SYNCOPE;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MELANOMA;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;ROLE OF RETINOIC ACID IN BIOLOGICAL PROCESSES;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;BACTERIAL PATHOGENESIS IN ANIMAL AND HUMAN HEALTH;BRANCHIAL ANOMALIES AND THYROID ABNORMALITIES;BREAST PATHOLOGY AND IMAGING TECHNIQUES","5;4;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","ANTIRETROVIRAL THERAPY;REGIMEN;HIV;DIABETES;DILATED CARDIOMYOPATHY;ECHOCARDIOGRAPHY;GOLD STANDARD (TEST);NEURALLY MEDIATED SYNCOPE;TREATMENT;ADHERENCE TO MEDICATION;AORTIC ROOT REPLACEMENT;BREAST IMAGING;CARDIAC IMAGING;CORONARY STENTS;GRADING (ENGINEERING);HEART TRANSPLANT;HYPERTENSION;IMAGING;LEFT VENTRICULAR FUNCTION;METASTATIC COLORECTAL CANCER","6;6;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","COLORECTAL CANCER;HEART FAILURE;ANTIRETROVIRAL THERAPY;DILATED CARDIOMYOPATHY;TRANSPLANT RECIPIENTS;ACUTE LYMPHOBLASTIC;ADJUVANT TREATMENT;BREAST CANCER;CARDIOMYOPATHY INDICATION;CODON K-RAS;CONGESTIVE HEART;CURRENT ROLE;HEART RATE;HEART TRANSPLANT;HIV--INFECTED PATIENTS;HIV-INFECTED PATIENTS;K-RAS MUTATIONS;LYMPH NODES;OCCULT METASTASES;ORAL CANCER;PILOT STUDY;PROGNOSTIC INDICATORS;RANDOMIZED STUDY;RATE RESPONSE;AC DEFECT-RELATED;ACCELERATED HYPERFRACTIONATED;ACTINIC KERATOSIS;ACTIVE ANTIRETROVIRAL;ACTIVE VIRUS;ACUTE MYELOGENOUS","5;5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","VIRAL LOAD;ANTIRETROVIRAL THERAPY;AORTIC VALVE;K-RAS MUTATIONS;CD CELL;STENTLESS AORTIC;HAART PATIENTS;LONG-TERM HAART;LVEF RECOVERY;MACRORESTRICTION TYPES;MV MUTATION;ACTIVE ANTIRETROVIRAL;AIRWAY INFECTIONS;CELL COUNTS;CODON K-RAS;CONVENTIONAL STENTED;EFFECTIVE ORIFICE;HIGHLY ACTIVE;INDEXED EFFECTIVE;LOAD COPIESML;LOWER AIRWAY;PATIENTS RECEIVED;SHORT-TERM HAART;VALVE IMPLANTATION;ALLELIC PROFILES;AV BLOCK;BLOOD PRESSURE;BRANCH BLOCK;BUNDLE BRANCH;CARDIAC DAMAGE","13;8;8;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,6.5,3687.5,1.39,0,0,176,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","2;1;1","CARDIOVASCULAR;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;NUTRITION","1;1;1;1;1","CANCER;CARDIOVASCULAR","1;1","6.1 PHARMACEUTICALS","1","PANCREATIC CANCER","1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIANCONA",2003,91,7.07692307692308,2.43956043956044,0.67032967032967,0.285714285714286,0.681318681318681,1.65972222222222,1.4,1.4,1.36170212765957,0.318681318681319,8,40,16,2,28,0.44,0.18,0.02,0.31,70.22,1.32670629188778,NA,0.142857142857143,0.67032967032967,0.445,0.352,0.343,0.352,"ROBERTO POZZI MUCELLI;MASSIMO ZECCHIN;MARINO ZORZON;GIUSEPPE REMUZZI;GIANFRANCO SINAGRA;EMILIO QUAIA;LAURA LOCATELLI;GIUSEPPE CAZZATO;MICHELE BERTOLOTTO;ALESSIO BRATINA;ROBERT ZIVADINOV;DAVIDE NASUELLI;ANDREA DI LENARDA;GIULIO GUAGLIUMI;MARIA ASSUNTA COVA;FULVIO STACUL;MARIA ANTONIETTA TOMMASI;GASTONE SABBADINI;MAJA UKMAR;GIOVANNI MOSCONI","8;6;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;3","MASSIMO ZECCHIN;FULVIO STACUL;MARIA ASSUNTA COVA;ROBERTO POZZI MUCELLI;GIUSEPPE REMUZZI;GIANFRANCO SINAGRA;DANIELA CAPELLO;VINDHYA SURESH;A SIGNORINI;ANA MARÍA HOLLAND OMETTO;EMILIO QUAIA;MICHELE BERTOLOTTO;GIOVANNI MOSCONI;ANDREA DI LENARDA;GASTONE SABBADINI;FREDY SUTER;ANNA FALANGA;MARINA MARCHETTI;TIZIANO BARBUI;PAOLA TORRE","2.75;1.84;1.81;1.16;1.15;1;1;1;1;1;0.9;0.9;0.9;0.83;0.75;0.61;0.58;0.58;0.58;0.54","ROBERTO POZZI MUCELLI;MASSIMO ZECCHIN;MARINO ZORZON;GIUSEPPE REMUZZI;GIANFRANCO SINAGRA;EMILIO QUAIA;LAURA LOCATELLI;GIUSEPPE CAZZATO;MICHELE BERTOLOTTO;ALESSIO BRATINA;ROBERT ZIVADINOV;DAVIDE NASUELLI;ANDREA DI LENARDA;GIULIO GUAGLIUMI;MARIA ASSUNTA COVA;FULVIO STACUL;MARIA ANTONIETTA TOMMASI;GASTONE SABBADINI;MAJA UKMAR;GIOVANNI MOSCONI","8;6;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;3","MASSIMO ZECCHIN;FULVIO STACUL;MARIA ASSUNTA COVA;ROBERTO POZZI MUCELLI;GIUSEPPE REMUZZI;GIANFRANCO SINAGRA;DANIELA CAPELLO;VINDHYA SURESH;A SIGNORINI;ANA MARÍA HOLLAND OMETTO;EMILIO QUAIA;MICHELE BERTOLOTTO;GIOVANNI MOSCONI;ANDREA DI LENARDA;GASTONE SABBADINI;FREDY SUTER;ANNA FALANGA;MARINA MARCHETTI;TIZIANO BARBUI;PAOLA TORRE","2.75;1.84;1.81;1.16;1.15;1;1;1;1;1;0.9;0.9;0.9;0.83;0.75;0.61;0.58;0.58;0.58;0.54","ALLAN M. SKENE;ANDREA DI LENARDA;ARMIN SCHERHAG;BEATRIX LUTIGER;CHRISTIAN TORP‐PEDERSEN;JACOBUS LUBSEN;JOHN G.F. CLELAND;KARL SWEDBERG;MARCO METRA;MICHEL KOMAJDA;PETER HANRATH;PHILIP A. POOLE‐WILSON;WILLEM J. REMME;GIULIO GUAGLIUMI;ADRIAN BANNING;ANTONIO COLOMBO;DARIUSZ DUDEK;EBERHARD GRUBE;FRANÇOIS SCHIELE;J DRZEWIECKI","1850;1850;1850;1850;1850;1850;1850;1850;1850;1850;1850;1850;1850;1049;1006;1006;1006;1006;1006;1006","ANDREA DI LENARDA;GIULIO GUAGLIUMI;AURELIO SONZOGNI;GIUSEPPE CAZZATO;ALESSIO BRATINA;DAVIDE NASUELLI;LAURA LOCATELLI;ROBERT ZIVADINOV;GIUSEPPE REMUZZI;MARIA ANTONIETTA TOMMASI;MARINO ZORZON;PIERO RUGGENENTI;CLAUDIA DE FILIPPI;ANTONIO BOSCO;ALBERTO M PEDRONCELLI;G. PAGANI;M MONTINI;MASCIA ALBIZZI;MICHELE BERTOLOTTO;BARBARA STIVAL","1850;1032;902;374;328;328;328;328;309;306;287;264;232;212;188;188;188;188;159;155","ALESSIO BRATINA;ANDREA DI LENARDA;DAVIDE NASUELLI;GIUSEPPE CAZZATO;LAURA LOCATELLI;ROBERT ZIVADINOV;FREDY SUTER;FULVIO STACUL;MARIA ANTONIETTA TOMMASI;MARINO ZORZON;MICHELE BERTOLOTTO;GIUSEPPE REMUZZI;ANNAPAOLA CALLEGARO;CLAUDIO ARICI;DIEGO RIPAMONTI;FRANCO MAGGIOLO;BARBARA STIVAL;MARIA ASSUNTA COVA;PAOLA TORRE;RITA MORETTI","5;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;CHEMISTRY;ENGINEERING;PSYCHOLOGY;BUSINESS;ECONOMICS;MATHEMATICS;GEOGRAPHY;SOCIOLOGY;POLITICAL SCIENCE","91;19;7;7;6;6;6;3;3;3;2;2;1","INTERNAL MEDICINE;IMMUNOLOGY;CARDIOLOGY;RADIOLOGY;PATHOLOGY;SURGERY;GASTROENTEROLOGY;BIOCHEMISTRY;PSYCHIATRY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;CANCER RESEARCH;GENETICS;ONCOLOGY;OPTICS;VIROLOGY;ANATOMY;PHARMACOLOGY;ANESTHESIA;CELL BIOLOGY;DERMATOLOGY;ECOLOGY;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;PALEONTOLOGY;PEDIATRICS;UROLOGY","65;23;22;22;21;18;16;11;11;10;8;7;6;6;5;5;5;4;4;3;3;3;3;3;3;3;3;3","DISEASE;HEART FAILURE;VIRUS;NEUROLOGY;DIABETES MELLITUS;GENE;REGIMEN;KIDNEY;CANCER;CHEMOTHERAPY;POPULATION;RANDOMIZED CONTROLLED TRIAL;INTERVENTIONAL RADIOLOGY;MAGNETIC RESONANCE IMAGING;MULTIPLE SCLEROSIS;ANTIBODY;CONFIDENCE INTERVAL;ENZYME;HEPATITIS C;LESION;LYMPHOMA;MYOCARDIAL INFARCTION;PROPORTIONAL HAZARDS MODEL;RENAL FUNCTION;STENT","14;11;10;9;8;8;8;7;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4","CARDIOMYOPATHY;DILATED CARDIOMYOPATHY;NEURORADIOLOGY;HAZARD RATIO;NEPHROPATHY;VIRAL LOAD;ALPHA INTERFERON;CHRONIC HEPATITIS;CLINICAL ENDPOINT;EJECTION FRACTION;GENOTYPE;HEPATITIS B VIRUS;HEPATITIS C VIRUS;MITRAL VALVE REPAIR;PRIMARY PREVENTION;PROTEINURIA;RESTENOSIS;ALLERGEN;BRAIN SIZE;COLORECTAL CANCER;DIABETIC NEPHROPATHY;END STAGE RENAL DISEASE;ENDOTHELIAL STEM CELL;GLOMERULONEPHRITIS;GROWTH HORMONE;LYMPHOPROLIFERATIVE DISORDERS;METASTASIS;MICROBUBBLES;OCTREOTIDE;PACLITAXEL;REVASCULARIZATION;RNA;TOLERABILITY;TYPE 2 DIABETES","7;7;7;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;RIBAVIRIN;ACROMEGALY;CRYOGLOBULINEMIA;DRUG-ELUTING STENT;LAMIVUDINE;REVERSE TRANSCRIPTASE;ACUTE PROMYELOCYTIC LEUKEMIA;ALLERGEN IMMUNOTHERAPY;ALVEOLAR RHABDOMYOSARCOMA;AORTIC RUPTURE;BOSENTAN;CITALOPRAM;CLAUDICATION;CORTICOBASAL DEGENERATION;CROSSOVER STUDY;CYCLIN D1;CYSTECTOMY;DEEP BRAIN STIMULATION;DEFIBROTIDE;DYSKINESIA;EMBRYONAL RHABDOMYOSARCOMA;ENDOTHELINS;FLUORESCENCE IN SITU HYBRIDIZATION;GERMINAL CENTER;GLOMERULOSCLEROSIS;IFOSFAMIDE;IMMUNOPEROXIDASE;IN SITU HYBRIDIZATION;INSULIN LISPRO;INTERMITTENT CLAUDICATION;KARYOTYPE;LIPOPROTEIN(A);MAMMOGRAPHY;MECHANICAL INDEX;MEMBRANOUS NEPHROPATHY;MITRAL VALVE ANNULOPLASTY;OXALIPLATIN;PANCREATIC HORMONE;PODOCYTE;PRIMARY TUMOR;RETINOIC ACID RECEPTOR;RIGHT CORONARY ARTERY;RISK MANAGEMENT PLAN;SECOND-HARMONIC IMAGING MICROSCOPY;SEPTAL MYECTOMY;SIDA;SOMATIC HYPERMUTATION;STAPHYLOCOCCUS;SUBLINGUAL IMMUNOTHERAPY;THROMBOMODULIN;TIMI;TRANSFERRIN SATURATION;VASOSPASTIC ANGINA;VINORELBINE","4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;KIDNEY DISEASES;DIABETIC NEPHROPATHIES;;ITALY;TREATMENT OUTCOME;ADOLESCENT;FOLLOW-UP STUDIES;HEPATITIS C, CHRONIC;HIV INFECTIONS;KIDNEY;POSTOPERATIVE COMPLICATIONS;STENTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADENOCARCINOMA","76;49;47;38;33;32;16;15;14;14;12;11;11;11;10;10;10;10;9;8","DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;HEPATITIS C INFECTION AND TREATMENT;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;MANAGEMENT AND OUTCOMES OF ACUTE KIDNEY INJURY;MANAGEMENT OF VALVULAR HEART DISEASE;MEDICAL EQUIPMENT MAINTENANCE AND MANAGEMENT;MELANOMA;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY","5;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1","TREATMENT;DILATED CARDIOMYOPATHY;NEURORADIOLOGY;REGIMEN;INTERVENTIONAL RADIOLOGY;HEPATITIS C;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;CORONARY STENTS;DRUG-ELUTING STENTS;LEFT VENTRICULAR FUNCTION;PARENCHYMA;PONS;PRIMARY PREVENTION;SUDDEN CARDIAC DEATH;SUPRAVENTRICULAR TACHYCARDIA;VENTRICULAR RECONSTRUCTION;VENTRICULAR TACHYCARDIA;ABACAVIR;ACROMEGALY","9;7;7;6;5;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2","DILATED CARDIOMYOPATHY;MULTIPLE SCLEROSIS;CARDIOMYOPATHY RESULTS;CISPLATIN VERSUS;CONTRAST MEDIA;IDIOPATHIC DILATED;MAGNETIC RESONANCE;RESONANCE IMAGING;SECONDARY PREVENTION;SUDDEN DEATH;SUSTAINED VENTRICULAR;VENTRICULAR TACHYCARDIA;ACTIVE ANTIRETROVIRAL;ANTIRETROVIRAL THERAPY;CELIAC DISEASE;CHRONIC HEPATITIS;COLOR DOPPLER;COMPUTED TOMOGRAPHY;HEART FAILURE;HIGHLY ACTIVE;MELANOMA PATIENTS;MITRAL VALVE;P- ICD;P- LACK;RENAL INFECTIONS;SEXUAL DYSFUNCTION;VALVE REPAIR;VERSUS VINORELBINE;ACID ANDBLEEDINGTHROMBOSIS;ACROMEGALIC PATIENTS","6;5;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","ANGIOTENSIN II;PUBMED SCOPUS;MITRAL VALVE;CROSSREF PUBMED;RENAL DISEASE;PROXIMAL TUBULAR;PUBMED GOOGLE;TUBULAR CELLS;LVOT OBSTRUCTION;SEPTAL MYECTOMY;SOC NEPHROL;END-STAGE RENAL;NS- N-;VALVE REPAIR;INT -ABSTRACT;LEFT VENTRICULAR;RENAL FUNCTION;GLOMERULAR CAPILLARY;KIDNEY DISEASE;MONTHS FU;OUTFLOW TRACT;POSTERIOR LEAFLET;CHRONIC RENAL;CLIN INVEST;GLOMERULAR FILTRATION;INVEST -CROSSREF;NEPHROL -PUBMED;PROSTHETIC RING;TRACT OBSTRUCTION;ACE INHIBITOR","36;35;20;17;17;12;12;12;11;11;11;10;10;9;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6;5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,5,870.33,2.21,0,0,113.67,0,0,0,0,2,0,1,0,0,3,0,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","3;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;CARDIOVASCULAR;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEART DISEASE;PATIENT SAFETY;RARE DISEASES","2;2;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","2;1","6.1 PHARMACEUTICALS;6.3 MEDICAL DEVICES","2;1","COLON AND RECTAL CANCER;MYELOMA","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIANCONA",2004,114,10.0789473684211,2.46491228070175,0.464912280701754,0.263157894736842,0.578947368421053,1.5414364640884,1.26190476190476,1.36363636363636,1.3469387755102,0.324561403508772,5,60,16,10,15,0.53,0.14,0.09,0.13,58.3,1.23897490183399,NA,0.333333333333333,0.850877192982456,0.438,0.391,0.403,0.397,"JOHN G.F. CLELAND;ANDREA DI LENARDA;GIANFRANCO SINAGRA;WILLEM J. REMME;MARCO METRA;KARL SWEDBERG;CHRISTIAN TORP‐PEDERSEN;BEATRIX LUTIGER;TIZIANO BARBUI;GIUSEPPE REMUZZI;PETER HANRATH;ANDREW CHARLESWORTH;ROBERTO LABIANCA;GASTONE SABBADINI;MICHÈLE MORETTI;MICHEL KOMAJDA;PHILIP A. POOLE‐WILSON;ALESSANDRO RAMBALDI;MASSIMO ZECCHIN;ROBERTO POZZI MUCELLI","11;11;10;10;10;9;8;8;7;6;6;6;6;6;6;6;6;5;4;4","ROBERTO LABIANCA;ROBERTO POZZI MUCELLI;ANDREA DI LENARDA;MASSIMO ZECCHIN;GIANFRANCO SINAGRA;JOHN G.F. CLELAND;MICHELA ZANETTI;WILLEM J. REMME;MARCO METRA;DALLA PALMA L;TIZIANO BARBUI;GIUSEPPE REMUZZI;KARL SWEDBERG;GIANCARLO TIRELLI;M RUSSOLO;BEATRIX LUTIGER;MICHÈLE MORETTI;CHRISTIAN TORP‐PEDERSEN;GASTONE SABBADINI;PIERO RUGGENENTI","1.51;1.45;1.33;1.32;1.27;1.16;1.14;1.04;1.04;1;0.97;0.97;0.93;0.9;0.9;0.86;0.85;0.81;0.8;0.67","ANDREA DI LENARDA;GIANFRANCO SINAGRA;TIZIANO BARBUI;GIUSEPPE REMUZZI;ROBERTO LABIANCA;MICHÈLE MORETTI;ALESSANDRO RAMBALDI;MASSIMO ZECCHIN;ROBERTO POZZI MUCELLI;MICHELE BERTOLOTTO;A DILENARDA;ELISA CARNIEL;AURELIO SONZOGNI;A ALUFFI;CLAUDIO ARICI;CLAUDIO FARINA;EMILIO QUAIA;MARIO STRAZZABOSCO;GIANCARLO TIRELLI;CARMELO MAMMANA","11;10;7;6;6;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3","ROBERTO LABIANCA;ROBERTO POZZI MUCELLI;ANDREA DI LENARDA;MASSIMO ZECCHIN;GIANFRANCO SINAGRA;MICHELA ZANETTI;DALLA PALMA L;TIZIANO BARBUI;GIUSEPPE REMUZZI;GIANCARLO TIRELLI;M RUSSOLO;MICHÈLE MORETTI;PIERO RUGGENENTI;ANTONIO GOGLIO;MICHELE BERTOLOTTO;F BIGONI;ROBERTO COPETTI;RICCARDO GERLONI;EMILIO QUAIA;CLAUDIO FARINA","1.51;1.45;1.33;1.32;1.27;1.14;1;0.97;0.97;0.9;0.9;0.85;0.67;0.64;0.6;0.5;0.5;0.5;0.45;0.41","TIZIANO BARBUI;GIUSEPPE REMUZZI;PIERO RUGGENENTI;BOGDAN ENE‐IORDACHE;GIULIA GHERARDI;MARÍA GANEVA;ANELIYA PARVANOVA;ILIAN ILIEV;ROBERTO TREVISAN;ALESSANDRO ROBERTO DODESINI;ANNA FASSI;ANNALISA PERNA;ANTONIO BOSSI;FEDERICA ARNOLDI;FLAVIO GASPARI;NADIA RUBIS;SIMONA BRUNO;VARUSCA BRUSEGAN;CARLO PATRONO;GIANNI TOGNONI","1301;1257;1217;1172;1172;1172;1046;1046;1046;1002;1002;1002;1002;1002;1002;1002;1002;1002;960;960","GIUSEPPE REMUZZI;TIZIANO BARBUI;PIERO RUGGENENTI;ROBERTO POZZI MUCELLI;MICHELE BERTOLOTTO;ALBERTO SOLANO;ALESSANDRO SALVI;GIANFRANCO SINAGRA;ALESSANDRA MANDOLESI;GUIDALBERTO FABRIS;ITALO BEARZI;MARIO SCARTOZZI;ROSSANA BERARDI;STEFANO CASCINU;D RIPAMONTI;FRANCO MAGGIOLO;G. GREGIS;GIAMPAOLO QUINZAN;ETTORE SQUILLACI;FULVIO STACUL","1256;1224;1217;691;590;466;321;321;256;256;256;256;256;256;223;223;223;223;213;213","ANDREA DI LENARDA;GIANFRANCO SINAGRA;ROBERTO LABIANCA;ALESSANDRO RAMBALDI;GIUSEPPE REMUZZI;PIERO RUGGENENTI;TIZIANO BARBUI;A DILENARDA;MARIO STRAZZABOSCO;MASSIMO ZECCHIN;CARMELO MAMMANA;GIANCARLO TIRELLI;GIORDANO BERETTA;MICHELE BERTOLOTTO;ROBERTO POZZI MUCELLI;ANNA FALANGA;ANTONIO GOGLIO;AURELIO SONZOGNI;CARLO TONDINI;CLAUDIO ARICI","11;8;6;5;5;5;5;4;3;3;3;3;3;3;3;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;ENGINEERING;PSYCHOLOGY;SOCIOLOGY;CHEMISTRY;PHILOSOPHY;POLITICAL SCIENCE;BUSINESS;ECONOMICS;ENVIRONMENTAL SCIENCE;GEOLOGY;MATERIALS SCIENCE","109;23;14;6;5;4;4;4;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;GASTROENTEROLOGY;PATHOLOGY;IMMUNOLOGY;ENDOCRINOLOGY;RADIOLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;ANESTHESIA;ONCOLOGY;VIROLOGY;CANCER RESEARCH;DERMATOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;GENETICS;PSYCHIATRY;UROLOGY","83;38;29;21;17;14;12;12;10;9;8;8;8;7;7;7;6;6;6;6","HEART FAILURE;TRANSPLANTATION;CANCER;DISEASE;METOPROLOL;CHEMOTHERAPY;BIOPSY;COHORT;CONFIDENCE INTERVAL;POPULATION;GENE;MYOCARDIAL INFARCTION;ANTIBODY;BLOOD PRESSURE;DIABETES MELLITUS;LYMPHOMA;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;COMET;COMPLICATION;LESION;ODDS RATIO;THROMBOSIS;VIRUS","21;14;12;10;10;9;8;8;8;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5","CARVEDILOL;DILATED CARDIOMYOPATHY;KIDNEY TRANSPLANTATION;LIVER TRANSPLANTATION;BREAST CANCER;CARDIOMYOPATHY;VIRAL LOAD;COLORECTAL CANCER;EJECTION FRACTION;NEURORADIOLOGY;PLACEBO;UNIVARIATE ANALYSIS;ALPHA INTERFERON;AMPHOTERICIN B;ANTIPHOSPHOLIPID SYNDROME;AZATHIOPRINE;CD8;CISPLATIN;CLONE (JAVA METHOD);CONSTRUCT VALIDITY;CONTRAST-ENHANCED ULTRASOUND;CUMULATIVE INCIDENCE;CYCLOPHOSPHAMIDE;CYTOKERATIN;DEMENTIA;ETOPOSIDE;FLUCONAZOLE;FLUOROURACIL;FOLLICULAR LYMPHOMA;GENOTYPE;GROWTH HORMONE;HAZARD RATIO;HEART RATE;HEART TRANSPLANTATION;HEPATITIS C VIRUS;LIVE BIRTH;LIVER BIOPSY;LUPUS ANTICOAGULANT;METOPROLOL TARTRATE;MONOCLONAL ANTIBODY;MULTICENTER STUDY;MYCOSIS FUNGOIDES;NODULAR MELANOMA;OCTREOTIDE;ORGAN TRANSPLANTATION;POWER DOPPLER;PROTEINURIA;T CELL;TOLERABILITY","12;6;5;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;ACROMEGALY;ALPHA (FINANCE);CETUXIMAB;FLUDARABINE;MONOCLONAL;RIBAVIRIN;SENTINEL LYMPH NODE;SENTINEL NODE;THIOTEPA;ACE INHIBITOR;ADAMTS13;ADJUVANT CHEMOTHERAPY;ANTI-NUCLEAR ANTIBODY;AXILLA;BORRELIA;CARBOPLATIN;CD3;EGFR INHIBITORS;ENOS;ERYTHEMA CHRONICUM MIGRANS;FENOLDOPAM;FLUCYTOSINE;GERMINAL CENTER;GLOMERULOSCLEROSIS;HBSAG;HOUSEKEEPING GENE;IFOSFAMIDE;INTERFERON ALFA;INTERNATIONAL PROGNOSTIC INDEX;KIDNEY TRANSPLANT;LANGERIN;LYME BORRELIOSIS;MAMMOGRAPHY;MEAN ARTERIAL PRESSURE;MECHANICAL INDEX;MISSENSE MUTATION;MULTILOCUS SEQUENCE TYPING;MUTANT PROTEIN;NODULAR REGENERATIVE HYPERPLASIA;PEAK INSPIRATORY PRESSURE;PERIPHERAL T-CELL LYMPHOMA;PRIMARY TUMOR;PROSTATECTOMY;PULSED-FIELD GEL ELECTROPHORESIS;SIDA;T-CELL RECEPTOR;TAKAYASU ARTERITIS;TAKAYASU'S ARTERITIS;TARGET LESION;URINE CYTOLOGY;VASCULAR DEMENTIA;VASCULAR ENDOTHELIAL GROWTH FACTOR A","4;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;AGED;;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;LIVER NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;THROMBOSIS;NEOPLASMS;CARDIOMYOPATHY, DILATED;INTERFERON-ALPHA;MELANOMA;RETROSPECTIVE STUDIES;HEART FAILURE;PROGNOSIS","73;56;52;47;45;37;34;19;18;16;15;13;12;11;10;10;10;10;9;9","DIAGNOSIS AND TREATMENT OF HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MELANOMA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;EFFECTS OF MEDICATION ON PREGNANCY OUTCOMES;FOCUSED ULTRASOUND TECHNOLOGY AND APPLICATIONS;HEPATITIS C INFECTION AND TREATMENT;KIDNEY TRANSPLANTATION;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;MOLECULAR RESEARCH ON BREAST CANCER;POLYPHARMACY AND INAPPROPRIATE MEDICATION USE IN ELDERLY;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME","5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","CARVEDILOL;DILATED CARDIOMYOPATHY;MELANOMA;REGIMEN;TREATMENT;ADVERSE DRUG EVENTS;BETA (PROGRAMMING LANGUAGE);HEPATITIS C;LIVER TRANSPLANTATION;LIVING DONOR LIVER TRANSPLANTATION;MANTLE CELL LYMPHOMA;NEURORADIOLOGY;PREGNANCY;STROKE (ENGINE);UNIVARIATE ANALYSIS;ACROMEGALY;ADHERENCE TO MEDICATION;ADJUVANT CHEMOTHERAPY;ALPHA (FINANCE);ANTIRETROVIRAL THERAPY","12;7;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","HEART FAILURE;CHRONIC HEART;DILATED CARDIOMYOPATHY;PATIENTS TREATED;ATRIAL FIBRILLATION;BREAST CANCER;CD LYMPHOCYTES;CELL TRANSPLANTATION;CHRONIC HEPATITIS;CLINICAL PROFILE;COMET TRIAL;CONTRAST AGENT;FAILURE PATIENTS;FAILURE RESULTS;FOCAL LIVER;GROWTH FACTOR;HYPERTROPHIC CARDIOMYOPATHY;IDIOPATHIC DILATED;ITALIAN PATIENTS;ITALIAN SOCIETY;LIVER LESIONS;LIVER TRANSPLANTATION;MYCOSIS FUNGOIDES;NATURAL HISTORY;NODE BIOPSY;NODULAR-TYPE MELANOMA;ORGAN TRANSPLANTATION;RANDOMIZED TRIAL;RETROSPECTIVE ANALYSIS;RETROSPECTIVE SURVEY","11;5;5;4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADHERENCE RATE;ANTIRETROVIRAL THERAPY;SPLIT LIVER;DELAYED PRESENTATION;PRIMARY TUMORS;ADC VALUES;LIVER TRANSPLANTATION;ORGAN TRANSPLANTATION;PATIENTS RECEIVING;RNA COPIESML;VIROLOGIC FAILURE;ANG II;AORTIC VALVE;DECISIONMAKING PROCESS;EGFR STATUS;LATE TESTING;LOG RNA;MONTH VL;PHYSICIANPATIENT COMMUNICATION;SUBJECTS RECEIVING;ADDITIONAL MONTH;BLOOD CULTURES;BRONCHIAL BIOPSIES;DISEASE PROGRESSION;GENOTYPIC RESISTANCE;HR CI;HUMAN IMMUNODEFICIENCY;IMMUNODEFICIENCY VIRUS;IP REGIMEN;LUNG FUNCTION","8;8;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,7,956,1.24,0,0,87,0,0,1,0,1,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","2;1;1;1","CANCER;CARDIOVASCULAR;CHILDHOOD LEUKEMIA;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;HEMATOLOGY;HYPERTENSION;ORPHAN DRUG;PEDIATRIC;PEDIATRIC CANCER;RARE DISEASES;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;TRANSPLANTATION","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","1;1","6.1 PHARMACEUTICALS","1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA","1;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIANCONA",2005,114,10.4736842105263,2.73684210526316,0.5,0.333333333333333,0.535087719298246,1.37610619469027,1.14,1.2258064516129,1.15094339622642,0.254385964912281,6,67,13,5,17,0.59,0.11,0.04,0.15,47.41,0.89552213121146,NA,0.333333333333333,0.780701754385965,0.45,0.361,0.426,0.361,"TIZIANO BARBUI;ALESSANDRO RAMBALDI;ANDREA ROSSI;STEFANO CASCINU;RENATO BASSAN;GIUSEPPE REMUZZI;GIANFRANCO SINAGRA;ROSSANA BERARDI;ELENA OLDANI;EMILIO QUAIA;MARIA ASSUNTA COVA;M. COLLEDAN;ROBERTO LABIANCA;ANDREA DI LENARDA;MARINO ZORZON;AURELIO SONZOGNI;BRUNO GRIDELLI;PAOLA TORRE;ROBERTO POZZI MUCELLI;FRANCESCA BERNABÈ","12;10;6;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3","RENATO BASSAN;M. COLLEDAN;TIZIANO BARBUI;GIUSEPPE LAZZARI;MATTEO GALLI;GABRIELE POZZATO;ALESSANDRO COSENZI;ALESSANDRO RAMBALDI;FRANCESCA BERNABÈ;UMBERTO LUCANGELO;GIUSEPPE REMUZZI;GIULIO MILANESE;EMILIO QUAIA;MARCO DELLABELLA;GIOVANNI MUZZONIGRO;ROBERTO POZZI MUCELLI;MARIA ASSUNTA COVA;GIULIO GUAGLIUMI;PAOLA TORRE;RITA MORETTI","1.24;1.2;1.13;1;1;1;1;0.99;0.79;0.79;0.69;0.67;0.67;0.67;0.67;0.65;0.63;0.62;0.6;0.6","TIZIANO BARBUI;ALESSANDRO RAMBALDI;ANDREA ROSSI;RENATO BASSAN;GIUSEPPE REMUZZI;GIANFRANCO SINAGRA;ROSSANA BERARDI;ELENA OLDANI;EMILIO QUAIA;MARIA ASSUNTA COVA;M. COLLEDAN;ROBERTO LABIANCA;ANDREA DI LENARDA;MARINO ZORZON;AURELIO SONZOGNI;BRUNO GRIDELLI;PAOLA TORRE;ROBERTO POZZI MUCELLI;FRANCESCA BERNABÈ;GIULIO GUAGLIUMI","12;10;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3","RENATO BASSAN;M. COLLEDAN;TIZIANO BARBUI;GIUSEPPE LAZZARI;MATTEO GALLI;GABRIELE POZZATO;ALESSANDRO COSENZI;ALESSANDRO RAMBALDI;FRANCESCA BERNABÈ;UMBERTO LUCANGELO;GIUSEPPE REMUZZI;GIULIO MILANESE;EMILIO QUAIA;MARCO DELLABELLA;GIOVANNI MUZZONIGRO;ROBERTO POZZI MUCELLI;MARIA ASSUNTA COVA;GIULIO GUAGLIUMI;PAOLA TORRE;RITA MORETTI","1.24;1.2;1.13;1;1;1;1;0.99;0.79;0.79;0.69;0.67;0.67;0.67;0.67;0.65;0.63;0.62;0.6;0.6","TIZIANO BARBUI;GIUSEPPE REMUZZI;PIERO RUGGENENTI;MARTA TURTURRO;ADALBERTO SESSA;ANNALISA PERNA;BOGDAN ENE‐IORDACHE;CARLO BASILE;CARMINE ZOCCALI;DANIELA LEONARDIS;ELENA PERTICUCCI;G GARINI;GIACOMINA LORIGA;GIANBATTISTA SORBA;IVAN NEDIYALKOV CHAKARSKI;MARIADOMENICA LESTI;MARÍA GANEVA;MIRELLA ALPA;RENZO SCANZIANI;GUIDO FINAZZI","887;798;781;651;624;624;624;624;624;624;624;624;624;624;624;624;624;624;624;579","GIUSEPPE REMUZZI;PIERO RUGGENENTI;TIZIANO BARBUI;ELENA PERTICUCCI;GUIDO FINAZZI;GIOVANNI MUZZONIGRO;GIULIO MILANESE;ANTÔNIO ROSSI;C. GREGORETTI;JOHN OSBORN;GIULIO GUAGLIUMI;MARCO DELLABELLA;FRANCESCA BERNABÈ;UMBERTO LUCANGELO;ANDREA ROSSI;ANNA FALANGA;GABRIELE POZZATO;ALESSANDRO RAMBALDI;M. COLLEDAN;GIORDANO BERETTA","780;780;777;624;579;410;410;339;339;339;310;279;272;272;225;187;179;165;154;141","ALESSANDRO RAMBALDI;TIZIANO BARBUI;ANDREA ROSSI;ANDREA DI LENARDA;GIANFRANCO SINAGRA;RENATO BASSAN;EMILIO QUAIA;M. COLLEDAN;VITTORIA GUERINI;ELENA OLDANI;GIORDANO BERETTA;GIUSEPPE REMUZZI;GUIDO FINAZZI;MARIA ASSUNTA COVA;TAMARA INTERMESOLI;ANNA SALVI;AURELIO SONZOGNI;FRANCESCA BERNABÈ;GIULIO GUAGLIUMI;PIERO RUGGENENTI","10;10;6;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;CHEMISTRY;COMPUTER SCIENCE;POLITICAL SCIENCE;PSYCHOLOGY;BUSINESS;MATERIALS SCIENCE;ECONOMICS;GEOLOGY;HISTORY;PHILOSOPHY;SOCIOLOGY","109;25;15;9;8;5;4;4;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;CARDIOLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;ONCOLOGY;PATHOLOGY;PSYCHIATRY;ANESTHESIA;RADIOLOGY;GENETICS;BIOCHEMISTRY;OPTICS;PHARMACOLOGY;UROLOGY;MECHANICAL ENGINEERING;PEDIATRICS;NURSING;CANCER RESEARCH;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE","86;37;20;18;18;14;12;12;12;11;11;10;8;8;8;8;7;7;6;5;5;5","CHEMOTHERAPY;DISEASE;GENE;CANCER;TRANSPLANTATION;HEART FAILURE;REGIMEN;THROMBOSIS;CONFIDENCE INTERVAL;LEUKEMIA;LYMPHOMA;NEUROLOGY;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;IMMUNE SYSTEM;MECHANICAL VENTILATION;MULTIVARIATE ANALYSIS;POPULATION;ADVERSE EFFECT;ANTIBODY;COPD;INCIDENCE (GEOMETRY);RECEPTOR;RESPIRATORY SYSTEM;STAGE (STRATIGRAPHY);ULTRASOUND;VENTILATION (ARCHITECTURE);VIRUS","13;13;12;11;11;9;8;7;6;6;6;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4","COLORECTAL CANCER;HAZARD RATIO;NEURORADIOLOGY;LIVER TRANSPLANTATION;KIDNEY TRANSPLANTATION;PHASES OF CLINICAL RESEARCH;RITUXIMAB;ANTIPHOSPHOLIPID SYNDROME;ANTIPSYCHOTIC;BREAST CANCER;CARVEDILOL;CD8;CENTRAL VENOUS CATHETER;CHEMOTHERAPY REGIMEN;CHROMOSOME;CLINICAL ENDPOINT;COMPLEMENT SYSTEM;CYCLOPHOSPHAMIDE;CYTOTOXIC T CELL;DEMENTIA;DILATED CARDIOMYOPATHY;EJECTION FRACTION;GENOTYPE;GIST;HEPATITIS C VIRUS;HYPEREOSINOPHILIC SYNDROME;IMATINIB;LUNG VOLUMES;LYMPHOBLASTIC LEUKEMIA;METOPROLOL TARTRATE;MICROBUBBLES;NEUTROPENIA;RESPIRATORY PHYSIOLOGY;RNA;T CELL;TAMSULOSIN;THROMBOTIC MICROANGIOPATHY;TIDAL VOLUME;TOLERABILITY;TRANSFECTION;UNIVARIATE ANALYSIS;VENOUS THROMBOSIS;VIRAL LOAD;WORK OF BREATHING","6;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;ATYPICAL HEMOLYTIC UREMIC SYNDROME;IMATINIB MESYLATE;IRINOTECAN;PDGFRA;ACE INHIBITOR;ACUTE LYMPHOCYTIC LEUKEMIA;AKATHISIA;AMPLICON;AUTOIMMUNE REGULATOR;BOSENTAN;CAPECITABINE;CASPOFUNGIN;CD3;CHEMOIMMUNOTHERAPY;CLINICAL PHENOTYPE;COLONOSCOPY;COMPLEMENT FACTOR B;CRYOGLOBULINEMIA;CTL*;CUTANEOUS T-CELL LYMPHOMA;CYCLIN;CYTOGENETICS;CYTOLYSIS;DESMIN;DYNAMIC HYPERINFLATION;ENDOTHELIN RECEPTOR ANTAGONIST;ENDOTHELINS;ENOS;ESOPHAGEAL VARICES;EXCITOTOXICITY;FEBRILE NEUTROPENIA;FLUDARABINE;FOLINIC ACID;FUNCTIONAL RESIDUAL CAPACITY;GERMINAL CENTER;HAPLOTYPE;HISTONE DEACETYLASE;HYPERFRACTIONATION;IDARUBICIN;IMMUNOGLOBULIN M;INTERFERON ALFA;KARYOTYPE;LAMIVUDINE;MACE;MAMMOGRAPHY;MEFLOQUINE;MEMANTINE;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MICROCOCCACEAE;MODIFIED RANKIN SCALE;NEOADJUVANT THERAPY;NITROTYROSINE;OSTEOPENIA;OXALIPLATIN;PANCREATIC DUCTAL ADENOCARCINOMA;PERIPHERAL T-CELL LYMPHOMA;POLYMORPHISM (COMPUTER SCIENCE);PROLYMPHOCYTIC LEUKEMIA;PROTHROMBINASE;RIBAVIRIN;RIBOZYME;RNA EXTRACTION;SCHISTOCYTE;SECOND-HARMONIC IMAGING MICROSCOPY;SHIGA TOXIN;SINGLE-NUCLEOTIDE POLYMORPHISM;SUMATRIPTAN;SYSTOLE;THIOTEPA;THYMIC INVOLUTION;TOLL-LIKE RECEPTOR;VANCOMYCIN;VASCULAR DEMENTIA;VINCRISTINE","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;;ADULT;AGED;ITALY;PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;TREATMENT OUTCOME;COLORECTAL NEOPLASMS;HEART FAILURE;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;FLUOROURACIL;PROSPECTIVE STUDIES;AGED, 80 AND OVER;BRAIN NEOPLASMS;DISEASE PROGRESSION;GLIOBLASTOMA","77;59;56;42;33;33;29;19;16;15;12;11;10;10;10;10;9;9;9;9","LYMPHOID NEOPLASMS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF HEART FAILURE;FOCUSED ULTRASOUND TECHNOLOGY AND APPLICATIONS;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;STANDARDISATION AND MANAGEMENT OF COPD;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;HYPEREOSINOPHILIC SYNDROME AND RELATED DISORDERS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;NEUROPROTECTIVE AGENTS IN BRAIN INJURY AND DISEASES;PATHOPHYSIOLOGY AND MANAGEMENT OF CEREBRAL ANEURYSMS;PREVALENCE AND MANAGEMENT OF KIDNEY STONES;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE","4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","REGIMEN;NEURORADIOLOGY;POSITIVE END-EXPIRATORY PRESSURE;MECHANICAL VENTILATION;PULMONARY DISEASE;RESPIRATORY;TREATMENT;ULTRASOUND CONTRAST AGENTS;ANTIPHOSPHOLIPID SYNDROME;CENTRAL VENOUS CATHETERIZATION;CORONARY STENTS;DRUG-ELUTING STENTS;FOCUSED ULTRASOUND;HEMATOLOGY;HEPATITIS C;INTERVENTIONAL RADIOLOGY;NONINVASIVE VENTILATION;STROKE (ENGINE);ADJUVANT THERAPY;ADRENAL VEIN SAMPLING","8;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2","HEART FAILURE;STEM CELL;PHASE II;ADULT ACUTE;CENTRAL VENOUS;II STUDY;MULTIPLE SCLEROSIS;ACUTE LYMPHOBLASTIC;ACUTE MYELOID;ANTIPHOSPHOLIPID SYNDROME;BONE MARROW;CANCER PATIENTS;CELL LUNG;CELL TRANSPLANTATION;CHRONIC HEART;CHRONIC OBSTRUCTIVE;CLINICAL TRIAL;COLORECTAL CANCER;DILATED CARDIOMYOPATHY;ELDERLY PATIENTS;FAILURE PATIENTS;FOCAL LIVER;HEMOLYTIC UREMIC;IMATINIB MESYLATE;ITALIAN SOCIETY;JAK VALPHE;LIVER TRANSPLANTATION;LOCALLY ADVANCED;LYMPHOBLASTIC LEUKEMIA;MECHANICALLY VENTILATED","5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CROSSREF PUBMED;PUBMED SCOPUS;IMMUNOL -CROSSREF;INNATE IMMUNE;MG PATIENTS;MYASTHENIA GRAVIS;IMMUNE SYSTEM;INVOLUTED THYMUS;TOLL-LIKE RECEPTORS;MRNA LEVELS;APPLIED BIOSYSTEMS;MOUSE MONOCLONAL;MÜLLER-HERMELINK HK;RESPONSE RATE;REV IMMUNOL;THYMUS SPECIMENS;CELLS FIGURE;DISCONTINUATION DUE;HEALTHY THYMUSES;MONOCLONAL ANTIBODY;MYOID CELLS;PUBMED GOOGLE;TLR MRNA;TLR PROTEIN;TLR-POSITIVE CELLS;HIGH-INTENSITY WARFARIN;INNATE IMMUNITY;INVOLUTED THYMUSES;PATHOL -CROSSREF;SERIAL SECTIONS","31;30;12;11;11;11;10;9;9;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;5;5;5;5;5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,6,978,3.72,1,0.12,57.25,0,0,1,1,2,0,1,3,0,6,1,0,0,0,0,0,0,8,0,0,7,1,0,0,0,0,0,0,0,0,"United States;Italy","3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS","8;4;3;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;BIOENGINEERING;BIOTECHNOLOGY;CANCER;CARDIOVASCULAR;DIGESTIVE DISEASES;HEART DISEASE;HEMATOLOGY;NEUROSCIENCES;ORPHAN DRUG;OSTEOPOROSIS;PANCREATIC CANCER;PREVENTION;TRANSPLANTATION","6;4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;BLOOD;CARDIOVASCULAR;MUSCULOSKELETAL;NEUROLOGICAL","2;1;1;1;1","6.1 PHARMACEUTICALS;5.3 MEDICAL DEVICES","3;1","BRAIN TUMOR;LEUKEMIA / LEUKAEMIA;NERVOUS SYSTEM;PANCREATIC CANCER;STOMACH CANCER","1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","3;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIANCONA",2006,169,9.46745562130178,2.79289940828402,0.42603550295858,0.384615384615385,0.615384615384615,1.39349112426035,1.18032786885246,1.41304347826087,1.22352941176471,0.337278106508876,6,97,23,14,13,0.57,0.14,0.08,0.08,46.21,0.904634346865329,NA,0.230769230769231,0.822485207100592,0.421,0.336,0.467,0.384,"ALESSANDRO RAMBALDI;GIANFRANCO SINAGRA;TIZIANO BARBUI;MARIA ASSUNTA COVA;ROBERTO LABIANCA;AURELIO SONZOGNI;GIUSEPPE REMUZZI;ANDREA ROSSI;SERGIO CORTELAZZO;GIOVANNI PULIGNANO;A DILENARDA;GIOVANNI MOSCONI;BRUNO GRIDELLI;MARCO PAULLI;JOSÉE GOLAY;LUCA ARCAINI;MARIA LUISA MELZI;G. TORRE;MARTINO INTRONA;ANTONELLO GAVAZZI","12;10;9;7;7;6;6;6;6;5;5;4;4;4;4;4;4;4;4;4","NULL AUTHOR_ID;GIANFRANCO SINAGRA;MARIA ASSUNTA COVA;ALESSANDRO RAMBALDI;LUCA ARCAINI;ROBERTO LABIANCA;MASSIMO OFFIDANI;TIZIANO BARBUI;GIOVANNI MOSCONI;GIUSEPPE REMUZZI;AURELIO SONZOGNI;GILBERTO PIZZOLATO;MICHELE BERTOLOTTO;FABRIZIO MONTI;A DILENARDA;JOSÉE GOLAY;MARTINO INTRONA;GIOVANNI PULIGNANO;MAJA UKMAR;LAURA SCATI","4;1.32;1.26;1.21;1.15;1.09;1;0.9;0.82;0.74;0.71;0.67;0.67;0.67;0.62;0.57;0.57;0.57;0.51;0.5","ALESSANDRO RAMBALDI;GIANFRANCO SINAGRA;TIZIANO BARBUI;MARIA ASSUNTA COVA;ROBERTO LABIANCA;AURELIO SONZOGNI;GIUSEPPE REMUZZI;ANDREA ROSSI;SERGIO CORTELAZZO;A DILENARDA;GIOVANNI MOSCONI;JOSÉE GOLAY;LUCA ARCAINI;MARIA LUISA MELZI;G. TORRE;MARTINO INTRONA;ANTONELLO GAVAZZI;STEFANO CASCINU;PAOLO FERRAZZI;MICHELE SENNI","12;10;9;7;7;6;6;6;6;5;4;4;4;4;4;4;4;4;4;4","NULL AUTHOR_ID;GIANFRANCO SINAGRA;MARIA ASSUNTA COVA;ALESSANDRO RAMBALDI;LUCA ARCAINI;ROBERTO LABIANCA;MASSIMO OFFIDANI;TIZIANO BARBUI;GIOVANNI MOSCONI;GIUSEPPE REMUZZI;AURELIO SONZOGNI;GILBERTO PIZZOLATO;MICHELE BERTOLOTTO;FABRIZIO MONTI;A DILENARDA;JOSÉE GOLAY;MARTINO INTRONA;MAJA UKMAR;MARIA LUISA MELZI;CARLO TROMBETTA","4;1.32;1.26;1.21;1.15;1.09;1;0.9;0.82;0.74;0.71;0.67;0.67;0.67;0.62;0.57;0.57;0.51;0.5;0.5","VALERIO DE STEFANO;PELLEGRINO MUSTO;GIUSEPPE REMUZZI;MARIO BOCCADORO;ANTONIO PALUMBO;FAUSTO ROSSINI;MÓNICA GALLI;ANNA MARINA LIBERATI;CLOTILDE CANGIALOSI;ELENA ZAMAGNI;EMANUELA MERLA;GIOVANNINO CICCONE;ILARIA AVONTO;LUCIO CATALANO;MANUELA CECCARELLI;MARIA TERESA AMBROSINI;MARIA TERESA PETRUCCI;MARIELLA GRASSO;PATRIZIA FALCO;SARA GALIMBERTI","1211;964;860;831;828;828;828;827;827;827;827;827;827;827;827;827;827;827;827;827","MÓNICA GALLI;TIZIANO BARBUI;GIUSEPPE REMUZZI;PIERO RUGGENENTI;GUIDO FINAZZI;GIULIO GUAGLIUMI;GIUSEPPE LOCATELLI;PAOLO CRAVEDI;SERGIO CORTELAZZO;ANDREA ROSSI;ANDREA DI LENARDA;ALESSANDRO RAMBALDI;G. PAGANI;LIANA CORTESI;M MONTINI;MASCIA ALBIZZI;ROBERTO ATTANASIO;LUCA ARCAINI;MARIO STRAZZABOSCO;GILBERTA GIACCHETTI","828;816;757;718;564;498;474;474;424;388;316;315;225;225;225;225;225;224;214;186","ALESSANDRO RAMBALDI;TIZIANO BARBUI;GIANFRANCO SINAGRA;ROBERTO LABIANCA;ANDREA ROSSI;MARIA ASSUNTA COVA;AURELIO SONZOGNI;ANTONELLO GAVAZZI;GIOVANNI MOSCONI;GIUSEPPE REMUZZI;JOSÉE GOLAY;LUIGI FRIGERIO;MARTINO INTRONA;NULL AUTHOR_ID;PAOLO FERRAZZI;A DILENARDA;ANDREA DI LENARDA;COSIMO OTTOMANO;EMILIO QUAIA;FABRIZIO MONTI","12;9;9;7;6;6;5;4;4;4;4;4;4;4;4;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;MATHEMATICS;COMPUTER SCIENCE;PSYCHOLOGY;PHILOSOPHY;BUSINESS;POLITICAL SCIENCE;SOCIOLOGY;ART;ECONOMICS;MATERIALS SCIENCE","160;33;15;11;10;10;9;9;7;6;5;3;2;2;2","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;ONCOLOGY;CARDIOLOGY;IMMUNOLOGY;PATHOLOGY;RADIOLOGY;INTENSIVE CARE MEDICINE;GENETICS;BIOCHEMISTRY;UROLOGY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;VIROLOGY;OPTICS;ANESTHESIA;PALEONTOLOGY;PSYCHIATRY;ENDOCRINOLOGY","125;49;37;29;28;27;25;22;15;14;12;11;9;9;9;8;7;7;7;6","TRANSPLANTATION;CANCER;CHEMOTHERAPY;HEART FAILURE;ANTIBODY;LYMPHOMA;GENE;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;POPULATION;RADIATION THERAPY;VIRUS;ALTERNATIVE MEDICINE;IMMUNE SYSTEM;IMMUNOSUPPRESSION;INCIDENCE (GEOMETRY);MULTIVARIATE ANALYSIS;STAGE (STRATIGRAPHY);ULTRASOUND;ADVERSE EFFECT;ATRIAL FIBRILLATION;BONE MARROW;COMPLICATION;DIABETES MELLITUS;DISEASE;IN VITRO;LEUKEMIA;OBSERVATIONAL STUDY;POLYCYTHEMIA VERA;PROSPECTIVE COHORT STUDY;SIROLIMUS","24;22;21;19;14;14;13;10;8;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5","LIVER TRANSPLANTATION;COLORECTAL CANCER;B CELL;BREAST CANCER;CARDIOMYOPATHY;RITUXIMAB;TACROLIMUS;AUTOANTIBODY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CLINICAL ENDPOINT;CYCLOPHOSPHAMIDE;HAZARD RATIO;MELPHALAN;UNIVARIATE ANALYSIS;ADENOCARCINOMA;CD8;CHEMOTHERAPY REGIMEN;CHRONIC LYMPHOCYTIC LEUKEMIA;CISPLATIN;DIASTOLE;DILATED CARDIOMYOPATHY;ESSENTIAL THROMBOCYTHEMIA;HEART TRANSPLANTATION;HEPATITIS C VIRUS;IMATINIB;KIDNEY TRANSPLANTATION;OVARIAN CANCER;PERIPHERAL BLOOD MONONUCLEAR CELL;SALVAGE THERAPY;THALIDOMIDE;THROMBOCYTOSIS;VIRAL DISEASE","9;7;6;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","MARGINAL ZONE;CD3;OXALIPLATIN;BASILIXIMAB;BORRELIA;CARBOPLATIN;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY;DOPPLER ECHOCARDIOGRAPHY;FLUDARABINE;HBSAG;IMATINIB MESYLATE;MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY;MECHANICAL INDEX;RESTRICTIVE CARDIOMYOPATHY;ACE INHIBITOR;ACROMEGALY;ACUTE PROMYELOCYTIC LEUKEMIA;ADJUVANT CHEMOTHERAPY;ALPHA (FINANCE);ANAGRELIDE;ANTHRACYCLINE;ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY;ANTIRETROVIRAL THERAPY;ATRIAL TACHYCARDIA;BORRELIA BURGDORFERI INFECTION;CAPECITABINE;CARMUSTINE;CASPOFUNGIN;CELL MEDIATED IMMUNITY;CLADE;CONGENITAL HEPATIC FIBROSIS;CORONARY RESTENOSIS;CYTOGENETICS;DESTINATION THERAPY;DISKECTOMY;DISTANT METASTASIS;DRUG-ELUTING STENT;ECHINOCANDIN;ENALAPRIL;ESOPHAGOGASTRIC JUNCTION;EVANS SYNDROME;EXHALED NITRIC OXIDE;FLUORESCENCE IN SITU HYBRIDIZATION;FULMINANT HEPATIC FAILURE;FUNCTIONAL MITRAL REGURGITATION;GASTRIC ADENOCARCINOMA;GASTROESOPHAGEAL JUNCTION;GASTROINTESTINAL CANCER;GENOTYPING;GERMINAL CENTER;HAPLOTYPE;HERPESVIRIDAE;HISTONE DEACETYLASE;HORMONAL THERAPY;HYPERFRACTIONATION;IBRUTINIB;IFOSFAMIDE;IGHV@;INTERNATIONAL PROGNOSTIC INDEX;INTRAPERITONEAL CHEMOTHERAPY;IRINOTECAN;ISCHEMIC CARDIOMYOPATHY;LAMIVUDINE;LEFT ATRIAL MYXOMA;LENTIVIRUS;LIVING DONOR LIVER TRANSPLANTATION;LOWER URINARY TRACT SYMPTOMS;MASTECTOMY;MEAN ARTERIAL PRESSURE;METHYLENETETRAHYDROFOLATE REDUCTASE;MUCOSA-ASSOCIATED LYMPHOID TISSUE;NEOADJUVANT THERAPY;OCCUPATIONAL ACCIDENT;PAIN LADDER;PANCREAS DIVISUM;PHILADELPHIA CHROMOSOME;PLEURAL DISEASE;POLYCYSTIC LIVER DISEASE;POLYMORPHISM (COMPUTER SCIENCE);PROSTATITIS;PROTEUS;PROTEUS MIRABILIS;RIBAVIRIN;RUXOLITINIB;SCHISTOSOMA MANSONI;SEROSTATUS;SIDA;SPIROCHAETACEAE;SPLENIC MARGINAL ZONE LYMPHOMA;SUPRACLAVICULAR LYMPH NODES;TARGET LESION;THYMIDYLATE SYNTHASE;TOTAL BODY IRRADIATION;TWO-DIMENSIONAL GEL ELECTROPHORESIS;VARICOCELE","5;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;MIDDLE AGED;AGED;ADULT;TREATMENT OUTCOME;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;PROSPECTIVE STUDIES;HEART FAILURE;LYMPHOMA, B-CELL;AGED, 80 AND OVER;FOLLOW-UP STUDIES;HEPATITIS C;LIVER TRANSPLANTATION;BREAST NEOPLASMS;RETROSPECTIVE STUDIES;SIROLIMUS","102;74;73;63;58;50;43;24;23;20;18;16;15;14;14;14;14;12;12;12","LYMPHOID NEOPLASMS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;DIAGNOSIS AND TREATMENT OF HEART FAILURE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;HEPATITIS C INFECTION AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;GASTRIC CANCER RESEARCH AND TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GYNECOLOGIC ONCOLOGY","9;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","TREATMENT;IMMUNOSUPPRESSION;DILATED CARDIOMYOPATHY;SIROLIMUS;AUTOLOGOUS STEM-CELL TRANSPLANTATION;B-CELL RECEPTOR SIGNALING;CARDIAC IMAGING;CLINICAL ENDPOINT;LIVER DISEASE;LIVER TRANSPLANTATION;MELPHALAN;UNIVARIATE ANALYSIS;ADJUVANT CHEMOTHERAPY;ADJUVANT THERAPY;CHEMOTHERAPY REGIMEN;HEPATITIS C;INTERNATIONAL MYELOMA WORKING GROUP;MANTLE CELL LYMPHOMA;NEOADJUVANT THERAPY;PAIN MANAGEMENT","8;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","HEART FAILURE;CELL TRANSPLANTATION;LIVER TRANSPLANTATION;STEM CELL;AUTOLOGOUS STEM;BREAST CANCER;CANCER PATIENTS;DILATED CARDIOMYOPATHY;DOSE MG;MARGINAL ZONE;MULTICENTER STUDY;OBSERVATIONAL STUDY;OVARIAN CANCER;PHASE II;POLYCYTHEMIA VERA;ALLOGENEIC STEM;ATRIAL FIBRILLATION;B-CELL LYMPHOMAS;B-CELL NON-HODGKINS;BONE MARROW;CHRONIC MYELOID;CLINICAL REMISSION;COMPUTED TOMOGRAPHY;CONCOMITANT RADIOTHERAPY;CONDITIONING ALLOGENEIC;CONVENTIONAL RADIOTHERAPY;CORD BLOOD;CYTOKINE INDUCED;DERIVED CYTOKINE;DOPPLER ECHOCARDIOGRAPHIC","12;6;6;6;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;ATRIAL SEPTAL;CARDIAC PERFORATION;AMPLATZER SEPTAL;SEPTAL DEFECTS;CARDIOVASC INTERV;INTERV -CROSSREF;SEPTAL OCCLUDER;PATENT FORAMEN;CARDIOL -ABSTRACT;COLL CARDIOL;SECUNDUM ATRIAL;ATRIAL WALL;BASS JL;CHEATHAM JP;CS EROSION;DEFECTS REVIEW;FUTURE RISKCATHETER;HIGH-FREQUENCY PERCUSSIVE;HIJAZI ZM;JL CHEATHAM;JP HELLENBRAND;KLEINMAN CS;LATE CARDIAC;MINIMIZE FUTURE;OCCLUDER DEVICE;PULMONARY EMBOLISM;RISKCATHETER CARDIOVASC;SEPTAL DEFECT","69;43;35;30;28;22;21;21;19;15;14;13;13;12;12;12;12;12;12;12;12;12;12;12;12;12;12;12;12;12",1,0.01,3,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,47,48,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,3.29,585.8,3.37,0,0,38.36,0,0,4,0,3,0,3,1,0,4,1,0,0,0,0,0,0,10,0,1,5,6,0,0,0,0,0,0,0,0,"Germany;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;41 ENVIRONMENTAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","11;5;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NEUROSCIENCES;BRAIN DISORDERS;CARDIOVASCULAR;NEURODEGENERATIVE;PATIENT SAFETY;ATHEROSCLEROSIS;CANCER;DIABETES;DRUG ABUSE (NIDA ONLY);EMERGING INFECTIOUS DISEASES;EPILEPSY;HEART DISEASE;LUNG;PARKINSON'S DISEASE;STROKE;SUBSTANCE MISUSE","5;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE","3;2;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","7;1","MYELOMA;COLON AND RECTAL CANCER;GASTROINTESTINAL TRACT;LUNG CANCER","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;1.4 CANCER PROGRESSION AND METASTASIS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIANCONA",2007,177,9.84180790960452,3.19774011299435,0.418079096045198,0.389830508474576,0.502824858757062,1.60339943342776,1.1044776119403,1.81578947368421,1.09876543209877,0.299435028248588,2,101,41,10,11,0.57,0.23,0.06,0.06,57.38,1.08720897611764,NA,0.322033898305085,0.796610169491525,0.481,0.435,0.484,0.427,"M. COLLEDAN;MARIA LUISA MELZI;TIZIANO BARBUI;G. TORRE;P. STROPPA;D. PINELLI;ALESSANDRO RAMBALDI;M. CANDUSSO;V. CORNO;MARIA ASSUNTA COVA;ROBERTO LABIANCA;M. BRAVI;A. LUCIANETTI;M. GUIZZETTI;M. ZAMBELLI;GIUSEPPE REMUZZI;M. BOSISIO;FREDY SUTER;S. FAGIUOLI;MARIO STRAZZABOSCO","15;12;11;10;10;10;10;10;9;9;9;9;8;8;7;7;7;7;7;6","ROBERTO LABIANCA;TIZIANO BARBUI;M. COLLEDAN;MARIA ASSUNTA COVA;MARIA LUISA MELZI;GIUSEPPE REMUZZI;SALVATORE SIRACUSANO;GIUSEPPE DI LORENZO;P. STROPPA;G. TORRE;M. CANDUSSO;M. BRAVI;D. PINELLI;ALESSANDRO RAMBALDI;M. BOSISIO;FREDY SUTER;UGO PAOLO GUERRA;GIANFRANCO SINAGRA;MARIO STRAZZABOSCO;GUIDO FINAZZI","1.7;1.45;1.39;1.12;1.09;1.05;1;1;0.97;0.93;0.93;0.88;0.81;0.81;0.76;0.72;0.72;0.7;0.7;0.7","M. COLLEDAN;MARIA LUISA MELZI;TIZIANO BARBUI;G. TORRE;P. STROPPA;D. PINELLI;ALESSANDRO RAMBALDI;M. CANDUSSO;V. CORNO;MARIA ASSUNTA COVA;ROBERTO LABIANCA;M. BRAVI;A. LUCIANETTI;M. GUIZZETTI;M. ZAMBELLI;GIUSEPPE REMUZZI;M. BOSISIO;FREDY SUTER;S. FAGIUOLI;MARIO STRAZZABOSCO","15;12;11;10;10;10;10;10;9;9;9;9;8;8;7;7;7;7;7;6","ROBERTO LABIANCA;TIZIANO BARBUI;M. COLLEDAN;MARIA ASSUNTA COVA;MARIA LUISA MELZI;GIUSEPPE REMUZZI;SALVATORE SIRACUSANO;GIUSEPPE DI LORENZO;P. STROPPA;G. TORRE;M. CANDUSSO;M. BRAVI;D. PINELLI;ALESSANDRO RAMBALDI;M. BOSISIO;FREDY SUTER;UGO PAOLO GUERRA;GIANFRANCO SINAGRA;MARIO STRAZZABOSCO;GUIDO FINAZZI","1.7;1.45;1.39;1.12;1.09;1.05;1;1;0.97;0.93;0.93;0.88;0.81;0.81;0.76;0.72;0.72;0.7;0.7;0.7","TIZIANO BARBUI;ALESSANDRO RAMBALDI;FREDY SUTER;VITTORIA GUERINI;GIOVANNI BAROSI;ALBERTO BOSI;ALESSANDRO M. VANNUCCHI;PAOLA GUGLIELMELLI;ELISABETTA ANTONIOLI;G. MAZZELLA;PIETRO ANDREONÉ;TERESA SANTANTONIO;S. FAGIUOLI;GUIDO FINAZZI;ROBERTO MARCHIOLI;ROSA MARIA MARFISI;ALESSANDRA MANGIA;ANTONIO ASCIONE;F PICCININO;GIOVANNI BATTISTA GAETA","1709;1313;1160;1132;815;812;797;797;795;669;669;669;629;626;616;616;609;609;609;609","TIZIANO BARBUI;ALESSANDRO RAMBALDI;VITTORIA GUERINI;FREDY SUTER;GUIDO FINAZZI;S. FAGIUOLI;LUIGI NALDI;ROBERTO LABIANCA;JOSÉE GOLAY;A. PEZZAROSSA;ELIANA GOTTI;STEFANO GASPARINI;FRANCA DORE;MARTINO INTRONA;VALENTINA BARBUI;ALDO SALVI;UGO PAOLO GUERRA;MAURIZIO FONDA;MASSIMO GALLI;STEFANO CASCINU","1701;1313;1132;998;626;609;516;403;373;346;334;318;267;261;261;256;237;235;214;200","M. COLLEDAN;TIZIANO BARBUI;ALESSANDRO RAMBALDI;ROBERTO LABIANCA;MARIA ASSUNTA COVA;FREDY SUTER;JOSÉE GOLAY;VITTORIA GUERINI;UGO PAOLO GUERRA;FRANCO MAGGIOLO;GIANFRANCO SINAGRA;GUIDO FINAZZI;MARIA GRAZIA ALESSIO;STEFANO CASCINU;ROSSANA BERARDI;ANNAPAOLA CALLEGARO;AURELIO SONZOGNI;BARTOLO ZINGONE;DIEGO RIPAMONTI;ELIANA GOTTI","14;10;10;9;8;7;5;5;5;4;4;4;4;4;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PSYCHOLOGY;PHYSICS;ENGINEERING;PHILOSOPHY;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;ART;BUSINESS;HISTORY;MATERIALS SCIENCE","170;47;16;13;11;6;5;3;2;2;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;IMMUNOLOGY;PATHOLOGY;RADIOLOGY;GENETICS;ONCOLOGY;CARDIOLOGY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;PALEONTOLOGY;PEDIATRICS;CANCER RESEARCH;PSYCHIATRY;PHARMACOLOGY;MEDICAL PHYSICS;NUCLEAR MEDICINE;VIROLOGY","130;42;38;27;25;25;24;23;22;17;17;14;11;11;10;10;9;8;8;8","TRANSPLANTATION;CANCER;DISEASE;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;HEART FAILURE;LIVER DISEASE;ANTIBODY;CIRRHOSIS;COHORT;HUMAN IMMUNODEFICIENCY VIRUS (HIV);RANDOMIZED CONTROLLED TRIAL;PROSPECTIVE COHORT STUDY;REGIMEN;VIRUS;CLINICAL TRIAL;NEUROLOGY;PREGNANCY;CYSTIC FIBROSIS;EPILEPSY;KIDNEY;LUNG;LYMPHOMA;MYOCARDIAL INFARCTION;POLYCYTHEMIA VERA;POPULATION;RECEPTOR;STAGE (STRATIGRAPHY)","24;23;18;18;17;11;11;11;10;9;9;8;8;7;7;7;6;6;6;5;5;5;5;5;5;5;5;5;5","LIVER TRANSPLANTATION;VIRAL LOAD;HAZARD RATIO;DEMENTIA;BREAST CANCER;COLORECTAL CANCER;ESSENTIAL THROMBOCYTHEMIA;MUTATION;NEURORADIOLOGY;EPIDERMAL GROWTH FACTOR RECEPTOR;GEMCITABINE;METASTASIS;PORTAL HYPERTENSION;ADENOCARCINOMA;ALAGILLE SYNDROME;CARVEDILOL;CHRONIC LIVER DISEASE;CISPLATIN;CLINICAL ENDPOINT;FOLLICULAR LYMPHOMA;HISTONE;INSULIN RESISTANCE;PANCREATIC CANCER;RITUXIMAB;TEMPORAL LOBE","18;9;8;7;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;BILIARY ATRESIA;CONGENITAL HEPATIC FIBROSIS;EGFR INHIBITORS;HISTONE DEACETYLASE;LAMIVUDINE;PARAHIPPOCAMPAL GYRUS;CETUXIMAB;COGNITIVE DECLINE;DONEPEZIL;ERLOTINIB;FULMINANT HEPATIC FAILURE;IRINOTECAN;METASTATIC BREAST CANCER;MILAN CRITERIA;ORTHOTOPIC LIVER TRANSPLANTATION;REVERSE TRANSCRIPTASE;RIBAVIRIN;ABDOMINOPERINEAL RESECTION;ABL;ACROMEGALY;ACUTE LYMPHOCYTIC LEUKEMIA;ALPHA (FINANCE);ANGIOTENSIN RECEPTOR BLOCKERS;ANTHRACYCLINE;ANTI-NUCLEAR ANTIBODY;ANTI-THYROID AUTOANTIBODIES;AUTOIMMUNE THYROIDITIS;BILIARY TRACT CANCER;BISHOP SCORE;BREAST CARCINOMA;CATENIN;CHROMOSOME INSTABILITY;CLINICAL DEMENTIA RATING;CMIN;CONTRAST-INDUCED NEPHROPATHY;CRITICAL ILLNESS POLYNEUROPATHY;CROSSOVER STUDY;CRYOGLOBULINEMIA;CXCR4;CYCLIN D1;CYTOGENETICS;DEFIBROTIDE;DEMENTIA WITH LEWY BODIES;DIASTOLIC HEART FAILURE;DISEASE MANAGEMENT;DYSCRASIA;ENDOMYSIUM;ENDOVASCULAR ANEURYSM REPAIR;EPIRUBICIN;EXCITATORY AMINO-ACID TRANSPORTER;FEBRILE NEUTROPENIA;FLUORESCENCE IN SITU HYBRIDIZATION;FOLINIC ACID;FORAMEN OVALE (HEART);GEFITINIB;GERMLINE MUTATION;GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE;GROWTH HORMONE RECEPTOR;HBSAG;HEPATOPULMONARY SYNDROME;HERPESVIRIDAE;IIF;IMATINIB MESYLATE;IN SITU HYBRIDIZATION;INSULIN SENSITIVITY;LACUNAR STROKE;LARGE CELL;LEFT ATRIAL ENLARGEMENT;LEUKOARAIOSIS;LOSS OF HETEROZYGOSITY;MACULOPATHY;MALE BREAST CANCER;MALE INFERTILITY;MAMMARY GLAND;MAMMOGRAPHY;MARGINAL ZONE;MEMBRANOUS NEPHROPATHY;MISSENSE MUTATION;MONOCLONAL;MUCOSA-ASSOCIATED LYMPHOID TISSUE;MULTICENTER TRIAL;OCCUPATIONAL INJURY;OLIGOHYDRAMNIOS;OXALIPLATIN;P-SELECTIN;PDGFRA;PEROXYNITRITE;PLASMA CELL DYSCRASIA;PLATELET-POOR PLASMA;PRIMARY TUMOR;PROSTATECTOMY;PULMONARY HYPOPLASIA;RETINOBLASTOMA PROTEIN;RYANODINE RECEPTOR 2;SEMEN ANALYSIS;SEVERE SEPSIS;SHORT QT SYNDROME;SODIUM CHANNEL BLOCKER;SPIRILLACEAE;STEATOHEPATITIS;STROKE VOLUME;SUBLINGUAL IMMUNOTHERAPY;TAKOTSUBO SYNDROME;THROMBOMODULIN;UREA BREATH TEST;VASCULAR DEMENTIA;VINCRISTINE;ZEAXANTHIN","8;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;;AGED;ADULT;TREATMENT OUTCOME;HIV INFECTIONS;AGED, 80 AND OVER;HEART FAILURE;POLYCYTHEMIA VERA;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES;VENTRICULAR DYSFUNCTION, LEFT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;THROMBOCYTHEMIA, ESSENTIAL;CARDIOVASCULAR DISEASES;INFLAMMATION","114;80;79;62;57;53;50;23;22;19;15;14;14;14;14;13;12;12;11;11","LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;LYMPHOID NEOPLASMS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;HEPATITIS C INFECTION AND TREATMENT;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;PATHOGENESIS AND MANAGEMENT OF BILIARY ATRESIA;;ADVANCEMENTS IN LUNG CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ENHANCING WORKPLACE SAFETY CULTURE AND PRACTICES;FOCUSED ULTRASOUND TECHNOLOGY AND APPLICATIONS","7;7;6;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","LIVER TRANSPLANTATION;LIVER DISEASE;TREATMENT;LIVING DONOR LIVER TRANSPLANTATION;REGIMEN;ANTIRETROVIRAL THERAPY;JAK2 MUTATION;NEURORADIOLOGY;CARDIAC IMAGING;HIV;IMMUNOSUPPRESSION;INBORN ERRORS OF METABOLISM;MEMORY IMPAIRMENT;POLYCYTHEMIA VERA;ALAGILLE SYNDROME;CARVEDILOL;CEREBRAL HYPOPERFUSION;CHRONIC LIVER DISEASE;CLINICAL ENDPOINT;COMPUTED TOMOGRAPHY ANGIOGRAPHY","15;11;10;8;7;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3","LIVER TRANSPLANTATION;HEART FAILURE;CANCER PATIENTS;ESSENTIAL THROMBOCYTHEMIA;POLYCYTHEMIA VERA;DEACETYLASE INHIBITOR;HISTONE DEACETYLASE;STEM CELL;BREAST CANCER;CELL TRANSPLANTATION;CHRONIC HEPATITIS;COGNITIVE IMPAIRMENT;COHORT STUDY;CYSTIC FIBROSIS;HEPATOCELLULAR CARCINOMA;INHIBITOR ITF;MILD COGNITIVE;MULTIPLE MYELOMA;PANCREATIC CANCER;ADEFOVIR MONOTHERAPY;ALZHEIMERS DISEASE;AMNESTIC MILD;CELIAC DISEASE;CELL PROLIFERATION;CEREBRAL PERFUSION;CHILDREN MORTALITY;CHRONIC HEART;CLINICAL COHORT;CLINICAL INDICATIONS;CLINICAL SIGNIFICANCE","11;7;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","HEART FAILURE;HR CI;INSULIN RESISTANCE;LPS MICE;HAZARD RATIO;PANCREATIC CANCER;VF JAK;CONFIDENCE INTERVAL;ENTERIC-COATED FORMULATION;HEART BLOCK;MYCOPHENOLIC ACID;CD T-CELL;JAK MUTATION;JAK VGTF;MYCOPHENOLATE MOFETIL;RATIO HR;SINGLE DOSE;VIROLOGICAL RESPONSE;ADHERENCE RATE;CHRONIC HEART;CONGENITAL HEART;MULTIVARIATE ANALYSIS;SONOGRAPHIC CL;BMIPP SUMMED;CELL DEPLETION;CLASS NYHA;FABRY PATIENTS;HISTOLOGICALLY PROVEN;JAK CARRIERS;LEFT VENTRICULAR","10;9;9;9;8;8;8;7;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4",1,0.01,6,2,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,0,81,81,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,4.6,935.4,2.19,1,0.14,27.29,0,1,1,0,3,0,2,0,0,5,0,0,0,0,0,0,0,7,0,0,5,2,0,0,0,0,0,0,0,0,"Italy","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY","7;4;2;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;CANCER;CARDIOVASCULAR;COLO-RECTAL CANCER;ASSISTIVE TECHNOLOGY;BIOENGINEERING;BIOTECHNOLOGY;CHRONIC PAIN;HEART DISEASE;KIDNEY DISEASE;ORPHAN DRUG;PAIN RESEARCH;PATIENT SAFETY;RARE DISEASES","5;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL","2;2;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.3 MEDICAL DEVICES;6.4 SURGERY","3;1;1;1","COLON AND RECTAL CANCER;MELANOMA;NOT SITE-SPECIFIC CANCER;SARCOMA","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIANCONA",2008,171,9.37426900584795,2.78947368421053,0.39766081871345,0.333333333333333,0.432748538011696,1.48286604361371,1.33333333333333,1.39024390243902,1.29824561403509,0.368421052631579,4,94,29,15,11,0.55,0.17,0.09,0.06,39.19,0.714157071949894,NA,0.292397660818713,0.818713450292398,0.438,0.391,0.458,0.395,"GIANFRANCO SINAGRA;ROBERTO LABIANCA;GIUSEPPE REMUZZI;M. COLLEDAN;A DILENARDA;ALESSANDRO RAMBALDI;MICHELE BERTOLOTTO;MARCO MERLO;MASSIMO PUOTI;ATTILIO IACOVONI;BRUNO PINAMONTI;ALBERTO PIVETTA;G. BARBATI;IRENE FLORIANI;FRANCESCO DI COSTANZO;STYLIANOS A. PYXARAS;EMILIO QUAIA;ROBERTA ZAPPETTI;MARIA ASSUNTA COVA;MONICA AIROLDI","13;13;8;8;8;7;7;7;6;5;5;5;4;4;4;4;4;4;4;4","GIANFRANCO SINAGRA;ROBERTO LABIANCA;MARCO CONFALONIERI;MICHELE BERTOLOTTO;FULVIO STACUL;GUIDO FINAZZI;A DILENARDA;GENNARO LIGUORI;GIUSEPPE REMUZZI;MARCO MERLO;ROBERTA ZAPPETTI;M. COLLEDAN;VITTORIO ANTONAGLIA;MARIO MANDALÁ;ATTILIO IACOVONI;EMILIO QUAIA;BRUNO PINAMONTI;ALBERTO PIVETTA;MARIA CHIARA SGHIRLANZONI;WALTER A. ZIN","1.69;1.63;1.5;1.39;1.23;1.05;1.02;1;0.93;0.88;0.85;0.8;0.78;0.74;0.71;0.65;0.62;0.62;0.61;0.58","GIANFRANCO SINAGRA;ROBERTO LABIANCA;GIUSEPPE REMUZZI;M. COLLEDAN;A DILENARDA;ALESSANDRO RAMBALDI;MICHELE BERTOLOTTO;MARCO MERLO;ATTILIO IACOVONI;BRUNO PINAMONTI;ALBERTO PIVETTA;IRENE FLORIANI;FRANCESCO DI COSTANZO;STYLIANOS A. PYXARAS;EMILIO QUAIA;ROBERTA ZAPPETTI;MARIA ASSUNTA COVA;MONICA AIROLDI;LUIGI NALDI;FRANCO MAGGIOLO","13;13;8;8;8;7;7;7;5;5;5;4;4;4;4;4;4;4;4;4","GIANFRANCO SINAGRA;ROBERTO LABIANCA;MARCO CONFALONIERI;MICHELE BERTOLOTTO;FULVIO STACUL;GUIDO FINAZZI;A DILENARDA;GENNARO LIGUORI;GIUSEPPE REMUZZI;MARCO MERLO;ROBERTA ZAPPETTI;M. COLLEDAN;VITTORIO ANTONAGLIA;MARIO MANDALÁ;ATTILIO IACOVONI;EMILIO QUAIA;BRUNO PINAMONTI;ALBERTO PIVETTA;MARIA CHIARA SGHIRLANZONI;WALTER A. ZIN","1.69;1.63;1.5;1.39;1.23;1.05;1.02;1;0.93;0.88;0.85;0.8;0.78;0.74;0.71;0.65;0.62;0.62;0.61;0.58","GIUSEPPE REMUZZI;ALESSANDRO RAMBALDI;ROBERTO LABIANCA;TIZIANO BARBUI;MARINA NORIS;ALESSANDRO M. VANNUCCHI;MARCO RUGGERI;PAOLA GUGLIELMELLI;MARINA MORIGI;NADIA AZZOLLINI;AURELIO SONZOGNI;BARBARA IMBERTI;DANIELA CUGINI;FEDERICA CASIRAGHI;MARTA TODESCHINI;NORBERTO PERICO;PAOLA CASSIS;REGIANE APARECIDA CAVINATO;SAMANTHA SOLINI;ALBERTO BOSI","944;830;618;580;579;557;557;557;482;482;416;416;416;416;416;416;416;416;416;408","ALESSANDRO RAMBALDI;ROBERTO LABIANCA;GIUSEPPE REMUZZI;TIZIANO BARBUI;AURELIO SONZOGNI;CATERINA MICÒ;GUIDO FINAZZI;R BARCELLONA;EMILIO QUAIA;VITTORIA GUERINI;MAURO GORI;PAOLO CRAVEDI;GIANFRANCO SINAGRA;FEDERICA DELAINI;EUGENIA CAGGESE;ELENA PERTICUCCI;VINCENZO GAMBARA;BRUNO FABRIS;NADIA RENZI;DANIELA CORNA","830;618;583;580;416;359;350;312;272;271;264;262;247;220;208;198;198;195;183;163","ROBERTO LABIANCA;GIANFRANCO SINAGRA;A DILENARDA;ALESSANDRO RAMBALDI;M. COLLEDAN;GIUSEPPE REMUZZI;MICHELE BERTOLOTTO;A. GAMBA;ATTILIO IACOVONI;EMILIO QUAIA;ROBERTA ZAPPETTI;FRANCO MAGGIOLO;FULVIO STACUL;GABRIELE GRASSI;ANTONELLO GAVAZZI;MARIA ASSUNTA COVA;MICHELE TRIGGIANI;MONICA AIROLDI;PAOLO CRAVEDI;PIERO RUGGENENTI","13;13;8;7;7;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;MATHEMATICS;ENGINEERING;PSYCHOLOGY;ECONOMICS;MATERIALS SCIENCE;SOCIOLOGY;ART;BUSINESS;POLITICAL SCIENCE;GEOLOGY;HISTORY","165;38;19;14;11;10;8;8;6;5;3;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;PATHOLOGY;IMMUNOLOGY;CARDIOLOGY;ENDOCRINOLOGY;GENETICS;ONCOLOGY;RADIOLOGY;PEDIATRICS;PSYCHIATRY;VIROLOGY;ENVIRONMENTAL HEALTH;QUANTUM MECHANICS;ANESTHESIA;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;CANCER RESEARCH;NUCLEAR MEDICINE;PHARMACOLOGY","130;44;30;30;29;27;18;18;17;17;15;11;11;10;10;9;9;9;8;7;7","TRANSPLANTATION;CANCER;GENE;CHEMOTHERAPY;HEART FAILURE;DISEASE;DIABETES MELLITUS;ADVERSE EFFECT;KIDNEY;VIRUS;ANTIBODY;CONFIDENCE INTERVAL;POPULATION;RANDOMIZED CONTROLLED TRIAL;BLOOD PRESSURE;COHORT;HEPATITIS C;HUMAN IMMUNODEFICIENCY VIRUS (HIV);NEUROLOGY;TERM (TIME)","19;17;16;15;14;12;10;9;9;9;8;8;8;8;7;7;7;7;7;7","LIVER TRANSPLANTATION;DILATED CARDIOMYOPATHY;CARDIOMYOPATHY;EJECTION FRACTION;HEPATITIS C VIRUS;COLORECTAL CANCER;GENOTYPE;NEURORADIOLOGY;TACROLIMUS;VIRAL LOAD;BREAST CANCER;CISPLATIN;CYCLOPHOSPHAMIDE;CHROMOSOMAL TRANSLOCATION;CLINICAL ENDPOINT;DIABETIC NEPHROPATHY;HAZARD RATIO;MUTATION;NEPHROPATHY;PHENOTYPE;RITUXIMAB","11;8;7;6;6;5;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3","DACLIZUMAB;RIBAVIRIN;ANTIRETROVIRAL THERAPY;BREAKPOINT;CARDIAC RESYNCHRONIZATION THERAPY;ISCHEMIC CARDIOMYOPATHY;LIVING DONOR LIVER TRANSPLANTATION;MIGRAINE WITH AURA;VAGUS NERVE STIMULATION;VINCRISTINE;ACE INHIBITOR;ACROMEGALY;ANTHRACYCLINE;ANTI-NUCLEAR ANTIBODY;ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY;ANTIGEN PRESENTATION;ANTIGEN-PRESENTING CELL;ANTIVIRAL THERAPY;ANTIVIRAL TREATMENT;ATYPICAL HEMOLYTIC UREMIC SYNDROME;BLOOD LACTATE;BRAIN-DERIVED NEUROTROPHIC FACTOR;BRONCHOPULMONARY DYSPLASIA;CAPECITABINE;CARBOPLATIN;CD3;CETUXIMAB;CHEMOIMMUNOTHERAPY;COLONOSCOPY;CONDITIONING REGIMEN;CORONARY STENT;CROSSOVER STUDY;CYCLIN-DEPENDENT KINASE 2;DASATINIB;DEOXYCYTIDINE;DOSE-VOLUME HISTOGRAM;EPIRUBICIN;ERDHEIM–CHESTER DISEASE;ERLOTINIB;ESOPHAGECTOMY;ESOPHAGITIS;FLUDARABINE;FLUORESCENCE IN SITU HYBRIDIZATION;FOLINIC ACID;FUNCTIONAL MITRAL REGURGITATION;GANCICLOVIR;GERMINAL CENTER;GERMLINE MUTATION;HEMATOPOIETIC CELL;HEPACIVIRUS;HERPESVIRIDAE;HEXOKINASE;HUMAN GENOME;IMATINIB MESYLATE;INTERMEDIATE UVEITIS;IRINOTECAN;ISLET CELL TRANSPLANTATION;KRAS;LOSS OF HETEROZYGOSITY;LUNG CANCER STAGING;LYMPHOPLASMACYTIC LYMPHOMA;MARGINAL ZONE;MEGAKARYOCYTE;MEMBRANOUS NEPHROPATHY;MHC CLASS I;MISSENSE MUTATION;MOLECULAR MEDICINE;OXCARBAZEPINE;PALONOSETRON;PCA3;PEMETREXED;PENETRANCE;PHILADELPHIA CHROMOSOME;PHOSPHOFRUCTOKINASE;PHOSPHOGLYCERATE MUTASE;PLASMA RENIN ACTIVITY;PODOCYTE;PORTAL VENOUS PRESSURE;PORTOSYSTEMIC SHUNT;PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS;PROSTATE-SPECIFIC ANTIGEN;PYRUVATE KINASE;RENAL ARTERY STENOSIS;RENAL HYPERTROPHY;RUBELLA;SINGLE-NUCLEOTIDE POLYMORPHISM;SPECTRIN;TAXANE;TOTAL MESORECTAL EXCISION;TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;TRASTUZUMAB;TROPOMYOSIN RECEPTOR KINASE B;TUMOR SUPPRESSOR GENE;VASCULAR ENDOTHELIAL GROWTH FACTOR A;VINCULIN;VINORELBINE","4;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;MIDDLE AGED;ADULT;AGED;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;TREATMENT OUTCOME;AGED, 80 AND OVER;ANTIBODIES, MONOCLONAL;ADOLESCENT;EPILEPSY;FOLLOW-UP STUDIES;IMMUNOSUPPRESSIVE AGENTS;KIDNEY NEOPLASMS;LIVER NEOPLASMS;PROSPECTIVE STUDIES;MULTIPLE MYELOMA","105;80;73;61;57;54;41;29;28;26;20;16;15;14;13;13;13;13;13;12","HEPATITIS C INFECTION AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION;KIDNEY TRANSPLANTATION;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;RENAL CELL CARCINOMA;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASES;EFFICACY AND RESISTANCE IN CML TREATMENT;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;GASTRIC CANCER RESEARCH AND TREATMENT;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MANAGEMENT AND OUTCOMES OF ACUTE KIDNEY INJURY;MANAGEMENT OF VALVULAR HEART DISEASE","9;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","TREATMENT;DILATED CARDIOMYOPATHY;HEPATITIS C;REGIMEN;DYNAMIC CONTRAST-ENHANCED MRI;IMMUNOSUPPRESSION;LIVER TRANSPLANTATION;NEURORADIOLOGY;ANTIVIRAL THERAPY;DACLIZUMAB;LIVING DONOR LIVER TRANSPLANTATION;PEGYLATED INTERFERON;CARDIAC RESYNCHRONIZATION THERAPY;CLINICAL ENDPOINT;CONCOMITANT;DEEP VEIN THROMBOSIS;DIAGNOSTIC ACCURACY;INTERNATIONAL MYELOMA WORKING GROUP;MRI CONTRAST AGENTS;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE","12;8;7;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3","DILATED CARDIOMYOPATHY;LIVER TRANSPLANTATION;PEGYLATED INTERFERON;PHASE III;CANCER PATIENTS;CONTRAST-ENHANCED CT;DACLIZUMAB INDUCTION;HEART FAILURE;III TRIAL;LEFT VENTRICULAR;MULTIPLE MYELOMA;TACROLIMUS MONOTHERAPY;TERM OUTCOME;ACCESS PROGRAM;ADJUVANT CHEMOTHERAPY;ADVANCED NON-SMALL;AUTOIMMUNE HEPATITIS;BODY MASS;BRAIN SPECT;CARDIAC RESYNCHRONIZATION;CELL CARCINOMA;CELL LUNG;CHRONIC HEPATITIS;CONTRAST MEDIA;CONTRAST-ENHANCED SONOGRAPHY;CONTROLLED TRIAL;DELETION SYNDROME;DI MIDOLLO;DISEASE REGISTRY;ESSENTIAL THROMBOCYTHEMIA","7;6;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LEFT VENTRICULAR;PUBMED SCOPUS;PEGYLATED INTERFERON;ANTI HCV;ISLET TRANSPLANTATION;HCV GENOTYPE;CROSSREF PUBMED;CONCURRENT ABACAVIR;ATRIAL FIBRILLATION;CARDIOVASC SURG;MBL GENOTYPE;THORAC CARDIOVASC;VIROLOGIC RESPONSE;HIV INFECTED;HR CI;LIVER TRANSPLANTATION;REGRESSION ANALYSIS;SURG -ABSTRACT;CI -P;DILATED CARDIOMYOPATHY;EXACT TEST;FISHERS EXACT;GADOPENTATE DIMEGLUMINE;HCV TREATMENT;INTERFERON ALFA;INTRACELLULAR PHOSPHORILATION;ISCHEMIC DILATED;MULTIVARIATE ANALYSIS;MULTIVARIATE ANALYSISRESULTS;PRIMARY TUMORS","22;20;19;15;13;12;11;9;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6",1,0.01,3,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,111,112,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,4.36,334.75,4.39,3,0.23,38.92,0,2,5,0,5,0,1,0,0,12,0,0,0,0,0,0,0,13,0,0,12,1,0,0,0,0,0,0,0,0,"Italy;Germany;United States","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3213 PAEDIATRICS;3204 IMMUNOLOGY","13;8;3;2;2;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;PEDIATRIC;RARE DISEASES;BREAST CANCER;BIOTECHNOLOGY;INFANT MORTALITY;LUNG;LUNG CANCER;PATIENT SAFETY;PEDIATRIC CANCER;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN;TRANSPLANTATION;AGING;CARDIOVASCULAR;CHILDHOOD LEUKEMIA;COLO-RECTAL CANCER","12;9;8;4;4;4;3;2;2;2;2;2;2;2;2;2;1;1;1;1","CANCER;BLOOD;CARDIOVASCULAR;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","8;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS","12;3;2","BREAST CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;MELANOMA;COLON AND RECTAL CANCER;STOMACH CANCER","3;3;2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","9;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIANCONA",2009,177,10.5310734463277,2.29378531073446,0.451977401129944,0.338983050847458,0.655367231638418,1.37162162162162,1.19402985074627,1.2,1.24731182795699,0.35593220338983,4,90,39,8,28,0.51,0.22,0.05,0.16,44.15,0.954500513687789,NA,0.271186440677966,0.819209039548023,0.397,0.301,0.375,0.3,"ALESSANDRO RAMBALDI;ROBERTO LABIANCA;GIANANTONIO ROSTI;GIUSEPPE REMUZZI;MICHELE BACCARANI;FABRIZIO PANE;MARILINA AMABILE;GIOVANNI MARTINELLI;MASSIMO BRECCIA;GIUSEPPE SAGLIO;MARIO TIRIBELLI;FAUSTO CASTAGNETTI;MARIA ASSUNTA COVA;NICOLETTA TESTONI;TAMARA INTERMESOLI;S. FAGIUOLI;FRANCESCA PALANDRI;JOSÉE GOLAY;MARCO CONFALONIERI;GIOVANNA REGE CAMBRIN","15;10;7;7;6;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4","ALESSANDRO RAMBALDI;GIOVANNI MOSCONI;ENRICO ROBOTTI;GIUSEPPE REMUZZI;MICHELE BERTOLOTTO;ANTONIO MAZZONI;GIAN PIERO PERNA;MARIA ASSUNTA COVA;ROBERTO LABIANCA;CESARE MARIOTTI;PIERGIORGIO NERI;S. FAGIUOLI;EMILIO QUAIA;PAOLO BALERCIA;RICCARDO GIROTTO;E LUPÍ;L. PASULO;FULVIO STACUL;MARIA IASCONE;JOSÉE GOLAY","1.41;1.33;1.14;1.09;1.03;1;1;0.98;0.82;0.75;0.75;0.72;0.68;0.67;0.67;0.67;0.65;0.64;0.63;0.57","ALESSANDRO RAMBALDI;ROBERTO LABIANCA;GIUSEPPE REMUZZI;MARIA ASSUNTA COVA;TAMARA INTERMESOLI;S. FAGIUOLI;JOSÉE GOLAY;MARCO CONFALONIERI;MARTINO INTRONA;MICHELE BERTOLOTTO;TIZIANO BARBUI;MASSIMO OFFIDANI;BRUNO MARTINO;A. MAMOLI;MARIO MANDALÁ;ATTILIO IACOVONI;CESARE MARIOTTI;MARIA IASCONE;ROSSANA BERARDI;EMILIO QUAIA","15;10;7;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3","ALESSANDRO RAMBALDI;GIOVANNI MOSCONI;ENRICO ROBOTTI;GIUSEPPE REMUZZI;MICHELE BERTOLOTTO;ANTONIO MAZZONI;GIAN PIERO PERNA;MARIA ASSUNTA COVA;ROBERTO LABIANCA;CESARE MARIOTTI;PIERGIORGIO NERI;S. FAGIUOLI;EMILIO QUAIA;PAOLO BALERCIA;RICCARDO GIROTTO;E LUPÍ;L. PASULO;FULVIO STACUL;MARIA IASCONE;JOSÉE GOLAY","1.41;1.33;1.14;1.09;1.03;1;1;0.98;0.82;0.75;0.75;0.72;0.68;0.67;0.67;0.67;0.65;0.64;0.63;0.57","MÓNICA GALLI;ARMANDO TRIPODI;GUIDO REBER;JACOB H. RAND;PHILIP G. DE GROOT;THOMAS L. ORTEL;VITTORIO PENGO;ROBERTO LABIANCA;ALESSANDRO RAMBALDI;GIANCARLO AGNELLI;MARIO MANDALÁ;GIUSEPPE REMUZZI;LUIGI NALDI;C. BIANCHINI;SANDRO BARNI;AD ORMEROD;ALAN MENTER;ALESSANDRO GIUNTA;ALEXANDER NAST;BERNADETTE EBERLEIN","1216;1118;1118;1118;1118;1118;1118;1096;878;779;767;754;688;682;676;670;670;670;670;670","MÓNICA GALLI;ROBERTO LABIANCA;ALESSANDRO RAMBALDI;LUIGI NALDI;MARIO MANDALÁ;AURELIO SONZOGNI;TIZIANO BARBUI;GUIDO FINAZZI;TAMARA INTERMESOLI;FEDERICA DELAINI;MASSIMO BARBERIS;F. BALSEMIN;GIUSEPPE REMUZZI;M. CAMERLINGO;MARCO CONFALONIERI;ALESSANDRA CAROBBIO;JOSÉE GOLAY;RICCARDO UTILI;A. MAMOLI;G. C. GAZZANIGA","1216;908;877;688;582;465;462;251;240;211;211;197;190;163;155;150;136;122;112;112","ALESSANDRO RAMBALDI;ROBERTO LABIANCA;TAMARA INTERMESOLI;BRUNO MARTINO;FRANCO MAGGIOLO;GIUSEPPE REMUZZI;JOSÉE GOLAY;MARCO CONFALONIERI;MARIA ASSUNTA COVA;MARTINO INTRONA;TIZIANO BARBUI;CATERINA MICÒ;CESARE MARIOTTI;EMILIO QUAIA;GUIDO FINAZZI;LUIGI NALDI;M. CAMERLINGO;MICHELE BERTOLOTTO;PIERGIORGIO NERI;PIERO RUGGENENTI","14;7;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;ENGINEERING;COMPUTER SCIENCE;PHYSICS;CHEMISTRY;PSYCHOLOGY;MATHEMATICS;PHILOSOPHY;SOCIOLOGY;ECONOMICS;HISTORY;BUSINESS;MATERIALS SCIENCE;POLITICAL SCIENCE;ART;GEOGRAPHY","167;46;11;9;9;8;7;4;4;4;3;3;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;IMMUNOLOGY;PATHOLOGY;GENETICS;RADIOLOGY;CARDIOLOGY;ENDOCRINOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;ONCOLOGY;ANESTHESIA;CANCER RESEARCH;DERMATOLOGY;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;PSYCHIATRY;ANATOMY;UROLOGY;VIROLOGY","120;60;39;34;34;26;24;18;17;16;16;13;10;10;9;8;8;8;7;7;7","GENE;CANCER;DISEASE;CHEMOTHERAPY;TRANSPLANTATION;POPULATION;VIRUS;ADVERSE EFFECT;ANTIBODY;CONFIDENCE INTERVAL;LEUKEMIA;ALTERNATIVE MEDICINE;HEART FAILURE;MYELOID LEUKEMIA;PROSPECTIVE COHORT STUDY;THROMBOSIS;BLOOD PRESSURE;RANDOMIZED CONTROLLED TRIAL;ANTIGEN;BIOPSY;COHORT;DIABETES MELLITUS;LUNG;MAGNETIC RESONANCE IMAGING","24;18;17;15;15;14;10;9;9;9;9;8;8;8;8;8;7;7;6;6;6;6;6;6","IMATINIB;CLINICAL ENDPOINT;GENOTYPE;HAZARD RATIO;BREAST CANCER;COLORECTAL CANCER;MUTATION;PLACEBO;CONTRAST-ENHANCED ULTRASOUND;CYCLOPHOSPHAMIDE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;VIRAL LOAD;BRAIN NATRIURETIC PEPTIDE;CARDIOMYOPATHY;CD34;CHROMOSOME;CHRONIC HEPATITIS;EJECTION FRACTION;EPSTEIN–BARR VIRUS;ESSENTIAL THROMBOCYTHEMIA;IMMUNOTHERAPY;LIVER TRANSPLANTATION;NATRIURETIC PEPTIDE;NEUTROPENIA;PHASES OF CLINICAL RESEARCH;PROGRESSIVE DISEASE;RITUXIMAB;THROMBOCYTOSIS;TOLERABILITY;VAGUS NERVE;VENOUS THROMBOSIS","7;6;6;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","IMATINIB MESYLATE;ANTIRETROVIRAL THERAPY;FLUORESCENCE IN SITU HYBRIDIZATION;NILOTINIB;TRANSFERRIN SATURATION;ANTIVIRAL THERAPY;CASPOFUNGIN;HERPESVIRIDAE;IPILIMUMAB;RIBAVIRIN;VAGUS NERVE STIMULATION;ABL;ACE INHIBITOR;ACROMEGALY;ACUTE LYMPHOCYTIC LEUKEMIA;ADCY9;AMINO ACID SUBSTITUTION;ANGIOTENSIN II RECEPTOR TYPE 1;ANTERIOR CEREBRAL ARTERY;ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY;ANTIVIRAL TREATMENT;ARTIFICIAL VENTILATION;AUTOIMMUNE THYROIDITIS;BONE DENSITY CONSERVATION AGENTS;BREAST RECONSTRUCTION;BRONCHIAL HYPERRESPONSIVENESS;BRONCHOPLEURAL FISTULA;BRONCHOPULMONARY DYSPLASIA;BUSULFAN;CABERGOLINE;CARDIAC RESYNCHRONIZATION THERAPY;CARDIOLIPIN;CD117;CD3;CD38;CETUXIMAB;CLOFARABINE;COLONOSCOPY;COPY-NUMBER VARIATION;CORONAVIRUS DISEASE 2019 (COVID-19);CYCLIN;CYCLIN-DEPENDENT KINASE 1;CYTOGENETICS;DASATINIB;DNA METHYLATION;DONEPEZIL;DOPPLER IMAGING;ECHINOCANDIN;EICOSAPENTAENOIC ACID;EXHALED NITRIC OXIDE;FACTOR V LEIDEN;FALLOPIAN TUBE CANCER;FEBRILE NEUTROPENIA;FOOD HYPERSENSITIVITY;FRACTIONAL ANISOTROPY;GASTRO-;GASTROINTESTINAL CANCER;GERMINAL CENTER;GLOSSOPHARYNGEAL NERVE;GP41;GREY MATTER;HAPLOTYPE;HEART RATE VARIABILITY;INGUINAL CANAL;INTERLEUKIN-6 RECEPTOR;IRINOTECAN;IRON STATUS;ISCHEMIC CARDIOMYOPATHY;ISOTYPE;JAG1;JAK2 V617F;KARYOTYPE;LEVODOPA;LISINOPRIL;LOWER URINARY TRACT SYMPTOMS;MAMMOGRAPHY;MOLECULAR MEDICINE;NEOADJUVANT THERAPY;NEUROPSYCHOLOGICAL ASSESSMENT;OCCUPATIONAL INJURY;OSTEONECROSIS OF THE JAW;PHARMACOGENETICS;PHILADELPHIA CHROMOSOME;POINT MUTATION;POLYMORPHISM (COMPUTER SCIENCE);POSACONAZOLE;PRESSURE OVERLOAD;PRIMARY CILIARY DYSKINESIA;PRIMARY TUMOR;PROMOTER;PROSTATECTOMY;RELATIVE SURVIVAL;RENAL ARTERY STENOSIS;RETICULOCYTE;RETINAL VASCULITIS;RETINOBLASTOMA PROTEIN;SENTINEL LYMPH NODE;SIRTUIN;SMALL INTERFERING RNA;SOLID ORGAN;SUBLINGUAL IMMUNOTHERAPY;SYSTEMIC THERAPY;T-CELL RECEPTOR;TARGET LESION;TENECTEPLASE;TOTAL BODY IRRADIATION;TRANSACTIVATION;VASCULAR DEMENTIA;VASCULAR ENDOTHELIAL GROWTH FACTOR A;VECTOR (MOLECULAR BIOLOGY);VINCRISTINE","6;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;;ADULT;AGED;TREATMENT OUTCOME;AGED, 80 AND OVER;ITALY;HIV INFECTIONS;YOUNG ADULT;HEART FAILURE;ADOLESCENT;NEOPLASMS;RISK FACTORS;POSTOPERATIVE COMPLICATIONS;RETROSPECTIVE STUDIES;ANIMALS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS","111;81;76;63;59;55;55;26;25;23;21;20;18;16;15;14;13;13;12;12","EFFICACY AND RESISTANCE IN CML TREATMENT;HEPATITIS C INFECTION AND TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MICROSURGICAL RECONSTRUCTION TECHNIQUES;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ASTHMA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF HEART FAILURE;DIFFUSION MAGNETIC RESONANCE IMAGING;DYSPHAGIA AND SWALLOWING DISORDERS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF OCULAR INFLAMMATORY DISEASES","9;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","TREATMENT;CLINICAL ENDPOINT;IMATINIB;IMATINIB MESYLATE;REGIMEN;CONTRAST-ENHANCED ULTRASOUND;INTERNATIONAL MYELOMA WORKING GROUP;ANTIRETROVIRAL THERAPY;BRAIN NATRIURETIC PEPTIDE;CARDIAC IMAGING;COMBINATION THERAPY;ECHOCARDIOGRAPHY;HEMATOLOGY;HEPATITIS C;LEUKOCYTOSIS;MICROSURGICAL RECONSTRUCTION;POSITIVE END-EXPIRATORY PRESSURE;RESPIRATORY;STROKE (ENGINE);THROMBOCYTOSIS","15;6;6;6;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","CHRONIC MYELOID;MYELOID LEUKEMIA;GRUPPO ITALIANO;PHASE II;CHRONIC HEPATITIS;GIMEMA CML;CONTRAST-ENHANCED ULTRASOUND;ELDERLY PATIENTS;ESSENTIAL THROMBOCYTHEMIA;GROWTH FACTOR;IMATINIB IM;MULTIPLE MYELOMA;PH CHRONIC;TREATMENT OUTCOME;ACE INHIBITOR;ACUTE LYMPHOBLASTIC;ADI NUTRITIONAL;ADULT PATIENTS;ALLERGIC RHINITIS;ANTIVIRAL THERAPY;CANCER PATIENTS;CELL TRANSPLANTATION;CHRONIC PHASE;CLINICAL OUTCOME;CML PATIENTS;COMPLETE CYTOGENETIC;CONTACT DERMATITIS;CORONARY ANGIOGRAPHY;CYTOGENETIC RESPONSE;DIABETES MELLITUS","7;7;5;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CROSSREF PUBMED;PUBMED SCOPUS;CHRONIC MYELOID;HAEMOST -CROSSREF;RESIDUAL DISEASE;MYELOID LEUKEMIA;LUPUS ANTICOAGULANT;LEUKEMIC CELLS;CHAIN REACTION;HR CI;POLYMERASE CHAIN;STEM CELL;VAN DER;CLOTTING TIME;EGFR GCN;HAZARD RATIO;REAL-TIME QUANTITATIVE;SAMPLESBONE MARROW;ADVERSE EVENTS;CANCER PROGRAMLEUKEMIA;CLINICAL TRIALS;CUTOFF VALUES;DER VELDEN;DISEASE DETECTION;DONGEN JJ;GOLDMAN JM;LUPUS ANTICOAGULANTS;PROGRAMLEUKEMIA -CROSSREF;PSORIASIS VULGARIS;VAN DONGEN","58;56;24;18;17;15;14;12;11;11;11;11;11;9;9;9;9;9;8;8;8;8;8;8;8;8;8;8;8;8",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,5.69,343.31,5.47,5,0.33,53.73,0,0,2,0,7,0,3,3,0,11,2,0,0,0,0,0,0,12,0,3,13,2,0,0,0,0,0,0,0,0,"United States;Germany;Italy;Japan","3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","15;8;8;3;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;PATIENT SAFETY;BIOENGINEERING;CARDIOVASCULAR;HEART DISEASE;LYMPHOMA;PROSTATE CANCER;UROLOGIC DISEASES;AGING;BRAIN DISORDERS;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEALTH SERVICES;INFECTIOUS DISEASES;NEUROSCIENCES;SEPSIS","13;10;7;5;5;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE","6;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING","12;2;1;1;1","NON-HODGKIN'S LYMPHOMA;PROSTATE CANCER;BLOOD CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;LEUKEMIA / LEUKAEMIA;LUNG CANCER;RESPIRATORY SYSTEM","2;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","6;1;1;1",1,5623414,401672.43,7,14,10,1,15,57381.7755102041,3.08460305430118,"ARISTOTLE UNIVERSITY OF THESSALONIKI;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI;BELFAST HEALTH AND SOCIAL CARE TRUST;CHARLES UNIVERSITY;CLALIT HEALTH SERVICES;ERASMUS MC;NORTHERN OSTROBOTHNIA HOSPITAL DISTRICT;ROBERT BOSCH (GERMANY);TU DRESDEN;UNIVERSITY OF GÖTTINGEN;UNIVERSITY OF OULU;UNIVERSITY OF TÜBINGEN;UNIVERSITY OF ZURICH","1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2007-B (CALL FOR PROPOSAL)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3213 PAEDIATRICS","1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;INFANT MORTALITY;LUNG;NEONATAL RESPIRATORY DISTRESS;NEUROSCIENCES;PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN;PREVENTION","1;1;1;1;1;1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIANCONA",2010,182,11.0659340659341,2.62637362637363,0.494505494505495,0.318681318681319,0.714285714285714,1.43975903614458,1.23287671232877,1.23404255319149,1.3,0.346153846153846,6,103,31,11,23,0.57,0.17,0.06,0.13,52.82,1.16891971511593,NA,0.285714285714286,0.763736263736264,0.47,0.366,0.411,0.392,"GIUSEPPE REMUZZI;PIETRO LEONI;ROBERTO LABIANCA;ROBIN FOÀ;ALESSANDRO RAMBALDI;ANDREA BENEDETTO GALOSI;FRANCESCO DI RAIMONDO;PIERO RUGGENENTI;TAMARA INTERMESOLI;BOGDAN ENE‐IORDACHE;GIOVANNI MUZZONIGRO;PAOLO CRAVEDI;ANTONIO BRUCATO;MARCO GOBBI;FORTUNATO MORABITO;GIORGIO LA NASA;MICHELE BACCARANI;PELLEGRINO MUSTO;SILVIA GENTILI;RENATO CANTAFFA","12;11;8;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5","GIUSEPPE REMUZZI;SALVATORE SIRACUSANO;ANDREA BENEDETTO GALOSI;FRANCO MAGGIOLO;EMILIO QUAIA;ROBERTO LABIANCA;STEFANO GASPARINI;GIOVANNI MUZZONIGRO;GIAMMARCO FAVA;PIERO RUGGENENTI;MARIO MANDALÁ;VITO LACETERA;PIETRO LEONI;MICHELE SENNI;LUCIA TORRACCA;FILIPPO CAPESTRO;SEBASTIANO LEONE;ALESSANDRO BRUNELLI;MARCO POZZI;PAOLO CRAVEDI","2.04;2;1.67;1.3;1.29;1.27;1.17;1.04;1;0.97;0.93;0.9;0.81;0.79;0.75;0.75;0.7;0.68;0.66;0.64","GIUSEPPE REMUZZI;PIETRO LEONI;ROBERTO LABIANCA;ALESSANDRO RAMBALDI;ANDREA BENEDETTO GALOSI;PIERO RUGGENENTI;TAMARA INTERMESOLI;GIOVANNI MUZZONIGRO;PAOLO CRAVEDI;ANTONIO BRUCATO;SILVIA GENTILI;MASSIMO OFFIDANI;RENATO BASSAN;GIULIO GUAGLIUMI;VIRGILIO CARNIELLI;ANNA FALANGA;CLAUDIA POLLONI;MARCO POZZI;ALESSANDRO BRUNELLI;FRANCO MAGGIOLO","12;11;8;7;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4","GIUSEPPE REMUZZI;SALVATORE SIRACUSANO;ANDREA BENEDETTO GALOSI;FRANCO MAGGIOLO;EMILIO QUAIA;ROBERTO LABIANCA;STEFANO GASPARINI;GIOVANNI MUZZONIGRO;GIAMMARCO FAVA;PIERO RUGGENENTI;MARIO MANDALÁ;VITO LACETERA;PIETRO LEONI;MICHELE SENNI;LUCIA TORRACCA;FILIPPO CAPESTRO;SEBASTIANO LEONE;ALESSANDRO BRUNELLI;MARCO POZZI;PAOLO CRAVEDI","2.04;2;1.67;1.3;1.29;1.27;1.17;1.04;1;0.97;0.93;0.9;0.81;0.79;0.75;0.75;0.7;0.68;0.66;0.64","ANTONIO PALUMBO;FRANCESCA PATRIARCA;MICHÈLE CAVO;FRANCESCO DI RAIMONDO;GIUSEPPE REMUZZI;MICHELE BACCARANI;MASSIMO OFFIDANI;PAOLO CORRADINI;GIORGIO LA NASA;A LEDDA;ANTONIO SPADANO;CLAUDIA CELLINI;CLAUDIA CRIPPA;ELENA ZAMAGNI;FRANCO NARNI;LUCIA PANTANI;MARIA TERESA PETRUCCI;MÓNICA GALLI;NORBERT PESCOSTA;PAOLA TACCHETTI","1195;1189;1185;1122;954;854;843;819;817;815;815;815;815;815;815;815;815;815;815;815","MÓNICA GALLI;VALENTINO CONTER;ANTONIO BRUCATO;ROBERTO LABIANCA;GIUSEPPE REMUZZI;ANTONELLO GAVAZZI;PIERO RUGGENENTI;ALESSANDRO RAMBALDI;SILVIA GENTILI;ANNA FALANGA;GIORGIO FASOLINI;MARIATERESA CAFARO;ALESSANDRO BRUNELLI;CECILIA POMPILI;CARLOS SIMÓN;PAOLO FERRAZZI;SILVIA MAESTRONI;ALFREDO RAGLIO;ARMANDO SABBATINI;VIRGILIO CARNIELLI","815;735;722;711;556;484;466;422;398;379;303;303;288;278;258;258;258;232;232;230","PIETRO LEONI;ROBERTO LABIANCA;PIERO RUGGENENTI;ALESSANDRO RAMBALDI;TAMARA INTERMESOLI;GIUSEPPE REMUZZI;SILVIA GENTILI;ANDREA BENEDETTO GALOSI;GIUSEPPE MUSUMECI;ANTONIO BRUCATO;ALESSANDRO BRUNELLI;CLAUDIA POLLONI;FREDY SUTER;GIULIO GUAGLIUMI;MASSIMO OFFIDANI;RENATO BASSAN;VIRGILIO CARNIELLI;FRANCO MAGGIOLO;FILIPPO CAPESTRO;LUCIA TORRACCA","10;8;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;MATERIALS SCIENCE;PSYCHOLOGY;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;BUSINESS;GEOLOGY;PHILOSOPHY;SOCIOLOGY;HISTORY","172;39;15;9;9;6;5;5;4;4;4;3;3;3;2;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;GASTROENTEROLOGY;PATHOLOGY;INTENSIVE CARE MEDICINE;GENETICS;RADIOLOGY;IMMUNOLOGY;ONCOLOGY;ANESTHESIA;UROLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;ENDOCRINOLOGY;PHARMACOLOGY;PEDIATRICS;NUCLEAR MEDICINE;OPTICS;VIROLOGY","137;69;28;27;26;25;23;21;19;19;16;15;14;12;12;10;9;8;8;8","CANCER;GENE;CHEMOTHERAPY;RANDOMIZED CONTROLLED TRIAL;MYOCARDIAL INFARCTION;POPULATION;DISEASE;LEUKEMIA;TRANSPLANTATION;ALTERNATIVE MEDICINE;PROSPECTIVE COHORT STUDY;REGIMEN;ADVERSE EFFECT;BIOPSY;CLINICAL TRIAL;CONFIDENCE INTERVAL;KIDNEY;MYELOID LEUKEMIA;BLOOD PRESSURE;COHORT;DIABETES MELLITUS;HEART FAILURE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);MULTIPLE MYELOMA;STENOSIS;TOXICITY","22;21;13;13;11;11;10;10;10;9;9;9;8;8;8;8;8;8;7;7;7;7;7;7;7;7","PLACEBO;VIRAL LOAD;COLORECTAL CANCER;HAZARD RATIO;IMATINIB;BREAST CANCER;GENOTYPE;PROSTATE;THALIDOMIDE;BORTEZOMIB;LENALIDOMIDE;NEUTROPENIA;PERCUTANEOUS CORONARY INTERVENTION;TYPE 2 DIABETES;ALLELE;ANGIOTENSIN-CONVERTING ENZYME;CD34;CISPLATIN;CLINICAL ENDPOINT;GESTATIONAL AGE;HAEMATOPOIESIS;HEART RATE;MELPHALAN;MINIMAL RESIDUAL DISEASE;MUCOSITIS;MUTATION;PROGRESSION-FREE SURVIVAL;PROSTATE CANCER;PROTEINURIA;RESTENOSIS;ST ELEVATION;UNIVARIATE ANALYSIS","7;7;6;6;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;IMATINIB MESYLATE;ACE INHIBITOR;DRUG-ELUTING STENT;ACUTE LYMPHOCYTIC LEUKEMIA;ANTHRACYCLINE;BRONCHOPULMONARY DYSPLASIA;CD38;CROSSOVER STUDY;DASATINIB;IDARUBICIN;LAMIVUDINE;LOWER URINARY TRACT SYMPTOMS;MAMMOGRAPHY;MISSENSE MUTATION;NILOTINIB;PROSTATECTOMY;SINGLE-NUCLEOTIDE POLYMORPHISM;TIMI;VAGUS NERVE STIMULATION;VINCRISTINE;VO2 MAX","6;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;;ADULT;TREATMENT OUTCOME;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PROSPECTIVE STUDIES;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;ADOLESCENT;HIV INFECTIONS;LIVER NEOPLASMS;MYOCARDIAL INFARCTION;RISK FACTORS;CHILD;MULTIPLE MYELOMA","125;82;80;69;56;53;46;44;30;29;21;20;18;17;16;16;16;16;15;13","EFFICACY AND RESISTANCE IN CML TREATMENT;DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASES;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ACUTE MYELOID LEUKEMIA;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;MICROSURGICAL RECONSTRUCTION TECHNIQUES;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PELVIC FLOOR DISORDERS;PROSTATE CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;CHOLANGIOCARCINOMA;CHOLESTEROL-LOWERING TREATMENT;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES","6;5;5;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2","REGIMEN;REFRACTORY (PLANETARY SCIENCE);ANTIRETROVIRAL THERAPY;IMATINIB;IMATINIB MESYLATE;MANTLE CELL LYMPHOMA;RECURRENT PERICARDITIS;SIROLIMUS;TREATMENT OUTCOMES;CARDIOVASCULAR EVALUATION;CLINICAL ENDPOINT;CONSTRICTIVE PERICARDITIS;CORONARY STENTS;DEEP VEIN THROMBOSIS;DRUG-ELUTING STENTS;EFAVIRENZ;ETIOLOGY;HIV;HIV INFECTION;INTERNATIONAL MYELOMA WORKING GROUP","9;6;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","CANCER PATIENTS;ELDERLY PATIENTS;MULTIPLE MYELOMA;MYELOID LEUKEMIA;MYOCARDIAL INFARCTION;TYPE DIABETES;ACUTE LYMPHOBLASTIC;CHRONIC HEART;CHRONIC MYELOID;COLORECTAL CANCER;ESMO CLINICAL;HEART FAILURE;ITALIAN ASSOCIATION;LYMPHOBLASTIC LEUKEMIA;NEWLY DIAGNOSED;NITRIC OXIDE;PROSPECTIVE STUDY;ST-SEGMENT ELEVATION;ADIPOSE TISSUE;BLOODSTREAM INFECTIONS;CELL CARCINOMA;CELL LEUKEMIA;CELL TRANSPLANTATION;CHRONIC LYMPHOCYTIC;CHRONIC PHASE;CLINICAL PRACTICE;CLINICAL TRIAL;CML WP;COLON CANCER;COMBINED EZETIMIBE","4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","SCIENCEGOOGLE SCHOLAR;CANCER PATIENTS;COLON CANCER;COLORECTAL CANCER;CATTINARA HOSPITAL;HOSPITAL UNIVERSITY;MD DEPARTMENT;RADIOLOGY CATTINARA;TRIESTE ITALYSEARCH;TRIESTE TRIESTE;CHEST TUBES;STAGE III;CUFF-LEAK TEST;CHEST TUBE;CLINICAL TRIALS;RADIOL CASPUBMEDWEB;RADIOLOGY RADIOL;RISK SCORE;STAGE II;CLINICAL PRACTICE;KO MICE;PUBMED SCOPUS;PULMONARY LOBECTOMY;RANDOMIZED CLINICAL;CONSECUTIVE PATIENTS;CONTRAST AGENT;CORD BLOOD;EMILIO QUAIA;INTRAPLEURAL PRESSURE;MECHANICAL VENTILATION","28;21;21;18;14;14;14;14;12;12;11;11;9;8;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6;6",2,0.01,15.5,5.75,0,0,0,1,1,0,1.75,8.75,0,1,2.75,0,0,0,1,1.75,1,0.75,0,301.5,302.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,5.33,632.75,4.93,3,0.2,54.07,0,0,8,0,3,0,0,4,0,9,3,0,0,0,0,0,0,14,1,0,12,3,0,0,0,0,0,0,0,0,"United States","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4012 FLUID MECHANICS AND THERMAL ENGINEERING;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;46 INFORMATION AND COMPUTING SCIENCES;49 MATHEMATICAL SCIENCES;4905 STATISTICS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","13;8;4;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;DIGESTIVE DISEASES;ORPHAN DRUG;AGING;CHILDHOOD LEUKEMIA;HEMATOLOGY;PANCREATIC CANCER;PATIENT SAFETY;PEDIATRIC;PEDIATRIC CANCER;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BIOTECHNOLOGY;BRAIN DISORDERS;BREAST CANCER;COMPARATIVE EFFECTIVENESS RESEARCH","9;7;7;6;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;NEUROLOGICAL;CARDIOVASCULAR;STROKE","8;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","10;1","LEUKEMIA / LEUKAEMIA;PANCREATIC CANCER;BREAST CANCER;GASTROINTESTINAL TRACT;LIVER CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;STOMACH CANCER","4;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.2 SURVEILLANCE","10;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIANCONA",2011,219,11.5159817351598,2.4703196347032,0.305936073059361,0.264840182648402,0.388127853881279,1.43501326259947,1.11666666666667,1.23404255319149,1.13333333333333,0.484018264840183,4,126,43,17,17,0.58,0.2,0.08,0.08,54.49,1.28115820332676,NA,0.378995433789954,0.881278538812785,0.435,0.308,0.445,0.337,"ALESSANDRO RAMBALDI;GIUSEPPE REMUZZI;MASSIMO OFFIDANI;S. FAGIUOLI;FRANCESCO DI RAIMONDO;PIETRO LEONI;MARIO BOCCADORO;PAOLO CORRADINI;FRANCESCA PATRIARCA;TAMARA INTERMESOLI;ENRICO MARIA POGLIANI;VALENTINO CONTER;LUCA ANSALONI;PATRIZIA BURRA;ROBERTO LABIANCA;BRUNO FABRIS;NICOLÒ DE MANZINI;FRANCESCO PASSAMONTI;IRENE BERTOZZI;MARIO MANDALÁ","21;8;8;8;7;7;6;6;6;6;6;5;5;5;5;4;4;4;4;4","ANNA FALANGA;ALESSANDRO RAMBALDI;ROCCO BARAZZONI;EMILIO QUAIA;CARLO ARATARI;GIOVANNI MUZZONIGRO;GIUSEPPE REMUZZI;S. FAGIUOLI;DANIELE MINARDI;CLAUDIA PASSAMONTI;GIOVANNI MOSCONI;UMBERTO MARIANI;ALESSANDRO VILLA;GIORGIO BERLOT;NICOLÒ DE MANZINI;MARIO MANDALÁ;SERENA BONIN;I. LORENZINI;ORAZIO VALSECCHI;MORENO CECCONI","1.71;1.38;1.31;1.11;1;0.85;0.84;0.75;0.74;0.68;0.67;0.67;0.67;0.67;0.64;0.63;0.62;0.61;0.58;0.58","ALESSANDRO RAMBALDI;GIUSEPPE REMUZZI;MASSIMO OFFIDANI;S. FAGIUOLI;PIETRO LEONI;TAMARA INTERMESOLI;VALENTINO CONTER;LUCA ANSALONI;ROBERTO LABIANCA;BRUNO FABRIS;NICOLÒ DE MANZINI;MARIO MANDALÁ;ORIETTA SPINELLI;ANNA FALANGA;SILVIA GENTILI;MARIA ASSUNTA COVA;SERENA BONIN;M. COLLEDAN;L. PASULO;TIZIANO BARBUI","21;8;8;8;7;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4","ANNA FALANGA;ALESSANDRO RAMBALDI;ROCCO BARAZZONI;EMILIO QUAIA;CARLO ARATARI;GIOVANNI MUZZONIGRO;GIUSEPPE REMUZZI;S. FAGIUOLI;DANIELE MINARDI;CLAUDIA PASSAMONTI;GIOVANNI MOSCONI;UMBERTO MARIANI;ALESSANDRO VILLA;GIORGIO BERLOT;NICOLÒ DE MANZINI;MARIO MANDALÁ;SERENA BONIN;I. LORENZINI;ORAZIO VALSECCHI;MORENO CECCONI","1.71;1.38;1.31;1.11;1;0.85;0.84;0.75;0.74;0.68;0.67;0.67;0.67;0.67;0.64;0.63;0.62;0.61;0.58;0.58","ALESSANDRO RAMBALDI;AZIZ SHEIKH;BERNARD YU‐HOR THONG;DENNIS K. LEDFORD;F. ESTELLE R. SIMONS;GIANENRICO SENNA;JOHANNES RING;LEDIT ARDUSSO;MARIA BEATRICE BILÒ;MARIO SÁNCHEZ‐BORGES;YEHIA EL‐GAMAL;FRANCESCO DI RAIMONDO;MICHELE BACCARANI;GIUSEPPE REMUZZI;FRANCO MANDELLI;MARCO VIGNETTI;ANNA FALANGA;GIORGINA SPECCHIA;MARIO MANDALÁ;FRANCESCA PATRIARCA","1731;1430;1430;1430;1430;1430;1430;1430;1430;1430;1430;983;943;915;844;844;830;822;720;714","ALESSANDRO RAMBALDI;MARIA BEATRICE BILÒ;ANNA FALANGA;GIUSEPPE REMUZZI;MARIO MANDALÁ;ROBERTO LABIANCA;CARMEN J. ALLEGRA;DANIEL J. SARGENT;FRANK A. SINICROPE;G MONGES;GREG YOTHERS;MALCOLM J. MOORE;NATHAN R. FOSTER;SILVIA MARSONI;STEPHEN N. THIBODEAU;STEVEN GALLINGER;VALENTINO CONTER;PIETRO LEONI;PIERO RUGGENENTI;ANDREA ROSSI","1494;1430;794;711;683;666;481;481;481;481;481;481;481;481;481;481;478;454;451;429","ALESSANDRO RAMBALDI;MASSIMO OFFIDANI;S. FAGIUOLI;GIUSEPPE REMUZZI;PIETRO LEONI;LUCA ANSALONI;VALENTINO CONTER;GIUSEPPE MUSUMECI;M. COLLEDAN;NICOLÒ DE MANZINI;ROBERTO LABIANCA;SERENA BONIN;SILVIA GENTILI;TAMARA INTERMESOLI;BRUNO FABRIS;ELENA OLDANI;ORIETTA SPINELLI;ANNA FALANGA;ANTONIO BRUCATO;CLAUDIA PASSAMONTI","18;8;7;7;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;SOCIOLOGY;BUSINESS;PHILOSOPHY;PSYCHOLOGY;ECONOMICS;GEOGRAPHY;MATERIALS SCIENCE;POLITICAL SCIENCE;GEOLOGY","211;71;20;14;10;9;7;6;5;3;3;2;2;2;2;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;PATHOLOGY;IMMUNOLOGY;GENETICS;ONCOLOGY;BIOCHEMISTRY;RADIOLOGY;INTENSIVE CARE MEDICINE;CARDIOLOGY;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;ANESTHESIA;CANCER RESEARCH;OPTICS;MICROBIOLOGY;VIROLOGY;PEDIATRICS;UROLOGY","171;67;41;40;38;35;30;27;24;23;20;17;16;14;14;13;12;12;11;10","GENE;DISEASE;TRANSPLANTATION;CANCER;CHEMOTHERAPY;POPULATION;CONFIDENCE INTERVAL;LEUKEMIA;MULTIPLE MYELOMA;INCIDENCE (GEOMETRY);COHORT;DIABETES MELLITUS;ENZYME;KIDNEY;LYMPHOMA;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;ANTIBODY;BIOPSY;RECEPTOR;VIRUS","33;28;28;26;18;17;16;14;12;11;9;9;9;9;9;9;9;8;8;8;8","LIVER TRANSPLANTATION;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CYCLOPHOSPHAMIDE;LENALIDOMIDE;PERCUTANEOUS CORONARY INTERVENTION;COLORECTAL CANCER;GENE EXPRESSION;IMATINIB;MINIMAL RESIDUAL DISEASE;RITUXIMAB;BORTEZOMIB;CHROMOSOMAL TRANSLOCATION;CHRONIC HEPATITIS;CLINICAL ENDPOINT;CONVENTIONAL PCI;CUMULATIVE INCIDENCE;LYMPHOBLASTIC LEUKEMIA;METASTASIS;NEUTROPENIA;PHENOTYPE;PROSTATE CANCER;THALIDOMIDE;VENOUS THROMBOEMBOLISM","12;11;8;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","IMATINIB MESYLATE;ACUTE LYMPHOCYTIC LEUKEMIA;ANTIRETROVIRAL THERAPY;CORONAVIRUS DISEASE 2019 (COVID-19);DASATINIB;FLUDARABINE;KARYOTYPE;PHILADELPHIA CHROMOSOME;RIBAVIRIN;ACUTE PROMYELOCYTIC LEUKEMIA;CARDIAC RESYNCHRONIZATION THERAPY;CASPOFUNGIN;DONOR LYMPHOCYTE INFUSION;DRUG-ELUTING STENT;GENETIC HETEROGENEITY;MEMBRANOUS NEPHROPATHY;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MICROCOCCACEAE;PROSTATECTOMY;REVERSE TRANSCRIPTASE;SECONDARY HYPERPARATHYROIDISM;STAPHYLOCOCCAL INFECTIONS;TIMI;TOTAL BODY IRRADIATION","5;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;;ADULT;ITALY;AGED, 80 AND OVER;TREATMENT OUTCOME;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ANTINEOPLASTIC AGENTS;RETROSPECTIVE STUDIES;YOUNG ADULT;MYOCARDIAL INFARCTION;HIV INFECTIONS;PROSPECTIVE STUDIES;RISK FACTORS;CHILD","145;114;104;87;74;68;62;40;34;34;32;31;26;24;24;23;21;21;20;19","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;HEPATITIS C INFECTION AND TREATMENT;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;LYMPHOID NEOPLASMS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ACUTE MYELOID LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF APPENDICITIS;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASES;DIAGNOSIS AND MANAGEMENT OF SYNCOPE;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF VALVULAR HEART DISEASE;MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE","10;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","TREATMENT;TREATMENT OUTCOMES;LIVER TRANSPLANTATION;REGIMEN;DIAGNOSIS CRITERIA;IMATINIB MESYLATE;INTERNATIONAL MYELOMA WORKING GROUP;LIVER BIOPSY;LIVING DONOR LIVER TRANSPLANTATION;MINIMAL RESIDUAL DISEASE;VENOUS THROMBOEMBOLISM;CLINICAL ENDPOINT;CONCOMITANT;CUMULATIVE INCIDENCE;DEEP VEIN THROMBOSIS;HIV;TRANSCATHETER AORTIC-VALVE REPLACEMENT;ACUTE LYMPHOCYTIC LEUKEMIA;ANTIRETROVIRAL THERAPY;CONSTRICTIVE PERICARDITIS","9;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;3;3;3","LIVER TRANSPLANTATION;STEM CELL;MULTIPLE MYELOMA;CELL TRANSPLANTATION;ACUTE LYMPHOBLASTIC;MYELOID LEUKEMIA;MYOCARDIAL INFARCTION;EPIDERMAL GROWTH;FACTOR RECEPTOR;GROWTH FACTOR;LUNG CANCER;LYMPHOBLASTIC LEUKEMIA;MYELOMA TREATED;RISK FACTORS;ACUTE MYOCARDIAL;ALLOGENEIC STEM;AORTIC VALVE;CANCER PATIENTS;CHRONIC MYELOID;ESSENTIAL THROMBOCYTHEMIA;HCV RECURRENCE;HEART FAILURE;INFARCTION UNDERGOING;OXIDATIVE STRESS;PATIENTS TREATED;PERCUTANEOUS CORONARY;RESIDUAL DISEASE;SIROLIMUS-ELUTING STENT;TRANSPLANT PATIENTS;VALVE IMPLANTATION","10;9;8;7;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HAZARD RATIO;CONFIDENCE INTERVAL;EGFR PROMOTER;ANTIVIRAL THERAPY;MULTIVARIATE ANALYSIS;PATIENTS TREATED;PATIENTS UNDERWENT;ANTIVIRAL TREATMENT;CANCER PATIENTS;RESIDUAL DISEASE;ROS GENERATION;TABLE TABLE;CD T-CELL;CLINICAL OUTCOME;HAFS CELLS;INTRA-ABDOMINAL INFECTIONS;MINIMAL RESIDUAL;MUSCLE MITOCHONDRIAL;ODDS RATIO;PATIENT SURVIVAL;PATIENTS RECEIVING;RENAL FUNCTION;RISK FACTORS;CML PATIENTS;CONSECUTIVE PATIENTS;DILATED CARDIOMYOPATHY;DISEASE-FREE SURVIVAL;GLUCOSE METABOLISM;HCV RECURRENT;INTENSIVE CARE","14;12;12;10;10;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6",4,0.02,3.38,3.25,0,0,0,0,0,0,2,3.25,0,1,2.25,0,0,0,0,2,2,0.25,0,142.25,142.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,5.71,718.8,7,6,0.24,54.32,1,0,5,0,9,0,2,8,0,21,4,0,0,0,0,0,0,23,2,0,25,0,0,0,0,0,0,0,0,0,"Italy;Germany;Finland;United States","5;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","25;10;7;6;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;CARDIOVASCULAR;HEART DISEASE;PATIENT SAFETY;HEMATOLOGY;ORPHAN DRUG;HEART DISEASE - CORONARY HEART DISEASE;PEDIATRIC;TRANSPLANTATION;AGING;BIOENGINEERING;BRAIN DISORDERS;CHILDHOOD LEUKEMIA;DIGESTIVE DISEASES;EPILEPSY;KIDNEY DISEASE;NEURODEGENERATIVE","20;15;10;9;8;7;7;6;6;3;3;3;2;2;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;RENAL AND UROGENITAL;SKIN","8;7;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","13;4;3;1;1;1","LEUKEMIA / LEUKAEMIA;LIVER CANCER;MYELOMA;BREAST CANCER;COLON AND RECTAL CANCER;GALLBLADDER CANCER;HODGKIN'S DISEASE;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER;SKIN CANCER","4;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","10;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_RIUNITIANCONA",2012,246,13.9552845528455,2.45934959349594,0.317073170731707,0.288617886178862,0.585365853658537,1.62634408602151,1.25806451612903,1.3921568627451,1.58241758241758,0.365853658536585,0,140,39,18,23,0.57,0.16,0.07,0.09,48.79,1.16807668030715,6.79858299595143,0.308943089430894,0.869918699186992,0.415,0.492,0.503,0.466,"ALESSANDRO RAMBALDI;STEFANO CASCINU;GIUSEPPE REMUZZI;TAMARA INTERMESOLI;ELENA OLDANI;FRANCESCO DI RAIMONDO;PAOLO CORRADINI;LEONARDO ANTONICELLI;ORIETTA SPINELLI;ROSSANA BERARDI;FABIO CICERI;ANDREA ROSSI;GIORGINA SPECCHIA;TIZIANO BARBUI;GIOVANNI MARTINELLI;ROBERTO LABIANCA;ENRICO MARIA POGLIANI;FRANCESCO PASSAMONTI;AYALEW TEFFERI;LUCA ANSALONI","34;12;10;9;8;8;8;8;7;7;7;7;7;7;7;7;7;6;6;6","ALESSANDRO RAMBALDI;FEDERICO COCCOLINI;STEFANO CASCINU;LEONARDO ANTONICELLI;FAUSTO CATENA;ROBERTO LABIANCA;GIUSEPPE REMUZZI;GIOVANNI MUZZONIGRO;MARIO GANAU;GIULIA BARBATI;FRANCO MAGGIOLO;MARIA CHIARA MARINOZZI;ANTONELLA PAGLIARICCIO;ORIETTA SPINELLI;LUCIANO BURATTINI;MAURO SILVESTRINI;GIOVANNA VITICCHI;LORENZO FALSETTI;MARIA IASCONE;LUCA ANSALONI","2.24;1.18;1.16;0.9;0.86;0.83;0.82;0.78;0.75;0.71;0.69;0.67;0.67;0.64;0.63;0.62;0.62;0.62;0.61;0.6","ALESSANDRO RAMBALDI;GIUSEPPE REMUZZI;TAMARA INTERMESOLI;ELENA OLDANI;LEONARDO ANTONICELLI;ORIETTA SPINELLI;ROSSANA BERARDI;ANDREA ROSSI;TIZIANO BARBUI;ROBERTO LABIANCA;LUCA ANSALONI;FEDERICO COCCOLINI;FRANCO MAGGIOLO;S. FAGIUOLI;PIETRO LEONI;LUCIANO BURATTINI;GIANFRANCO SINAGRA;GIULIO GUAGLIUMI;MASSIMO OFFIDANI;ARIELA BENIGNI","34;10;9;8;8;7;7;7;7;7;6;6;6;6;6;5;5;5;5;5","ALESSANDRO RAMBALDI;FEDERICO COCCOLINI;LEONARDO ANTONICELLI;FAUSTO CATENA;ROBERTO LABIANCA;GIUSEPPE REMUZZI;GIOVANNI MUZZONIGRO;MARIO GANAU;GIULIA BARBATI;FRANCO MAGGIOLO;ANTONELLA PAGLIARICCIO;ORIETTA SPINELLI;LUCIANO BURATTINI;MAURO SILVESTRINI;GIOVANNA VITICCHI;LORENZO FALSETTI;MARIA IASCONE;LUCA ANSALONI;TAMARA INTERMESOLI;ELENA OLDANI","2.24;1.18;0.9;0.86;0.83;0.82;0.78;0.75;0.71;0.69;0.67;0.64;0.63;0.62;0.62;0.62;0.61;0.6;0.59;0.59","ROBERTO LABIANCA;BERNARD NORDLINGER;ERIC VAN CUTSEM;ANDREA DI LENARDA;GIANFRANCO SINAGRA;A. GARIN;ALBERTO SOBRERO;ALEXANDER STEIN;ANDREY MESHCHERYAKOV;ANDRÉS CERVANTES;BENGT GLIMELIUS;C.-H. KÖHNE;CORNELIS JH VAN DE VELDE;DAN ADERKA;DAVID J. KERR;DEMETRIS PAPAMICHAIL;DIRK ARNOLD;FORTUNATO CIARDIELLO;G. BODOKY;GEERARD L. BEETS","1820;1637;1637;1417;1411;1391;1391;1391;1391;1391;1391;1391;1391;1391;1391;1391;1391;1391;1391;1391","ROBERTO LABIANCA;GIANFRANCO SINAGRA;TIZIANO BARBUI;MARCO MERLO;ALESSANDRO RAMBALDI;GIUSEPPE REMUZZI;GIULIO GUAGLIUMI;GUIDO FINAZZI;PIERO RUGGENENTI;MARIA L FERARRI;GIUSEPPE MUSUMECI;NIKOLOZ LORTKIPANIDZE;HIDEYUKI IKEJIMA;ORAZIO VALSECCHI;VASILE SIRBU;ROBERTO TREVISAN;ALEKSANDRE MATIASHVILI;GIUSEPPE BIONDI‐ZOCCAI;ALESSANDRO ROBERTO DODESINI;ALESSANDRA CAROBBIO","1820;1406;1333;1299;1021;872;799;777;468;388;385;385;359;359;359;346;331;331;278;276","ALESSANDRO RAMBALDI;TAMARA INTERMESOLI;GIUSEPPE REMUZZI;ELENA OLDANI;LEONARDO ANTONICELLI;FRANCO MAGGIOLO;ANDREA ROSSI;ROBERTO LABIANCA;S. FAGIUOLI;PIETRO LEONI;ORIETTA SPINELLI;LUCA ANSALONI;MASSIMO OFFIDANI;FEDERICA DELAINI;FEDERICO COCCOLINI;GIANFRANCO SINAGRA;GIULIA BARBATI;GIULIO GUAGLIUMI;L. PASULO;M. COLLEDAN","33;9;8;8;8;7;7;7;6;6;6;5;5;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY;MATHEMATICS;MATERIALS SCIENCE;BUSINESS;ART;HISTORY","237;57;18;14;12;12;11;6;6;6;6;5;4;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;PATHOLOGY;CARDIOLOGY;GENETICS;PSYCHIATRY;RADIOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;PEDIATRICS;ANESTHESIA;CANCER RESEARCH;NURSING;PALEONTOLOGY;ENDOCRINOLOGY;PHYSICAL THERAPY","191;81;54;49;36;36;30;28;22;22;20;19;18;18;15;14;13;13;12;11","CANCER;TRANSPLANTATION;CHEMOTHERAPY;GENE;DISEASE;CONFIDENCE INTERVAL;POPULATION;BONE MARROW;COHORT;ADVERSE EFFECT;HEART FAILURE;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);KIDNEY;STAGE (STRATIGRAPHY);LEUKEMIA;LYMPHOMA;MULTIVARIATE ANALYSIS;REGIMEN;STEM CELL","37;35;26;26;20;19;17;16;16;14;13;13;13;11;11;11;10;10;10;10;10","CLINICAL ENDPOINT;BREAST CANCER;COLORECTAL CANCER;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;VIRAL LOAD;LIVER TRANSPLANTATION;AUTOLOGOUS STEM-CELL TRANSPLANTATION;MYELOFIBROSIS;CYCLOPHOSPHAMIDE;IMATINIB;MUTATION;TOLERABILITY;LENALIDOMIDE;METASTASIS;PROTEINURIA;RESPIRATORY DISEASE;RITUXIMAB;ADENOCARCINOMA;BORTEZOMIB;CARDIOMYOPATHY;CHEMOTHERAPY REGIMEN;CHROMOSOME;CHRONIC HEPATITIS;DIFFUSE LARGE B-CELL LYMPHOMA;GENOTYPE;HAEMATOPOIESIS;KIDNEY TRANSPLANTATION;PERCUTANEOUS CORONARY INTERVENTION;PHASES OF CLINICAL RESEARCH;RESTENOSIS;SORAFENIB;SUNITINIB;UNIVARIATE ANALYSIS","10;9;9;9;9;9;8;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4","ANTIRETROVIRAL THERAPY;IMATINIB MESYLATE;MYELOPROLIFERATIVE NEOPLASM;NILOTINIB;ANTHRACYCLINE;NEOADJUVANT THERAPY;PODOCYTE;ABDOMINOPERINEAL RESECTION;ANTIVIRAL THERAPY;ANTIVIRAL TREATMENT;CD38;COLONOSCOPY;CORONAVIRUS DISEASE 2019 (COVID-19);CYTOREDUCTIVE SURGERY;DASATINIB;GENE EXPRESSION PROFILING;GLOMERULOSCLEROSIS;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KARYOTYPE;METASTATIC BREAST CANCER;PLEURAL DISEASE;REVERSE TRANSCRIPTASE;SEPTAL MYECTOMY;SINGLE-NUCLEOTIDE POLYMORPHISM;TOTAL MESORECTAL EXCISION;VINCRISTINE","5;5;5;5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;;FEMALE;MIDDLE AGED;AGED;ADULT;TREATMENT OUTCOME;ITALY;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;FOLLOW-UP STUDIES;KIDNEY;PROSPECTIVE STUDIES;ANTINEOPLASTIC AGENTS;ADENOCARCINOMA;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CORONARY ARTERY DISEASE;ADOLESCENT;YOUNG ADULT","135;103;102;102;86;77;59;42;38;35;29;26;25;25;24;23;22;22;20;18","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;LYMPHOID NEOPLASMS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EFFICACY AND RESISTANCE IN CML TREATMENT;HEPATITIS C INFECTION AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASES;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEMATOPOIETIC STEM CELL BIOLOGY;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;ASTHMA;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GLIOMAS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;ORGAN TRANSPLANTATION AND REJECTION","10;8;8;7;7;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3","TREATMENT;CLINICAL ENDPOINT;REGIMEN;ANTIRETROVIRAL THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;TREATMENT OUTCOMES;REFRACTORY (PLANETARY SCIENCE);TOLERABILITY;ASTHMA;CORONARY STENTS;HEPATITIS C;HIV INFECTION;IMATINIB MESYLATE;INTERNATIONAL MYELOMA WORKING GROUP;MYELOPROLIFERATIVE NEOPLASM;CHEMOTHERAPY REGIMEN;CONCOMITANT;DIAGNOSIS CRITERIA;DRUG-ELUTING STENTS;EVEROLIMUS","12;10;10;7;7;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4","STEM CELL;CELL TRANSPLANTATION;PATIENTS RECEIVING;MULTIPLE MYELOMA;PHASE II;PRELIMINARY RESULTS;ACUTE LYMPHOBLASTIC;CELL CARCINOMA;CLINICAL OUTCOME;CLINICAL TRIAL;LIVER TRANSPLANTATION;LYMPHOBLASTIC LEUKEMIA;MYELOID LEUKEMIA;ALLOGENEIC STEM;AUTOLOGOUS STEM;CHRONIC MYELOID;COHORT STUDY;DI CHIRURGIA;ENDOTHELIAL GROWTH;GROWTH FACTOR;HEART FAILURE;HYPERTROPHIC CARDIOMYOPATHY;ITALIANA DI;MYELOPROLIFERATIVE NEOPLASM;PATIENTS UNDERGOING;RECTAL CANCER;RENAL CELL;SOCIETÀ ITALIANA;VASCULAR ENDOTHELIAL;CANCER PATIENTS","13;11;7;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3","PUBMED SCOPUS;PEAK VO;CROSSREF PUBMED;CELL LINES;POSTOPERATIVE PEAK;PREDICTED POSTOPERATIVE;TRANSPLANT RECIPIENTS;DE NOVO;DEACETYLASE INHIBITOR;HISTONE DEACETYLASE;CELL LINE;RENAL FUNCTION;CARDIAC SURGERY;HIV RNA;KIDNEY TRANSPLANT;ALTHE HISTONE;CELLS BEARING;CLINICAL PRACTICE;GENE EXPRESSION;INHIBITOR ITF;POSTPERICARDIOTOMY SYNDROME;ACTUAL POSTOPERATIVE;BEARING MUTATED;HAZARD RATIO;HEART TRANSPLANT;ITF SELECTIVELY;JAKVFLEUKEMIA -CROSSREF;MPN PATIENTS;MSC INFUSION;MUTATED JAKVFLEUKEMIA","33;32;30;29;26;14;13;12;12;12;11;11;10;10;10;9;9;9;9;9;9;8;8;8;8;8;8;8;8;8",5,0.02,6,13,11,3,0,4,8.5,0,0,13,0,1,41,0,1,3,11,28,8,0,0,63,63,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,6.66,1024.62,9.3,12,0.38,83.97,0,0,7,0,12,0,4,9,0,24,6,0,0,0,0,0,0,31,1,0,30,2,0,0,0,0,0,0,0,0,"United States;Germany;Canada;Italy","16;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3203 DENTISTRY;3210 NUTRITION AND DIETETICS;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","31;13;12;11;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;LYMPHOMA;CARDIOVASCULAR;HEART DISEASE;PREVENTION;BIOMEDICAL IMAGING;NEURODEGENERATIVE;PEDIATRIC;NEUROSCIENCES;BIOENGINEERING;BRAIN DISORDERS;EPILEPSY;PATIENT SAFETY;STEM CELL RESEARCH;TRANSPLANTATION;CHILDHOOD LEUKEMIA","28;17;16;13;13;7;6;6;6;5;5;5;4;3;3;3;3;3;3;2","CANCER;CARDIOVASCULAR;INFECTION;NEUROLOGICAL;RENAL AND UROGENITAL","13;5;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES;4.4 POPULATION SCREENING;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","19;8;3;2;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;MYELOMA;LUNG CANCER;BREAST CANCER;COLON AND RECTAL CANCER;PANCREATIC CANCER","7;5;3;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","15;3;1;1",1,1434978,286995.6,4,5,3,1,4,129130.675510204,1.90504695362304,"ANDALUSIAN HEALTH SERVICE;AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI;INSTITUT DE RECERCA DE L'ENERGIA DE CATALUNYA;LOCCIONI (ITALY);TECHNICAL UNIVERSITY OF CRETE","1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CIP - COMPETITIVENESS AND INNOVATION FRAMEWORK PROGRAMME (CIP)(2007-2013) (PROGRAMME);CIP-ICT-PSP-2011-5 (CALL FOR PROPOSAL);PB - PILOT TYPE B (FUNDING SCHEME)","1;1;1","33 BUILT ENVIRONMENT AND DESIGN;3301 ARCHITECTURE;3302 BUILDING;40 ENGINEERING","1;1;1;1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"B12 ENGINEERING","1","7 AFFORDABLE AND CLEAN ENERGY","1",3,"PUBLIC LIBRARY OF SCIENCE","3","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS","3;2;1;1","BIOTECHNOLOGY;GENETICS","1;1",NA,NA,"2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","BIOMEDICAL","1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","1;1",NA,NA,NA,NA
"AOU_RIUNITIANCONA",2013,195,13.3435897435897,2.63589743589744,0.312820512820513,0.266666666666667,0.446153846153846,1.5207100591716,1.19607843137255,1.33333333333333,1.24285714285714,0.394871794871795,0,116,26,16,24,0.59,0.13,0.08,0.12,38.17,1.09405425806338,6.67960288808664,0.287179487179487,0.871794871794872,0.467,0.449,0.482,0.496,"STEFANO CASCINU;LUCA FALOPPI;MARIO SCARTOZZI;MARISTELLA BIANCONI;MATTEO SANTONI;RICCARDO GIAMPIERI;ROSSANA BERARDI;ALESSANDRA MANDOLESI;ITALO BEARZI;ALESSANDRO BITTONI;ALESSANDRO RAMBALDI;CRISTIAN LORETELLI;GIOVANNI MOSCONI;GIANFRANCO SINAGRA;LUCIANO BURATTINI;GIULIA BARBATI;MICHELA DEL PRETE;MARIO BOCCADORO;LUCA ANSALONI;LUCA CECCHINI","24;14;13;13;11;10;10;10;10;9;9;9;8;8;7;7;7;6;6;6","STEFANO CASCINU;GIOVANNI MOSCONI;LUCA FALOPPI;MARIO SCARTOZZI;MARISTELLA BIANCONI;ALESSANDRA MANDOLESI;ITALO BEARZI;GIULIA BARBATI;RICCARDO GIAMPIERI;CRISTIAN LORETELLI;ROSSANA BERARDI;GIANFRANCO SINAGRA;MATTEO SANTONI;MASSIMO RIVA;ALESSANDRO BITTONI;MICHELE BERTOLOTTO;MICHELA DEL PRETE;LUCIANO BURATTINI;MARIA GRAZIA SANTINI;VIRGILIO CARNIELLI","2.15;1.68;1.37;1.24;1.24;1.05;1.05;0.99;0.93;0.91;0.87;0.85;0.84;0.84;0.82;0.62;0.61;0.59;0.59;0.58","STEFANO CASCINU;LUCA FALOPPI;MARIO SCARTOZZI;MARISTELLA BIANCONI;MATTEO SANTONI;RICCARDO GIAMPIERI;ROSSANA BERARDI;ALESSANDRA MANDOLESI;ITALO BEARZI;ALESSANDRO BITTONI;ALESSANDRO RAMBALDI;CRISTIAN LORETELLI;GIOVANNI MOSCONI;GIANFRANCO SINAGRA;GIULIA BARBATI;MICHELA DEL PRETE;MARIO BOCCADORO;LUCA ANSALONI;LUCA CECCHINI;TAMARA INTERMESOLI","24;14;13;13;11;10;10;10;10;9;9;9;8;8;7;7;6;6;6;6","STEFANO CASCINU;GIOVANNI MOSCONI;LUCA FALOPPI;MARIO SCARTOZZI;MARISTELLA BIANCONI;ALESSANDRA MANDOLESI;ITALO BEARZI;GIULIA BARBATI;RICCARDO GIAMPIERI;CRISTIAN LORETELLI;ROSSANA BERARDI;GIANFRANCO SINAGRA;MATTEO SANTONI;MASSIMO RIVA;ALESSANDRO BITTONI;MICHELE BERTOLOTTO;MICHELA DEL PRETE;MARIA GRAZIA SANTINI;VIRGILIO CARNIELLI;SILVIA GENTILI","2.15;1.68;1.37;1.24;1.24;1.05;1.05;0.99;0.93;0.91;0.87;0.85;0.84;0.84;0.82;0.62;0.61;0.59;0.58;0.57","TIZIANO BARBUI;HEINZ GISSLINGER;ALESSANDRO M. VANNUCCHI;FRANCESCO PASSAMONTI;FRANCO MAGGIOLO;ALESSANDRO RAMBALDI;ALESSANDRO BRUNELLI;ANDREA EBERHARD;ANTONIO ANTELA;BRIAN WYNNE;CATHERINE GRANIER;DAN DUICULESCU;FÉLIX GUTIÉRREZ;GARRETT NICHOLS;KEITH A. PAPPA;LAURENT HOCQUELOUX;NATHAN CLUMECK;SHARON WALMSLEY;SHERENE MIN;URIEL SANDKOVSKY","1044;1037;1005;1004;832;822;785;783;783;783;783;783;783;783;783;783;783;783;783;783","TIZIANO BARBUI;FRANCO MAGGIOLO;ALESSANDRO RAMBALDI;ALESSANDRO BRUNELLI;ALESSANDRA CAROBBIO;GUIDO FINAZZI;LUCA ANSALONI;FEDERICO COCCOLINI;MASSIMO OFFIDANI;M. COLLEDAN;GIUSEPPE REMUZZI;ROBERTO TREVISAN;STEFANO CASCINU;PIETRO LEONI;LUCA FABRIS;MARIO STRAZZABOSCO;MASSIMILIANO CADAMURO;ATTILIO OLIVIERI;VIRGILIO CARNIELLI;ANTONIETTA FALCONE","1036;832;786;785;593;593;490;429;398;395;256;213;185;155;154;154;154;153;148;141","MARIO SCARTOZZI;MATTEO SANTONI;STEFANO CASCINU;GIANFRANCO SINAGRA;LUCA ANSALONI;ALESSANDRO RAMBALDI;GIULIA BARBATI;MASSIMO OFFIDANI;TAMARA INTERMESOLI;FEDERICO COCCOLINI;FRANCO MAGGIOLO;M. COLLEDAN;MICHELE SENNI;PIETRO LEONI;TIZIANO BARBUI;AZZURRA ONOFRI;GIANLUCA VALERI;GIULIO GUAGLIUMI;MARCO MERLO;MARTINO INTRONA","12;8;8;7;6;6;6;6;6;5;5;4;4;4;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;ECONOMICS;POLITICAL SCIENCE;MATHEMATICS;PSYCHOLOGY;COMPUTER SCIENCE;PHILOSOPHY;SOCIOLOGY;MATERIALS SCIENCE;ART;BUSINESS;GEOLOGY;HISTORY","183;52;18;13;12;10;10;9;9;8;5;5;3;2;2;2;2","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ONCOLOGY;CARDIOLOGY;GASTROENTEROLOGY;CANCER RESEARCH;GENETICS;IMMUNOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;PSYCHIATRY;RADIOLOGY;PEDIATRICS;ANESTHESIA;PALEONTOLOGY;PHYSICAL THERAPY;ENDOCRINOLOGY;MOLECULAR BIOLOGY","138;54;48;45;29;24;21;21;20;20;18;18;17;17;14;11;11;11;10;10","CANCER;GENE;RANDOMIZED CONTROLLED TRIAL;CHEMOTHERAPY;DISEASE;POPULATION;PROSPECTIVE COHORT STUDY;COHORT;HEART FAILURE;TRANSPLANTATION;ALTERNATIVE MEDICINE;CONFIDENCE INTERVAL;HEPATOCELLULAR CARCINOMA;MULTIPLE MYELOMA;CLINICAL TRIAL;RECEPTOR;INCIDENCE (GEOMETRY);PROPORTIONAL HAZARDS MODEL;RENAL CELL CARCINOMA;STAGE (STRATIGRAPHY)","39;21;16;15;15;14;13;12;12;11;10;10;10;10;8;8;7;7;7;7","COLORECTAL CANCER;BREAST CANCER;PANCREATIC CANCER;SORAFENIB;BEVACIZUMAB;BORTEZOMIB;EJECTION FRACTION;HAZARD RATIO;METASTASIS;MUTATION;SUNITINIB;VASCULAR ENDOTHELIAL GROWTH FACTOR;ADENOCARCINOMA;CANCER CELL;DILATED CARDIOMYOPATHY;GENOTYPE;HEART RATE;LENALIDOMIDE;LIVER TRANSPLANTATION;UNIVARIATE ANALYSIS;VIRAL LOAD","10;8;7;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","PAZOPANIB;ANTHRACYCLINE;ANTIRETROVIRAL THERAPY;IMATINIB MESYLATE;KRAS;ABL;BAYLEY SCALES OF INFANT DEVELOPMENT;BENDAMUSTINE;CONTRAST-INDUCED NEPHROPATHY;IRINOTECAN;LAMIVUDINE;RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;TRPV1;TUMOR INITIATION;VO2 MAX;ACE INHIBITOR;ACHILLES TENDON RUPTURE;ACROMEGALY;ACUTE PROMYELOCYTIC LEUKEMIA;AFLIBERCEPT;ASYMMETRIC DIMETHYLARGININE;AUTOLYSIN;BAROREFLEX;BIVALIRUDIN;BLOOD LEAD LEVEL;BOARD CERTIFICATION;BREAST SURGERY;BRONCHOPULMONARY DYSPLASIA;BUSULFAN;CA19-9;CARDIAC RESYNCHRONIZATION THERAPY;CD117;CD24;CETUXIMAB;CHLORAMBUCIL;CITALOPRAM;CLADE;COPY-NUMBER VARIATION;CORONARY RESTENOSIS;DASATINIB;DEEP SEQUENCING;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DNA METHYLATION;DOPPLER ECHOCARDIOGRAPHY;DOPPLER IMAGING;DRONEDARONE;EGFR INHIBITORS;ENOS;ERLOTINIB;EXCESSIVE DAYTIME SLEEPINESS;FORAMEN OVALE (HEART);FULMINANT HEPATIC FAILURE;GASTROINTESTINAL CANCER;GEFITINIB;GENE EXPRESSION PROFILING;GLI1;GROWTH HORMONE RECEPTOR;HEART RATE MONITOR;HYMENOLEPIS NANA;IFOSFAMIDE;ILEITIS;IMMUNOGLOBULIN D;INJURY SEVERITY SCORE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRRITANT CONTACT DERMATITIS;KARYOTYPE;LYMPHANGIOGENESIS;LYMPHOPLASMACYTIC LYMPHOMA;MASPIN;MASTECTOMY;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MILAN CRITERIA;MODEL FOR END-STAGE LIVER DISEASE;MOLECULAR EPIDEMIOLOGY;MUSCULOSKELETAL DISORDER;MYCOBACTERIUM TUBERCULOSIS COMPLEX;MYELOPROLIFERATIVE NEOPLASM;NEOADJUVANT THERAPY;NEUROPEPTIDE Y RECEPTOR;NILOTINIB;OFATUMUMAB;OXALIPLATIN;PATCHED;PEMPHIGOID;PHENOCOPY;PHILADELPHIA CHROMOSOME;PITTSBURGH SLEEP QUALITY INDEX;PLASMA CELL DYSCRASIA;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;PLK1;POLOXAMER;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER;PROBAND;PROTEIN KINASE DOMAIN;PTCH1;REM SLEEP BEHAVIOR DISORDER;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;REVERSE TRANSCRIPTASE;RUXOLITINIB;SANGER SEQUENCING;SIDA;SMOOTHENED;STAPHYLOCOCCAL INFECTIONS;STROKE VOLUME;TARGET LESION;TAXANE;TIMI;TRICHURIS TRICHIURA;UNIT OF ALCOHOL;UROTHELIAL CELL;VANCOMYCIN;VASCULAR ENDOTHELIAL GROWTH FACTOR A;ZIDOVUDINE","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;AGED;MIDDLE AGED;ADULT;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;MULTIPLE MYELOMA;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES;POSTOPERATIVE COMPLICATIONS;HIV INFECTIONS;SURVIVAL RATE;ADOLESCENT;HEART DISEASES;LIVER TRANSPLANTATION","115;85;82;75;57;53;43;34;30;26;20;19;19;17;16;15;14;13;13;13","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;RENAL CELL CARCINOMA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EFFICACY AND RESISTANCE IN CML TREATMENT;EPILEPSY AND SEIZURES;PANCREATIC CANCER RESEARCH AND TREATMENT;ACUTE MYELOID LEUKEMIA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;DIAGNOSIS AND MANAGEMENT OF APPENDICITIS;HEPATITIS C INFECTION AND TREATMENT;OCCUPATIONAL HEALTH AND SAFETY IN WORKPLACES;PATENT FORAMEN OVALE AND CEREBROVASCULAR EVENTS;ADAPTATION OF TENDON AND SKELETAL MUSCLE TO MECHANICAL LOADING;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CANCER STEM CELLS AND TUMOR METASTASIS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF HEART FAILURE","9;7;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2","DIAGNOSIS;TREATMENT;REGIMEN;TUMOR MICROENVIRONMENT;PANCREATIC CANCER;DILATED CARDIOMYOPATHY;DISCONTINUATION;INTERNATIONAL MYELOMA WORKING GROUP;METASTATIC COLORECTAL CANCER;METASTATIC PANCREATIC CANCER;PAZOPANIB;UNIVARIATE ANALYSIS;ANTIRETROVIRAL THERAPY;CANCER STEM CELLS;CARDIAC IMAGING;CARDIOVASCULAR EVALUATION;CLINICAL ENDPOINT;CLINICAL PRACTICE;DIAGNOSIS CRITERIA;ETIOLOGY","8;8;6;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","CELL CARCINOMA;RENAL CELL;CANCER PATIENTS;CLINICAL OUTCOME;MULTIPLE MYELOMA;PATIENTS RECEIVING;METASTATIC RENAL;STEM CELL;PHASE II;PROSPECTIVE STUDY;AORTIC VALVE;CANCER CELLS;CARCINOMA MRCC;DILATED CARDIOMYOPATHY;ENDOTHELIAL GROWTH;GROWTH FACTOR;HEART FAILURE;II STUDY;ITALIAN REGISTRY;MYELOID LEUKEMIA;PANCREATIC CANCER;RECEIVING FIRST-LINE;VASCULAR ENDOTHELIAL;ACHILLES TENDON;ADULT PATIENTS;ALLOGENEIC HEMATOPOIETIC;ANTIRETROVIRAL THERAPY;BCR-ABL KINASE;BREAST CANCER;CANCER STEM","7;7;6;6;6;6;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","PUBMED SCOPUS;GLOMERULAR FILTRATION;CROSSREF PUBMED;CONSIDERED SEPARATELY;FILTRATION RATE;PATIENTS CONSIDERED;HYPERFILTERING NORMOFILTERING;HYPOFILTERING PATIENTS;PEAK VO;SUPPLEMENTARY TABLE;MULTIPLE MYELOMA;GFR DECLINE;RENAL DISEASE;DISEASE EPIDEMIOLOGY;IOHEXOL CLEARANCE;KIDNEY DISEASE;SEPARATELY VERSUS;VERSUS IOHEXOL;VERSUS PATIENTS;VEVCO SLOPE;CCA CELLS;CHRONIC KIDNEY;CLINICAL PRACTICE;LONG-TERM GFR;LUNG CANCER;SERUM CREATININE;CARE -CROSSREF;CONCORDANCE CORRELATION;HYPERFILTERING PATIENTS;INTRA-ABDOMINAL INFECTIONS","21;19;18;16;15;15;13;12;12;12;11;10;10;9;9;9;9;9;9;9;8;8;8;8;8;8;7;7;7;7",9,0.05,6,6,208.25,0,1,1,13,0,1,10,0,0,5,0,2,1,2,3.75,1.25,0,0,102,102,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,5.27,1634.48,7.9,10,0.38,84.88,0,0,2,1,9,0,0,14,0,14,12,0,0,0,0,0,0,24,2,0,26,0,0,0,0,0,0,0,0,0,"Italy;United States;Belgium;China;Hungary;Israel;Japan;Poland;United Kingdom","7;5;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4205 NURSING;4203 HEALTH SERVICES AND SYSTEMS;3215 REPRODUCTIVE MEDICINE;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","24;12;7;5;3;3;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;RARE DISEASES;HEMATOLOGY;CARDIOVASCULAR;AGING;BREAST CANCER;HEART DISEASE;TRANSPLANTATION;HEART DISEASE - CORONARY HEART DISEASE;PEDIATRIC;PREVENTION;BIOENGINEERING;LUNG;LYMPHOMA;ORPHAN DRUG;REHABILITATION;STEM CELL RESEARCH","25;14;13;9;9;8;6;4;4;4;4;3;3;3;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;BLOOD;INJURIES AND ACCIDENTS;REPRODUCTIVE HEALTH AND CHILDBIRTH","11;3;1;1;1","6.1 PHARMACEUTICALS;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES","11;2;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;MYELOMA;BLADDER CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;MELANOMA;NOT SITE-SPECIFIC CANCER;STOMACH CANCER;THYROID CANCER","5;3;3;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","10;4;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,"PUBLIC LIBRARY OF SCIENCE","9","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3402 INORGANIC CHEMISTRY;4202 EPIDEMIOLOGY;49 MATHEMATICAL SCIENCES;52 PSYCHOLOGY;3105 GENETICS;4905 STATISTICS;5203 CLINICAL AND HEALTH PSYCHOLOGY","7;4;2;2;2;2;2;2;2;1;1;1","ASTHMA;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;LUNG;CLINICAL RESEARCH;PREVENTION","2;2;2;1;1","RESPIRATORY","3","4.4 POPULATION SCREENING","1","CLINICAL;HEALTH SERVICES & SYSTEMS;POPULATION & SOCIETY","2;1;1","CLINICAL MEDICINE AND SCIENCE","3",NA,NA,NA,NA
"AOU_RIUNITIANCONA",2014,184,14.6576086956522,2.66304347826087,0.326086956521739,0.298913043478261,0.440217391304348,1.4051724137931,1.11111111111111,1.27906976744186,1.10958904109589,0.407608695652174,5,109,35,12,15,0.59,0.19,0.07,0.08,45.93,1.21547274411826,6.89202657807308,0.315217391304348,0.885869565217391,0.432,0.398,0.418,0.377,"STEFANO CASCINU;MATTEO SANTONI;ALESSANDRO BITTONI;GIANLUCA VALERI;RICCARDO GIAMPIERI;MARIO SCARTOZZI;MARISTELLA BIANCONI;LUCA FALOPPI;ALESSANDRO CONTI;MASSIMO OFFIDANI;DANIELE SANTINI;GABRIELE GRASSI;ROSSANA BERARDI;GIANFRANCO SINAGRA;GIUSEPPE DI LORENZO;ALESSANDRA MANDOLESI;CRISTIAN LORETELLI;MICHELA DEL PRETE;ANTONELLA MELONI;LUCIANO BURATTINI","18;13;9;8;8;8;8;7;7;7;7;6;6;6;6;6;6;6;5;5","STEFANO CASCINU;MITJA JEVNIKAR;CATERINA ANTONAGLIA;GABRIELE GABRIELLI;LUCIA COMUZZI;BERARDI ROSSANA;MATTEO SANTONI;GABRIELE GRASSI;GIANLUCA VALERI;ALESSANDRO BITTONI;MARIO GRASSI;GIANCARLO TIRELLI;MARIA CHIARA MARINOZZI;ANTONELLA PAGLIARICCIO;ANDREA GIOVAGNONI;GIANFRANCO SINAGRA;RICCARDO GIAMPIERI;MARIO SCARTOZZI;MARISTELLA BIANCONI;INES CARLONI","1.61;1.12;1;1;1;1;0.98;0.89;0.86;0.81;0.76;0.7;0.7;0.7;0.7;0.68;0.67;0.67;0.67;0.64","STEFANO CASCINU;MATTEO SANTONI;GIANLUCA VALERI;RICCARDO GIAMPIERI;MARIO SCARTOZZI;MARISTELLA BIANCONI;LUCA FALOPPI;ALESSANDRO CONTI;MASSIMO OFFIDANI;GABRIELE GRASSI;ROSSANA BERARDI;GIANFRANCO SINAGRA;ALESSANDRA MANDOLESI;LUCIANO BURATTINI;MASSIMO SCERRATI;ANDREA GIOVAGNONI;MARIO GRASSI;MAURO MONTANARI;PIETRO LEONI;ATTILIO OLIVIERI","18;13;8;8;8;8;7;7;7;6;6;6;6;5;5;5;5;5;5;4","STEFANO CASCINU;MITJA JEVNIKAR;CATERINA ANTONAGLIA;GABRIELE GABRIELLI;LUCIA COMUZZI;BERARDI ROSSANA;MATTEO SANTONI;GABRIELE GRASSI;GIANLUCA VALERI;MARIO GRASSI;GIANCARLO TIRELLI;ANTONELLA PAGLIARICCIO;ANDREA GIOVAGNONI;GIANFRANCO SINAGRA;RICCARDO GIAMPIERI;MARIO SCARTOZZI;MARISTELLA BIANCONI;INES CARLONI;ALESSANDRO CONTI;MARGHERITA TOFANELLI","1.61;1.12;1;1;1;1;0.98;0.89;0.86;0.76;0.7;0.7;0.7;0.68;0.67;0.67;0.67;0.64;0.62;0.61","ADAM TORBICKI;ALDO SALVI;ANA PAULA FIGUEIREDO DE MONTALVÃO FRANÇA;ANNETTE GEIBEL;ANTONIU OCTAVIAN PETRIȘ;BENJAMIN BRENNER;BOŻENA SOBKOWICZ;BRANISLAV STEFANOVIĆ;CECILIA BECATTINI;CHRISTIAN KUPATT;CLAUDIA DELLAS;DAVID JIMÉNEZ;ERICH BLUHMKI;FRANCK VERSCHUREN;FRANÇIS COUTURAUD;G PACOURET;GIANCARLO AGNELLI;GUY MEYER;HÉLÈNE BOUVAIST;HÖLGER THIELE","1369;1369;1369;1369;1369;1369;1369;1369;1369;1369;1369;1369;1369;1369;1369;1369;1369;1369;1369;1369","ALDO SALVI;MARIA BEATRICE BILÒ;LUCA ANSALONI;FEDERICO COCCOLINI;FRANCO MAGGIOLO;GIANFRANCO SINAGRA;GIULIO GUAGLIUMI;F LEONCINI;F. BLANCO QUINTANA;DAVIDE CORBELLA;ELIA POIASINA;ORIETTA SPINELLI;MICHELE PISANO;MARIA IASCONE;BRUNO FABRIS;LAURA VITALI SERDOZ;ROBERTO MARASCA;MASSIMO OFFIDANI;GEORGIOS ELEFTHERIOU;STELLA BERNARDI","1369;1248;564;503;460;354;316;303;303;256;256;254;247;225;223;223;204;186;176;166","MATTEO SANTONI;MARIO SCARTOZZI;GIANLUCA VALERI;GABRIELE GRASSI;GIANFRANCO SINAGRA;MASSIMO OFFIDANI;PIETRO LEONI;INES CARLONI;LUCIANO BURATTINI;MAURO MONTANARI;MARIA BEATRICE BILÒ;ALESSANDRA MANDOLESI;BARBARA DAPAS;BRUNO FABRIS;CARLO TROMBETTA;FERNANDO M. DE BENEDICTIS;GIANCARLO TIRELLI;GIOVANNI LIGUORI;GIUSEPPE GATTI;LEONARDO ANTONICELLI","11;8;7;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;PSYCHOLOGY;COMPUTER SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS","180;45;18;17;10;9;7;7;4;3;3;2;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;CARDIOLOGY;PATHOLOGY;GASTROENTEROLOGY;RADIOLOGY;BIOCHEMISTRY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;GENETICS;CANCER RESEARCH;PSYCHIATRY;ENDOCRINOLOGY;ANESTHESIA;OPTICS;PEDIATRICS;DERMATOLOGY;PALEONTOLOGY;PHARMACOLOGY","134;64;34;29;29;28;27;23;21;19;14;14;12;11;10;9;9;9;8;8;8","CANCER;CHEMOTHERAPY;GENE;DISEASE;COHORT;POPULATION;TRANSPLANTATION;MULTIVARIATE ANALYSIS;HEART FAILURE;MAGNETIC RESONANCE IMAGING;RENAL CELL CARCINOMA;CONFIDENCE INTERVAL;PROPORTIONAL HAZARDS MODEL;RETROSPECTIVE COHORT STUDY;ATRIAL FIBRILLATION;LYMPHOMA;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;INCIDENCE (GEOMETRY);ADVERSE EFFECT;ANGIOGENESIS;MYOCARDIAL INFARCTION;ODDS RATIO;THROMBOSIS;VIRUS","29;20;19;14;13;13;12;11;10;10;10;9;9;9;8;8;8;8;7;6;6;6;6;6;6","UNIVARIATE ANALYSIS;GENOTYPE;BREAST CANCER;COLORECTAL CANCER;CLINICAL ENDPOINT;MUTATION;CARDIOMYOPATHY;EJECTION FRACTION;LIVER TRANSPLANTATION;NEUTROPENIA;SUNITINIB;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BEVACIZUMAB;CYCLOPHOSPHAMIDE;HAZARD RATIO;LYMPHADENECTOMY;NEPHRECTOMY;PANCREATIC CANCER;RITUXIMAB;SORAFENIB;VASCULAR ENDOTHELIAL GROWTH FACTOR;VIRAL LOAD","10;9;8;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4","DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;ANTIRETROVIRAL THERAPY;KRAS;OXALIPLATIN;PAZOPANIB;SINGLE-NUCLEOTIDE POLYMORPHISM;ANTHRACYCLINE;CD33;CHEMOIMMUNOTHERAPY;EXOME SEQUENCING;FLUDARABINE;GENOTYPING;INTERFACE (MATTER);IRINOTECAN;PRASUGREL;RIBAVIRIN;TAXANE;TICAGRELOR;ABSOLUTE NEUTROPHIL COUNT;ACHILLES TENDON RUPTURE;ACRYLIC ACID;ACUTE PROMYELOCYTIC LEUKEMIA;AGRAPHIA;ANAPHYLACTIC REACTIONS;ANTIPLATELET DRUG;ANTIVIRAL TREATMENT;ARTIFICIAL VENTILATION;ATOM-TRANSFER RADICAL-POLYMERIZATION;AUTOIMMUNE REGULATOR;AXILLA;BENDAMUSTINE;BUSULFAN;CA19-9;CAPECITABINE;CARDIAC RESYNCHRONIZATION THERAPY;CARFILZOMIB;CHIMERIC ANTIGEN RECEPTOR;COGNITIVE DECLINE;COLONOSCOPY;CORONAVIRUS DISEASE 2019 (COVID-19);CORPUS CALLOSOTOMY;COTTON WOOL SPOTS;DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING;DNA METHYLATION;DOCOSAHEXAENOIC ACID;DYSEXECUTIVE SYNDROME;EICOSAPENTAENOIC ACID;ELECTRICAL CARDIOVERSION;EPIRETINAL MEMBRANE;EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS;GANCICLOVIR;GENE MUTATION;GLI1;GLUCOSE HOMEOSTASIS;HEART RATE VARIABILITY;HEMOPHAGOCYTOSIS;HERPESVIRIDAE;HISTONE DEACETYLASE;IDH1;INTERNAL THORACIC ARTERY;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;LEUKOTRIENE RECEPTOR;LOW LEVEL LASER THERAPY;LOWER URINARY TRACT SYMPTOMS;METASTATIC BREAST CANCER;MICROARRAY;MITOPHAGY;MYH7;NONSYNONYMOUS SUBSTITUTION;OMALIZUMAB;OSTEOPROTEGERIN;P2Y12;PARKIN;PDGFRA;PENILE CURVATURE;PRIMARY CILIARY DYSKINESIA;PROBAND;PURINE ANALOGUE;REGORAFENIB;RENAL MASS;REVERSE TRANSCRIPTASE;RUXOLITINIB;SANGER SEQUENCING;SENTINEL LYMPH NODE;SMALL INTERFERING RNA;SPLENIC VEIN;TAMOXIFEN;TAQMAN;TOTAL BODY IRRADIATION;TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;TRIPLE-NEGATIVE BREAST CANCER;UNITED NETWORK FOR ORGAN SHARING;VASCULAR DEMENTIA;VASCULAR ENDOTHELIAL GROWTH FACTOR A;VEMURAFENIB;VINCRISTINE;VITAMIN K ANTAGONIST;VO2 MAX;WHOLE GENOME SEQUENCING","6;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;MIDDLE AGED;AGED;ADULT;ITALY;ATRIAL FIBRILLATION;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;FOLLOW-UP STUDIES;PROSPECTIVE STUDIES;ADOLESCENT;AGED, 80 AND OVER;ANTIBODIES, MONOCLONAL, HUMANIZED;MULTIPLE MYELOMA;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RISK FACTORS;POSTOPERATIVE COMPLICATIONS","111;86;82;71;63;56;50;33;27;26;21;20;20;17;16;14;14;13;13;12","RENAL CELL CARCINOMA;ATRIAL FIBRILLATION;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;PANCREATIC CANCER RESEARCH AND TREATMENT;ACUTE MYELOID LEUKEMIA;ASTHMA;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;GASTRIC CANCER RESEARCH AND TREATMENT;HEPATITIS C INFECTION AND TREATMENT;LYMPHOID NEOPLASMS;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;METABOLIC REPROGRAMMING IN CANCER BIOLOGY;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;DIAGNOSIS AND MANAGEMENT OF APPENDICITIS;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EFFECTS OF MEDICATION ON PREGNANCY OUTCOMES","10;5;5;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","UNIVARIATE ANALYSIS;RENAL CELL CARCINOMA;TREATMENT;CLINICAL ENDPOINT;ATRIAL FIBRILLATION;TEMSIROLIMUS;LYMPHADENECTOMY;METASTATIC PANCREATIC CANCER;PANCREATIC CANCER;ANTICOAGULANT THERAPY;ASTHMA;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CANCER CELL METABOLISM;CARDIAC ELECTROPHYSIOLOGY;CARDIAC IMAGING;GASTRIC CANCER;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;IRON OVERLOAD;LIVER TRANSPLANTATION;METASTATIC GASTRIC CANCER","10;8;8;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3","CELL CARCINOMA;RENAL CELL;ATRIAL FIBRILLATION;MULTIPLE MYELOMA;PATIENTS RECEIVING;ACUTE MYELOID;CANCER PATIENTS;CLINICAL OUTCOME;HEART FAILURE;LIVER TRANSPLANTATION;METASTATIC RENAL;MULTICENTER STUDY;MYELOID LEUKEMIA;CLINICAL PRACTICE;FIRST-LINE CHEMOTHERAPY;GASTRIC CANCER;MULTIPLE SCLEROSIS;PILOT STUDY;PROGNOSTIC FACTORS;SCLEROSIS PATIENTS;ACUTE CORONARY;ACUTE MYOCARDIAL;ANGIOGENESIS GENOTYPING;BONE MARROW;BREAST CANCER;CARCINOMA MRCC;CELL TRANSPLANTATION;CLINICAL TRIAL;CLINICOPATHOLOGIC STUDY;CONGENITAL HEART","10;9;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","ES-HC PATIENTS;HR CI;ATRIAL FIBRILLATION;COMPLEX GENOTYPES;CONSECUTIVE PATIENTS;EXCISED LNS;HEALTH CARE;MULTIVARIATE ANALYSIS;PATIENTS FREE;PATIENTS RECEIVING;REPERFUSION THERAPY;STEM CELL;SURGICAL REMOVAL;AC CT;CELL TRANSPLANTATION;DIABETIC PATIENTS;GRAFT LOSS;INCREASED RISK;ISOLATION FACILITIES;MINIMALLY INVASIVE;MULTIPLE SCLEROSIS;PATIENTS TREATED;QTC PROLONGATION;TOTAL REMOVAL;ALLERGIC REACTIONS;ALLOCATION MODEL;ANTITHROMBOTIC THERAPIES;BITA GRAFTING;BOOSTED PIS;CHEMOTHERAPY WITHWITHOUT","10;9;8;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4",7,0.04,4.75,4.5,7,17,0,34,4,0,1,4.5,0,1,5.25,0,0,4,20.5,19.5,10,0,0,100,100,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,6.03,504.68,9.85,13,0.41,74.84,0,1,9,0,9,0,2,11,0,23,9,0,0,0,0,0,0,29,2,1,32,0,0,0,0,0,0,0,0,0,"United States;Italy;Belgium;China;Japan","13;4;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;40 ENGINEERING","32;16;14;8;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;CARDIOVASCULAR;PEDIATRIC;PREVENTION;TRANSPLANTATION;CHILDHOOD LEUKEMIA;DIGESTIVE DISEASES;GENETICS;LYMPHOMA;ORPHAN DRUG;PATIENT SAFETY;PEDIATRIC CANCER;STEM CELL RESEARCH;AGING;LUNG;BIOENGINEERING","29;23;20;20;15;6;5;5;5;4;4;4;4;4;4;4;4;3;3;2","CANCER;BLOOD;CARDIOVASCULAR;CONGENITAL;GENERIC HEALTH RELEVANCE;INFECTION;RENAL AND UROGENITAL;RESPIRATORY","14;3;3;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","21;7;2;1;1","LEUKEMIA / LEUKAEMIA;MYELOMA;NON-HODGKIN'S LYMPHOMA;BLOOD CANCER;BREAST CANCER;PANCREATIC CANCER;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;LUNG CANCER;PROSTATE CANCER;STOMACH CANCER","9;4;4;2;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;1.4 CANCER PROGRESSION AND METASTASIS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","18;2;2;2;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,"PUBLIC LIBRARY OF SCIENCE","7","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;49 MATHEMATICAL SCIENCES;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","8;3;1;1;1;1","AUTOIMMUNE DISEASE;BIODEFENSE;BRAIN DISORDERS;CLINICAL RESEARCH;GENETICS;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;NEUROSCIENCES;PREVENTION;VACCINE RELATED","1;1;1;1;1;1;1;1;1;1",NA,NA,"4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","1;1","CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","3",NA,NA,NA,NA
"AOU_RIUNITIANCONA",2015,202,12.4306930693069,2.92574257425743,0.331683168316832,0.311881188118812,0.420792079207921,1.58870967741935,1.21818181818182,1.4,1.19718309859155,0.52970297029703,5,95,57,25,14,0.47,0.28,0.12,0.07,28.16,0.755561306727676,6.78723404255319,0.326732673267327,0.930693069306931,0.446,0.445,0.456,0.397,"STEFANO CASCINU;MATTEO SANTONI;GIANFRANCO SINAGRA;ROSSANA BERARDI;GIUSEPPE GATTI;MARIO SCARTOZZI;MARIO GRASSI;RODOLFO MONTIRONI;MARISTELLA BIANCONI;UGO DE GIORGI;FRANCESCA MORGESE;MASSIMO OFFIDANI;DANIELE SANTINI;AGNESE SAVINI;CARMELO MIGNOSA;A RUBINO;GIUSEPPE SANTARPINO;EMILIO QUAIA;ALBERTO ZANIBONI;FAUSTO BIANCARI","25;19;10;9;8;7;7;7;7;7;7;7;7;7;6;6;6;6;6;6","STEFANO CASCINU;ANTONIO MAZZONI;MARCO CONFALONIERI;GIORGIO STANTA;MATTEO SANTONI;EMILIO QUAIA;ANTONIO GIULIO GENNARI;MARIA ASSUNTA COVA;GIANCARLO TIRELLI;G BABIGHIAN;MARIA DI CICCO;MARIO GRASSI;GIANFRANCO SINAGRA;RODOLFO MONTIRONI;MARGHERITA TOFANELLI;PAOLO MANGANOTTI;EMANUELA FORMAGGIO;SILVIA FRANCESCA STORTI;MARISTELLA BIANCONI;MARIO SCARTOZZI","1.84;1.5;1.49;1.3;1.24;1.08;1.02;1.02;1.01;1;1;0.96;0.8;0.76;0.7;0.67;0.67;0.67;0.65;0.64","STEFANO CASCINU;MATTEO SANTONI;GIANFRANCO SINAGRA;ROSSANA BERARDI;GIUSEPPE GATTI;MARIO SCARTOZZI;RODOLFO MONTIRONI;MARISTELLA BIANCONI;FRANCESCA MORGESE;MASSIMO OFFIDANI;AGNESE SAVINI;EMILIO QUAIA;MIRIAM CARAMANTI;MARIANGELA TORNIAI;ANTONIO GIULIO GENNARI;BRUNO FABRIS;LUCA FALOPPI;RICCARDO GIAMPIERI;ANIELLO PAPPALARDO;GIANCARLO TIRELLI","25;19;10;9;8;7;7;7;7;7;7;6;6;6;5;5;5;5;5;5","STEFANO CASCINU;ANTONIO MAZZONI;MARCO CONFALONIERI;GIORGIO STANTA;MATTEO SANTONI;EMILIO QUAIA;ANTONIO GIULIO GENNARI;MARIA ASSUNTA COVA;GIANCARLO TIRELLI;G BABIGHIAN;MARIA DI CICCO;GIANFRANCO SINAGRA;RODOLFO MONTIRONI;MARGHERITA TOFANELLI;PAOLO MANGANOTTI;MARISTELLA BIANCONI;MARIO SCARTOZZI;ROBERTA ANGILERI;CLAUDIO TIRIBELLI;ROSSANA BERARDI","1.84;1.5;1.49;1.3;1.24;1.08;1.02;1.02;1.01;1;1;0.8;0.76;0.7;0.67;0.65;0.64;0.62;0.6;0.6","MASSIMO OFFIDANI;ANTONIO PALUMBO;ANDREW SPENCER;LUDĚK POUR;ROMAN HÁJEK;GIANLUCA GAÏDANO;ALBERT ORIOL;ALEKSANDR SUVOROV;ANTHONY P. SCHWARER;CARLA ARAUJO;DOUGLAS JOSHUA;ELENA RIMASHEVSKAYA;HARTMUT GOLDSCHMIDT;HEIDI H. GILLENWATER;HEINZ LUDWIG;IEVGENII KARAMANESHT;JÁN STRAUB;KATJA WEISEL;LAURA ROSIÑOL;LEONARD MINUK","1224;1148;1055;1055;1055;822;765;765;765;765;765;765;765;765;765;765;765;765;765;765","MASSIMO OFFIDANI;UMBERTO LUCANGELO;GIANFRANCO SINAGRA;GIUSEPPE GATTI;LAURA VITALI SERDOZ;ANIELLO PAPPALARDO;GABRIELE GRASSI;ROBERTO LABIANCA;MICHELA ABRAMI;STEFANO CASCINU;BRUNO PINAMONTI;BARBARA DAPAS;MAURO MONTANARI;BRUNO FABRIS;GUIDO GINI;STELLA BERNARDI;MATTEO SANTONI;ROSSANA BUSSANI;PAOLO FRATICELLI;SERENA BONIN","1148;427;318;318;223;210;201;191;177;175;174;159;155;137;126;126;124;118;107;104","MATTEO SANTONI;STEFANO CASCINU;GIUSEPPE GATTI;FRANCESCA MORGESE;ROSSANA BERARDI;MASSIMO OFFIDANI;AGNESE SAVINI;EMILIO QUAIA;GIANFRANCO SINAGRA;MARIANGELA TORNIAI;MIRIAM CARAMANTI;ANIELLO PAPPALARDO;ANTONIO GIULIO GENNARI;AZZURRA ONOFRI;BRUNO FABRIS;GIANCARLO TIRELLI;MARIA ASSUNTA COVA;DANIELE MINARDI;ILARIA FIORDOLIVA;MARCO CONFALONIERI","19;13;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5;4;4;4","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;CHEMISTRY;COMPUTER SCIENCE;MATERIALS SCIENCE;PSYCHOLOGY;ECONOMICS;MATHEMATICS;PHILOSOPHY;BUSINESS;POLITICAL SCIENCE;SOCIOLOGY;GEOLOGY;ENVIRONMENTAL SCIENCE;HISTORY","189;52;27;21;17;14;8;7;6;5;5;3;3;3;2;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;ONCOLOGY;CARDIOLOGY;PATHOLOGY;GENETICS;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;RADIOLOGY;IMMUNOLOGY;OPTICS;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;PALEONTOLOGY;CANCER RESEARCH;FAMILY MEDICINE;NUCLEAR MEDICINE;PSYCHIATRY;UROLOGY","146;62;39;39;31;29;25;23;22;21;15;13;12;12;10;10;9;9;9;9;9","CANCER;GENE;POPULATION;CHEMOTHERAPY;CONFIDENCE INTERVAL;HEART FAILURE;MULTIVARIATE ANALYSIS;PROPORTIONAL HAZARDS MODEL;COHORT;DISEASE;INCIDENCE (GEOMETRY);MULTIPLE MYELOMA;PATHOLOGICAL;RENAL CELL CARCINOMA;CLINICAL TRIAL;HEPATOCELLULAR CARCINOMA;IMMUNOHISTOCHEMISTRY;RADIATION THERAPY;STAGE (STRATIGRAPHY);ADVERSE EFFECT;CARDIAC SURGERY;LUNG;MAGNETIC RESONANCE IMAGING;STENOSIS","32;21;21;20;16;16;13;13;10;9;9;9;8;8;7;7;7;7;7;6;6;6;6;6","EJECTION FRACTION;COLORECTAL CANCER;HAZARD RATIO;GENOTYPE;PROGRESSION-FREE SURVIVAL;SUNITINIB;UNIVARIATE ANALYSIS;BREAST CANCER;CLINICAL ENDPOINT;NEUTROPENIA;PROSTATE CANCER;PROSTATE;RITUXIMAB;SORAFENIB;AORTIC VALVE REPLACEMENT;BORTEZOMIB;LENALIDOMIDE;MUCOSITIS;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BEVACIZUMAB;CYCLOPHOSPHAMIDE;EUROSCORE;GEMCITABINE;GENE SILENCING;HEART TRANSPLANTATION;NEURORADIOLOGY;PANCREATIC CANCER;VASCULAR SURGERY","10;9;9;8;7;7;7;6;6;6;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3","PAZOPANIB;PROSTATECTOMY;HAPLOTYPE;SINGLE-NUCLEOTIDE POLYMORPHISM;ANTIRETROVIRAL THERAPY;CARDIAC RESYNCHRONIZATION THERAPY;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;KRAS;MAMMOGRAPHY;OXALIPLATIN;PCA3;POLYMORPHISM (COMPUTER SCIENCE);SMALL INTERFERING RNA;ABSOLUTE NEUTROPHIL COUNT;ACINETOBACTER BAUMANNII;ADIPOKINE;ALPHA (FINANCE);ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;APREPITANT;ARTIFICIAL VENTILATION;BAROREFLEX;BENDAMUSTINE;BENTALL PROCEDURE;BK VIRUS;BONE METASTASIS;BROMELAIN;BUSULFAN;CARDIAC INDEX;CARFILZOMIB;CELL MECHANICS;CETUXIMAB;COLE1;CONNECTIVE TISSUE DISEASE;CONTRAST-TO-NOISE RATIO;CORONARY STENT;CORONAVIRUS DISEASE 2019 (COVID-19);CUTANEOUS MASTOCYTOSIS;CYCLIN D1;DASATINIB;DEFIBROTIDE;DESMIN;DIFFUSING CAPACITY;DNA MISMATCH REPAIR;E2F;E2F1;EGFR INHIBITORS;ENTAMOEBA COLI;EPLERENONE;EXOME SEQUENCING;FACTOR V LEIDEN;FLUDARABINE;FOURNIER GANGRENE;GENOTYPING;GERMLINE MUTATION;GLYCOGEN STORAGE DISEASE TYPE II;HBSAG;HEART FAILURE WITH PRESERVED EJECTION FRACTION;HEMOPHAGOCYTOSIS;HUMAN BREAST;HYMENOLEPIS NANA;HYPOPNEA;INGUINAL CANAL;INSULIN-LIKE GROWTH FACTOR;INTERNAL THORACIC ARTERY;INTERNATIONAL PROGNOSTIC INDEX;KLEBSIELLA PNEUMONIAE;LAMIVUDINE;LOW LEVEL LASER THERAPY;MALE INFERTILITY;MELANOCYTIC NEVUS;MITOPHAGY;MYELOPROLIFERATIVE NEOPLASM;NEOADJUVANT THERAPY;NILOTINIB;NUCLEOTIDE EXCISION REPAIR;OPEN SOURCE HARDWARE;OSTEONECROSIS OF THE JAW;PARKIN;PHARMACOGNOSY;PHOSPHATIDYLCHOLINE;PIN1;PINOCYTOSIS;PLEURAL DISEASE;PODOCYTE;POLOXAMER;RANKL;REGORAFENIB;RETINOBLASTOMA PROTEIN;RNA INTERFERENCE;SEROSTATUS;STROKE VOLUME;TAQMAN;TRANSCRIPTOME;TRANSPOSABLE ELEMENT;VAGUS NERVE STIMULATION;VARICOCELE;VINCRISTINE;VO2 MAX","4;4;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;AGED, 80 AND OVER;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;HEART FAILURE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RISK FACTORS;FOLLOW-UP STUDIES;PROGNOSIS;TIME FACTORS;ANTINEOPLASTIC AGENTS;POSTOPERATIVE COMPLICATIONS;YOUNG ADULT","124;96;93;71;68;64;48;39;32;27;24;21;20;18;17;17;17;16;16;16","RENAL CELL CARCINOMA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ATRIAL FIBRILLATION;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EFFICACY AND RESISTANCE IN CML TREATMENT;HEPATOCELLULAR CARCINOMA;LYMPHOID NEOPLASMS;MANAGEMENT OF VALVULAR HEART DISEASE;PANCREATIC CANCER RESEARCH AND TREATMENT;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ANALYSIS OF BRAIN FUNCTIONAL CONNECTIVITY NETWORKS;BREAST CANCER SCREENING TECHNOLOGY;CANCER OF UNKNOWN PRIMARY SITE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CELL MECHANICS AND EXTRACELLULAR MATRIX INTERACTIONS","7;6;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","TREATMENT;PROGRESSION-FREE SURVIVAL;UNIVARIATE ANALYSIS;CARDIAC IMAGING;CARDIAC SURGERY RISK MODELS;CLINICAL ENDPOINT;RENAL CELL CARCINOMA;STROKE (ENGINE);CARDIOVASCULAR EVALUATION;METASTATIC COLORECTAL CANCER;MUCOSITIS;PAZOPANIB;REFRACTORY (PLANETARY SCIENCE);REGIMEN;SURGICAL AORTIC-VALVE REPLACEMENT;TRANSCATHETER AORTIC-VALVE REPLACEMENT;AORTIC ROOT REPLACEMENT;ATRIAL FIBRILLATION;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CARDIAC METABOLISM","9;7;7;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3","CELL CARCINOMA;RENAL CELL;HEART FAILURE;CANCER PATIENTS;LEFT VENTRICULAR;PROSTATE CANCER;ATRIAL FIBRILLATION;COLORECTAL CANCER;METASTATIC RENAL;MULTIPLE MYELOMA;PATIENTS PTS;ADVANCED PANCREATIC;AORTIC VALVE;CORONARY ARTERY;PANCREATIC CANCER;PATIENTS RECEIVING;ADVANCED NON-SMALL;CANCER APDAC;CELL LUNG;CLINICAL OUTCOME;CONTRAST AGENT;ELDERLY PATIENTS;ITALIAN REGISTRY;LUNG CANCER;MAGNETIC RESONANCE;MULTICENTER STUDY;MYELOID LEUKEMIA;NON-SMALL CELL;PATIENTS TREATED;PROGNOSTIC ROLE","9;9;8;7;7;6;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;CROSSREF PUBMED;HR CI;CONFIDENCE INTERVAL;ADVERSE EVENTS;GOLD MARKER;AORTIC VALVE;CHRONIC MYELOID;CM HO;MYELOID LEUKEMIA;READING ALOUD;CORONARY ARTERY;FREE SURVIVAL;HAZARD RATIO;LEFT VENTRICULAR;MARKER DISTANCE;MULTIVARIATE ANALYSIS;CML PATIENTS;MEDICAL ONCOLOGY;INDEPENDENT PREDICTORS;NK CELLS;OSPEDALI RIUNITI;PRIMARY ENDPOINT;SURVIVAL OS;TKI TREATMENT;ARTERY BYPASS;BYPASS GRAFTING;HEART FAILURE;HIGH-DOSE MELPHALAN;ITALY MEDICAL","23;17;17;15;14;14;13;13;13;13;13;12;12;12;12;12;12;11;11;10;10;10;10;10;10;9;9;9;9;9",3,0.01,4.68,5,0,0,0,0,1,0,0,5,0,0,3.5,0,2,0,1,3,0,0,0,85,85,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,5.22,2022.83,5.17,11,0.61,131.06,0,0,3,1,5,1,1,7,0,13,5,0,0,0,0,0,0,17,0,1,17,0,0,1,0,0,0,0,0,0,"United States;Germany;Japan;Canada;Italy","5;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3209 NEUROSCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4205 NURSING","15;8;4;3;3;3;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;CARDIOVASCULAR;HEART DISEASE;HEMATOLOGY;RARE DISEASES;AGING;BRAIN DISORDERS;DIGESTIVE DISEASES;PATIENT SAFETY;NEURODEGENERATIVE;NEUROSCIENCES;ORPHAN DRUG;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;BIOTECHNOLOGY","16;12;4;4;4;4;4;3;3;3;3;2;2;2;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;NEUROLOGICAL;BLOOD;CONGENITAL;RENAL AND UROGENITAL;STROKE","3;3;3;2;1;1;1","6.1 PHARMACEUTICALS;6.3 MEDICAL DEVICES;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.3 MEDICAL DEVICES;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","12;2;1;1;1;1;1;1;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER;PROSTATE CANCER","1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","4",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,"PUBLIC LIBRARY OF SCIENCE","4","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;4206 PUBLIC HEALTH","4;4;2;2","CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - C;INFECTIOUS DISEASES;LIVER CANCER;LIVER DISEASE;ORGAN TRANSPLANTATION;PREVENTION;RARE DISEASES;TRANSPLANTATION","1;1;1;1;1;1;1;1;1;1;1;1;1","ORAL AND GASTROINTESTINAL","1",NA,NA,NA,NA,"HEALTH SERVICES RESEARCH;CLINICAL MEDICINE AND SCIENCE","2;1","LIVER CANCER","2",NA,NA
"AOU_RIUNITIANCONA",2016,202,12.7326732673267,2.84158415841584,0.336633663366337,0.331683168316832,0.440594059405941,1.53066666666667,1.17241379310345,1.52272727272727,1.15584415584416,0.52970297029703,3,88,53,29,17,0.44,0.26,0.14,0.08,26.31,0.80986739195688,6.46107784431138,0.297029702970297,0.920792079207921,0.392,0.401,0.384,0.41,"ROSSANA BERARDI;GIANFRANCO SINAGRA;STEFANO CASCINU;GIUSEPPE GATTI;A RUBINO;FAUSTO BIANCARI;THEODOR FISCHLEIN;MICHELE RICCIO;GABRIELE GRASSI;RICCARDO GIAMPIERI;MATTEO SANTONI;GIUSEPPE SANTARPINO;MAGNUS DALÉN;GIANCARLO TIRELLI;FRANCESCO ONORATI;MARCO MERLO;GIUSEPPE FAGGIAN;GIOVANNI MARISCALCO;ANDRÉA PERROTTI;DANIEL REICHART","9;9;9;9;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6","ROSSANA BERARDI;SERENA BONIN;GIANFRANCO SINAGRA;GIANCARLO TIRELLI;MICHELE RICCIO;ROMUALDO BELARDINELLI;GABRIELE GRASSI;MARCO MERLO;GIOVANNI PAPA;CLAUDIO TIRIBELLI;DEVIS PASCUT;NICOLETTA GARDENAL;STEFANO CASCINU;GIUSEPPE GATTI;MARGHERITA TOFANELLI;FABRIZIO ZANCONATI;PAOLO MANGANOTTI;STEFANIA MAGGI;VIRGILIO CARNIELLI;GIULIA BARBATI","1.63;1.26;1.24;1.07;1.02;1;0.86;0.76;0.67;0.67;0.67;0.66;0.64;0.58;0.58;0.57;0.55;0.55;0.54;0.52","ROSSANA BERARDI;GIANFRANCO SINAGRA;STEFANO CASCINU;GIUSEPPE GATTI;MICHELE RICCIO;GABRIELE GRASSI;RICCARDO GIAMPIERI;MATTEO SANTONI;GIANCARLO TIRELLI;MARCO MERLO;GIULIA BARBATI;FABRIZIO ZANCONATI;VIRGILIO CARNIELLI;MARIANGELA TORNIAI;FRANCESCA MORGESE;G. MANTELLO;ANIELLO PAPPALARDO;MARCO CONFALONIERI;LUCA MASCHIETTO;SILVIA RINALDI","9;9;9;9;7;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4","ROSSANA BERARDI;SERENA BONIN;GIANFRANCO SINAGRA;GIANCARLO TIRELLI;MICHELE RICCIO;ROMUALDO BELARDINELLI;GABRIELE GRASSI;MARCO MERLO;GIOVANNI PAPA;CLAUDIO TIRIBELLI;NICOLETTA GARDENAL;STEFANO CASCINU;GIUSEPPE GATTI;MARGHERITA TOFANELLI;FABRIZIO ZANCONATI;PAOLO MANGANOTTI;STEFANIA MAGGI;VIRGILIO CARNIELLI;GIULIA BARBATI;MARIA ASSUNTA COVA","1.63;1.26;1.24;1.07;1.02;1;0.86;0.76;0.67;0.67;0.66;0.64;0.58;0.58;0.57;0.55;0.55;0.54;0.52;0.49","MARIA BEATRICE BILÒ;ALICE KÖHLI;ANNE MONERET-VAUTRIN;ANTONELLA MURARO;EIRINI ROUMPEDAKI;FRANZISKA RUËFF;HAGEN OTT;IOANA MARIS;JONATHAN O’B HOURIHANE;KATHRIN SCHERER;KATJA NEMAT;KIRSTEN BEYER;LARS LANGE;LINUS GRABENHENRICH;MAREK L. KOWALSKI;MARGITTA WORM;MONTSERRAT FERNÁNDEZ‐RIVAS;NIKOLAOS G. PAPADOPOULOS;ROLAND LANG;SABINE DÖLLE","527;506;506;506;506;506;506;506;506;506;506;506;506;506;506;506;506;506;506;506","MARIA BEATRICE BILÒ;DAVIDE STOLFO;MASSIMO OFFIDANI;MATTEO DAL FERRO;ROSSANA BERARDI;GIUSEPPE GATTI;STEFANO CASCINU;MATTEO SANTONI;MARCO CONFALONIERI;ELENA CIRIELLO;FABRIZIO ZANCONATI;TATIANA CATTARUZZA;GIANFRANCO SINAGRA;LUCA MASCHIETTO;MICHELE RICCIO;FRANCESCA MORGESE;MARIANGELA TORNIAI;MIRIAM CARAMANTI;RICCARDO GIAMPIERI;LUCA FALOPPI","527;415;392;383;284;282;275;234;224;197;180;178;159;159;148;142;142;142;140;133","GIUSEPPE GATTI;ROSSANA BERARDI;STEFANO CASCINU;MICHELE RICCIO;GIANFRANCO SINAGRA;MATTEO SANTONI;GIANCARLO TIRELLI;RICCARDO GIAMPIERI;FRANCESCA MORGESE;MARCO CONFALONIERI;MARIANGELA TORNIAI;AGNESE SAVINI;ANIELLO PAPPALARDO;AZZURRA ONOFRI;FABRIZIO ZANCONATI;G. MANTELLO;LUCA MASCHIETTO;MASSIMO OFFIDANI;MIRIAM CARAMANTI;SERENA BONIN","9;9;7;7;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;MATERIALS SCIENCE;ECONOMICS;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY;PHILOSOPHY;BUSINESS;GEOLOGY;HISTORY","192;43;29;23;17;15;10;8;4;4;4;3;2;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;ONCOLOGY;BIOCHEMISTRY;RADIOLOGY;ENVIRONMENTAL HEALTH;GENETICS;INTENSIVE CARE MEDICINE;GASTROENTEROLOGY;IMMUNOLOGY;MECHANICAL ENGINEERING;ANESTHESIA;ENDOCRINOLOGY;NUCLEAR MEDICINE;OPTICS;PEDIATRICS;CANCER RESEARCH;PSYCHIATRY;QUANTUM MECHANICS","143;68;41;36;34;22;22;20;20;18;17;16;16;14;13;13;13;12;11;11;11","CANCER;POPULATION;GENE;HEART FAILURE;DISEASE;CONFIDENCE INTERVAL;PROSPECTIVE COHORT STUDY;ATRIAL FIBRILLATION;CHEMOTHERAPY;PERIOPERATIVE;STROKE (ENGINE);RADIATION THERAPY;ADVERSE EFFECT;PROPORTIONAL HAZARDS MODEL;RANDOMIZED CONTROLLED TRIAL;ARTERY;COHORT;MYOCARDIAL INFARCTION;PREGNANCY;BLOOD PRESSURE;DIABETES MELLITUS;IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);MULTIVARIATE ANALYSIS;MYELOID LEUKEMIA","33;20;17;15;14;13;11;10;10;10;10;9;8;8;8;7;7;7;7;6;6;6;6;6;6","BREAST CANCER;EJECTION FRACTION;COLORECTAL CANCER;DILATED CARDIOMYOPATHY;BORTEZOMIB;CARDIOMYOPATHY;CLINICAL ENDPOINT;GENOTYPE;PROGRESSION-FREE SURVIVAL;TYPE 2 DIABETES;ACUTE CORONARY SYNDROME;CORONARY ARTERY BYPASS SURGERY;HAZARD RATIO;HEART RATE;IMATINIB;PERFORMANCE STATUS;PROSTATE;PROSTATE CANCER;SUNITINIB;UNIVARIATE ANALYSIS","7;7;6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","CARDIAC RESYNCHRONIZATION THERAPY;NILOTINIB;CARFILZOMIB;GLYCATED HEMOGLOBIN;IMATINIB MESYLATE;SINGLE-NUCLEOTIDE POLYMORPHISM;TICAGRELOR;ACINETOBACTER BAUMANNII;ACUTE SEVERE ASTHMA;ALLELE FREQUENCY;ALTERNATIVE SPLICING;ANDROGEN RECEPTOR;BK VIRUS;BODE INDEX;BORRELIA;BRADYCARDIA;BRCA MUTATION;BREAST RECONSTRUCTION;BRENTUXIMAB VEDOTIN;BRONCHUS;BRUTON'S TYROSINE KINASE;CAMPESTEROL;CAPECITABINE;CASPOFUNGIN;CATENIN;CHROMOPHOBE CELL;COLONOSCOPY;CONNECTOMICS;CYSTECTOMY;DASATINIB;DNA METHYLATION;DNA MISMATCH REPAIR;EPITHELIAL–MESENCHYMAL TRANSITION;ERGOCALCIFEROL;ESTROGEN RECEPTOR;EXERCISE TOLERANCE TEST;FEBRILE NEUTROPENIA;FRAMESHIFT MUTATION;GENOTYPING;GLYCOGEN STORAGE DISEASE TYPE II;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HERPESVIRIDAE;IDARUBICIN;IN UTERO;INTEGRON;INTERATRIAL SEPTUM;INTERNAL THORACIC ARTERY;IONOTROPIC EFFECT;KLEBSIELLA PNEUMONIAE;LYMPHEDEMA;MAMMOGRAPHY;MICAFUNGIN;MICROSATELLITE;MISSENSE MUTATION;NEOADJUVANT THERAPY;NEONATAL RESPIRATORY DISTRESS SYNDROME;NEUROPEPTIDE Y RECEPTOR;ONCOGENE;OSTEOPROTEGERIN;OXALIPLATIN;P2Y12;PAZOPANIB;PENETRANCE;PHARMACOGENETICS;PHOSPHATIDYLCHOLINE;PHY;PODOCYTE;POSTERIOR SEMICIRCULAR CANAL;PRASUGREL;PROBAND;PROSTATE-SPECIFIC ANTIGEN;REGORAFENIB;STROKE VOLUME;TAQMAN;TELOMERASE REVERSE TRANSCRIPTASE;THYMIDYLATE SYNTHASE;TOCOPHEROL;TOTAL MESORECTAL EXCISION;VITAMIN K ANTAGONIST;VO2 MAX","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;;ITALY;ADULT;TREATMENT OUTCOME;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;RISK FACTORS;PROSPECTIVE STUDIES;LUNG NEOPLASMS;POSTOPERATIVE COMPLICATIONS;ANTINEOPLASTIC AGENTS;ATRIAL FIBRILLATION;PROGNOSIS;STROKE;LIVER NEOPLASMS","131;94;93;71;70;66;54;53;40;33;31;28;27;25;21;20;19;19;18;17","ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ATRIAL FIBRILLATION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;EFFICACY AND RESISTANCE IN CML TREATMENT;MANAGEMENT OF VALVULAR HEART DISEASE;RENAL CELL CARCINOMA;WOUND HEALING AND REGENERATION;CHOLESTEROL-LOWERING TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;LYMPHOID NEOPLASMS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ASTHMA;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;COLORECTAL CANCER RESEARCH AND TREATMENT","4;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2","STROKE (ENGINE);TREATMENT;DILATED CARDIOMYOPATHY;CLINICAL ENDPOINT;DISCONTINUATION;PRESENTATION (OBSTETRICS);PROGRESSION-FREE SURVIVAL;REGIMEN;ATRIAL FIBRILLATION;CARDIAC IMAGING;ECHOCARDIOGRAPHY;NILOTINIB;PERFORMANCE STATUS;POLYMERIC GELS;PROSTHETIC VALVES EVALUATION;TRANSCATHETER AORTIC-VALVE REPLACEMENT;TUMOR HETEROGENEITY;TUMOR MICROENVIRONMENT;UNIVARIATE ANALYSIS;WOUND HEALING","10;7;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","ATRIAL FIBRILLATION;CANCER PATIENTS;CLINICAL OUTCOME;CORONARY ARTERY;VALVE IMPLANTATION;BALLOON-EXPANDABLE VALVE;CANCER TREATED;CHRONIC MYELOID;DILATED CARDIOMYOPATHY;HEART FAILURE;MYELOID LEUKEMIA;PATIENTS TREATED;POSITION PAPER;RANDOMIZED CONTROLLED;ACUTE CORONARY;ARTERY BYPASS;CLINICAL PRACTICE;CONTROLLED TRIAL;CORONARY SURGERY;DECODE REGISTRY;GASTRIC CANCER;HEPATOCELLULAR CARCINOMA;IDIOPATHIC DILATED;MULTIPLE MYELOMA;PHASE III;PRETERM INFANTS;RANDOMIZED PHASE;RENAL CELL;TRANSCATHETER BALLOON-EXPANDABLE;ADVANCED GASTRIC","7;7;6;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2","HR CI;CANCER PATIENTS;ITALY DEPARTMENT;ADVERSE EVENTS;AIR LEAK;MULTIVARIATE ANALYSIS;PHYSICAL ACTIVITY;MEDICAL ONCOLOGY;PROLONGED AIR;RISK FACTORS;BLOOD PRESSURE;BRCA MUTATION;CONSECUTIVE PATIENTS;PATIENTS TREATED;PROGRESSION-FREE SURVIVAL;CLINICAL PRACTICE;CONFIDENCE INTERVAL;CORONARY ARTERY;MEDIAN PFS;OSPEDALI RIUNITI;PROGNOSTIC FACTOR;PULMONARY FIBROSIS;ADVISORY COMMITTEES;DEFECTIVE MMR;E-CABG BLEEDING;ENTITYS BOARD;FREE FLAP;GASTRIC CANCER;HR CI-;IDIOPATHIC PULMONARY","17;15;13;12;12;12;12;11;11;11;10;10;10;10;10;9;9;9;9;9;9;9;8;8;8;8;8;8;8;8",6,0.03,19,16.25,2.5,0,2,1.5,3,0,1,19,0,0,17,0,0,2.5,2.25,10,1.5,0,0,118.25,118.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,4.69,1040.37,9.72,19,0.54,79.89,1,1,8,0,12,0,1,12,0,23,12,0,0,0,0,0,0,35,0,0,35,0,0,0,0,0,0,0,0,0,"United States;Italy;Japan;Germany;Netherlands","8;5;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3203 DENTISTRY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","34;15;14;5;3;3;2;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;PATIENT SAFETY;RARE DISEASES;CARDIOVASCULAR;NEUROSCIENCES;PREVENTION;BRAIN DISORDERS;HEART DISEASE;INFECTIOUS DISEASES;BREAST CANCER;DIGESTIVE DISEASES;LUNG;LYMPHOMA;NEURODEGENERATIVE;PEDIATRIC;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE","33;24;16;15;12;11;7;5;5;4;4;4;3;3;3;3;3;3;2;2","CANCER;CARDIOVASCULAR;INFECTION;BLOOD;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","14;6;3;2;2;2;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","26;4;3;1;1;1;1","LEUKEMIA / LEUKAEMIA;MYELOMA;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;LUNG CANCER;COLON AND RECTAL CANCER;ENDOMETRIAL CANCER","5;4;3;3;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","14;2;2;1;1",2,4707882.5,594708.93,5.5,8.5,6,1,2,210345.642857143,0.960324146753014,"AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI;AGÈNCIA DE QUALITAT I AVALUACIÓ SANITÀRIES DE CATALUNYA;ANTONI VAN LEEUWENHOEK HOSPITAL;ANTWERP UNIVERSITY HOSPITAL;CENTRE HOSPITALIER RÉGIONAL ET UNIVERSITAIRE DE LILLE;DUBLIN CITY UNIVERSITY;ERASMUS MC;INVEST NORTHERN IRELAND;LUXINNOVATION;MARCHE POLYTECHNIC UNIVERSITY;OSAKIDETZA;REGION ZEALAND;UNIVERSITY OF CHIETI-PESCARA;UNIVERSITY OF LEICESTER;UNIVERSITY OF OULU;UNIVERSITY OF ULSTER","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-PHC-2015-SINGLE-STAGE (CALL FOR PROPOSAL);H2020-PHC-2015-TWO-STAGE (CALL FOR PROPOSAL);PCP - PRE-COMMERCIAL PROCUREMENT (FUNDING SCHEME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY","1;1;1;1;1","BRAIN DISORDERS;CANCER;CLINICAL RESEARCH;HEALTH SERVICES;LUNG;ORPHAN DRUG;RARE DISEASES;REHABILITATION;STROKE","1;1;1;1;1;1;1;1;1","CANCER;STROKE","1;1","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","1;1;1;1","LUNG CANCER","1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1",NA,NA,15,"PUBLIC LIBRARY OF SCIENCE","15","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY;4602 ARTIFICIAL INTELLIGENCE","12;3;2;1;1;1;1;1;1;1","BIOTECHNOLOGY;CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;RARE DISEASES","1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","1;1","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","1;1","CLINICAL","3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","3;1","NOT SITE-SPECIFIC CANCER","1",NA,NA
"AOU_RIUNITIANCONA",2017,187,13.2620320855615,2.6951871657754,0.342245989304813,0.310160427807487,0.401069518716578,1.48235294117647,1.23076923076923,1.38095238095238,1.27118644067797,0.631016042780749,2,88,48,22,14,0.47,0.26,0.12,0.07,17.84,0.605243623101993,6.20729927007299,0.272727272727273,0.903743315508021,0.434,0.362,0.426,0.357,"ROSSANA BERARDI;RICCARDO GIAMPIERI;GIANFRANCO SINAGRA;GABRIELE GRASSI;BRUNO FABRIS;NICOLÒ DE MANZINI;GUIDO GINI;STELLA BERNARDI;MARIO GRASSI;LEONARDO ANTONICELLI;GIULIA BARBATI;SIMONA SOVERINI;MARIO SCARTOZZI;STEFANO CASCINU;GIANCARLO TIRELLI;MICHELE BACCARANI;ROSSELLA FARRA;MICHÈLE CAVO;MICHELE RICCIO;GIUSEPPE GATTI","13;10;9;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5","LUCIO DELL’ATTI;ANDREA BENEDETTO GALOSI;GIANFRANCO SINAGRA;ROSSANA BERARDI;FABIO MONICA;GIORGIO BERLOT;MICHELE RICCIO;LEONARDO ANTONICELLI;MARIO GRASSI;GIULIA BARBATI;NICOLÒ DE MANZINI;GABRIELE GRASSI;RICCARDO GIAMPIERI;ARIANNA SARTORI;BRUNO FABRIS;STELLA BERNARDI;GIANCARLO TIRELLI;RICCARDO GERLONI;STEFANO CASCINU;GIANNI BIOLO","1.42;1.42;1.22;1.1;1;1;0.83;0.78;0.77;0.77;0.73;0.71;0.7;0.67;0.65;0.65;0.63;0.6;0.58;0.56","ROSSANA BERARDI;RICCARDO GIAMPIERI;GIANFRANCO SINAGRA;GABRIELE GRASSI;BRUNO FABRIS;NICOLÒ DE MANZINI;GUIDO GINI;STELLA BERNARDI;LEONARDO ANTONICELLI;GIULIA BARBATI;GIANCARLO TIRELLI;MICHELE RICCIO;GIUSEPPE GATTI;ANDREA DI LENARDA;ATTILIO OLIVIERI;ELENA MACCARONI;FABRIZIO ZANCONATI;LUCIO DELL’ATTI;STEFANO GASPARINI;SILVIA PAGLIARETTA","13;10;9;7;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4","LUCIO DELL’ATTI;ANDREA BENEDETTO GALOSI;GIANFRANCO SINAGRA;ROSSANA BERARDI;FABIO MONICA;GIORGIO BERLOT;MICHELE RICCIO;LEONARDO ANTONICELLI;GIULIA BARBATI;NICOLÒ DE MANZINI;GABRIELE GRASSI;RICCARDO GIAMPIERI;ARIANNA SARTORI;BRUNO FABRIS;STELLA BERNARDI;GIANCARLO TIRELLI;RICCARDO GERLONI;GIANNI BIOLO;CHIARA DOBRINJA;MICHELA ABRAMI","1.42;1.42;1.22;1.1;1;1;0.83;0.78;0.77;0.73;0.71;0.7;0.67;0.65;0.65;0.63;0.6;0.56;0.52;0.5","MARCO VIVARELLI;GIANFRANCO SINAGRA;ATTILIO OLIVIERI;PIETRO LEONI;ANDREA DI LENARDA;MICHELE BACCARANI;MICHÈLE CAVO;SIMONA SOVERINI;MASSIMILIANO BONIFACIO;MONICA BOCCHIA;NICOLÒ DE MANZINI;MICHELE CORREALE;ROBERTO BADAGLIACCA;ELENA ZAMBON;MARIO GRASSI;MARCO METRA;GIANFRANCO PARATI;GABRIELE GRASSI;CHIARA DOBRINJA;ANTONELLA POLONI","317;172;160;153;152;152;152;152;151;151;141;140;140;139;139;137;134;133;131;125","MARCO VIVARELLI;NICOLÒ DE MANZINI;CHIARA DOBRINJA;ROMUALDO BELARDINELLI;STELLA BERNARDI;ANNA RITA FERRARI;CARLA MARINI;CRISTINA PETRELLI;DANIELA PUCATTI;DAVIDE MEI;DOMENICA BATTAGLIA;ELENA PARRINI;FEDERICO SICCA;FRANCESCA RAGONA;G. AVANZINI;ILARIA CONTALDO;LAURA GRISOTTO;MARINA TRIVISANO;NELIA ZAMPONI;NICOLA SPECCHIO","220;141;131;124;113;106;106;106;106;106;106;106;106;106;106;106;106;106;106;106","ROSSANA BERARDI;RICCARDO GIAMPIERI;LEONARDO ANTONICELLI;GIANFRANCO SINAGRA;NICOLÒ DE MANZINI;GIULIA BARBATI;GUIDO GINI;MICHELE RICCIO;STELLA BERNARDI;ANDREA BENEDETTO GALOSI;BRUNO FABRIS;CHIARA DOBRINJA;ELENA MACCARONI;GIANCARLO TIRELLI;GIUSEPPE GATTI;LUCIO DELL’ATTI;SILVIA PAGLIARETTA;ALESSANDRA MANDOLESI;GIAN PIERO PERNA;AGNESE SAVINI","12;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;MATERIALS SCIENCE;COMPUTER SCIENCE;PSYCHOLOGY;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;GEOGRAPHY;HISTORY;PHILOSOPHY;SOCIOLOGY","180;41;15;9;8;8;6;6;4;4;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;ONCOLOGY;RADIOLOGY;GASTROENTEROLOGY;PATHOLOGY;GENETICS;IMMUNOLOGY;CANCER RESEARCH;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;GENERAL SURGERY;PEDIATRICS;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;ANESTHESIA;OPTICS;PSYCHIATRY;PHYSICAL THERAPY","147;71;38;31;25;22;21;20;17;13;13;13;12;12;11;11;9;9;8;7","CANCER;DISEASE;HEART FAILURE;GENE;CHEMOTHERAPY;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;LUNG;POPULATION;RETROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;ATRIAL FIBRILLATION;CLINICAL TRIAL;DIABETES MELLITUS;MYELOID LEUKEMIA;CARDIAC SURGERY;INCIDENCE (GEOMETRY);MYOCARDIAL INFARCTION;RECEPTOR;CORONARY ARTERY DISEASE;OBSERVATIONAL STUDY;RADIOGRAPHY;RENAL FUNCTION;TRANSPLANTATION","34;20;16;14;13;13;11;11;11;11;10;9;8;8;8;7;7;7;7;6;6;6;6;6","BREAST CANCER;COLORECTAL CANCER;EJECTION FRACTION;CLINICAL ENDPOINT;IMATINIB;BYPASS GRAFTING;HAZARD RATIO;MUTATION;PERCUTANEOUS CORONARY INTERVENTION;RITUXIMAB;CYCLOPHOSPHAMIDE;EPIDERMAL GROWTH FACTOR RECEPTOR;GENOTYPE;HEART TRANSPLANTATION;IMMUNOGLOBULIN E;LUNG FUNCTION;METASTASIS;PHASES OF CLINICAL RESEARCH;PREDICTIVE MARKER;PROGRESSION-FREE SURVIVAL;RANDOMIZATION;SUNITINIB","12;11;11;8;6;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","IRINOTECAN;NILOTINIB;CARDIAC RESYNCHRONIZATION THERAPY;CETUXIMAB;DIFFUSING CAPACITY;EGFR INHIBITORS;PAZOPANIB;ANTHRACYCLINE;COLONOSCOPY;DASATINIB;FOURNIER GANGRENE;IMATINIB MESYLATE;MACE;METASTATIC BREAST CANCER;MISSENSE MUTATION;MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION;ABDOMINOPERINEAL RESECTION;ACROMEGALY;AEROALLERGEN;AJCC STAGING SYSTEM;ANTI-NUCLEAR ANTIBODY;ANTISYNTHETASE SYNDROME;ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA;ASIALOGLYCOPROTEIN RECEPTOR;AXILLA;BENDAMUSTINE;BINGE-EATING DISORDER;BONE MARROW FAILURE;BOSENTAN;BRCA MUTATION;BREAST RECONSTRUCTION;BREAST SURGERY;BREAST TISSUE;BRENTUXIMAB VEDOTIN;CAMPESTEROL;CAMPYLOBACTER FETUS;CASPASE;CD90;CERVICAL LYMPH NODES;CHLORAMBUCIL;CIRCULATING TUMOR CELL;CONGENITAL DIAPHRAGMATIC HERNIA;CORONARY CALCIUM SCORE;CORTACTIN;CYBERKNIFE;CYCLIN;CYCLIN D1;DNA MISMATCH REPAIR;E2F;ENDOVASCULAR ANEURYSM REPAIR;ERDHEIM–CHESTER DISEASE;EXCITOTOXICITY;FAMILIAL ADENOMATOUS POLYPOSIS;FOSSA OVALIS;FRAMESHIFT MUTATION;GERMLINE MUTATION;GESTATIONAL DIABETES;HEMATOPOIETIC STEM CELL;HLA-G;IL-2 RECEPTOR;IMIPENEM;IMPAIRED GLUCOSE TOLERANCE;INNATE LYMPHOID CELL;INTERATRIAL SEPTUM;INTERNAL THORACIC ARTERY;INTRA ARTICULAR;LEFT ATRIAL MYXOMA;LIPOPROTEIN(A);MAMMOGRAPHY;MAMMOPLASTY;MASTECTOMY;METHYLTRANSFERASE;MILAN CRITERIA;NAB-PACLITAXEL;NEOADJUVANT THERAPY;NINTEDANIB;NORMAL PRESSURE HYDROCEPHALUS;NORMAL TENSION GLAUCOMA;OBINUTUZUMAB;OSTEOPROTEGERIN;OXALIPLATIN;PARATHYROID NEOPLASM;PARATHYROIDECTOMY;PEANUT ALLERGY;PERIPARTUM CARDIOMYOPATHY;PHILADELPHIA CHROMOSOME;PHOSPHOSERINE;PIRFENIDONE;PR INTERVAL;PRIMARY ANGIOPLASTY;PROBAND;PROSTATE BIOPSY;PULMONARY VEIN STENOSIS;REDUCTION MAMMOPLASTY;RENAL TUMOR;RIBAVIRIN;RIBOSOME;RIGHT BREAST;SCLERODACTYLY;SEROTONIN TRANSPORTER;SINGLE-NUCLEOTIDE POLYMORPHISM;SMALL INTERFERING RNA;SOX2;SPLENIC MARGINAL ZONE LYMPHOMA;STEATOHEPATITIS;STEREOTACTIC RADIOTHERAPY;SYNOVIAL FLUID;SYSTEMIC THERAPY;TAXANE;TRIPLE-NEGATIVE BREAST CANCER;VARICOCELE;VINCRISTINE;VINORELBINE","4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;MIDDLE AGED;AGED;ADULT;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;POSTOPERATIVE COMPLICATIONS;TIME FACTORS;FOLLOW-UP STUDIES;HEART FAILURE;SURVIVAL RATE;ADOLESCENT;PROSPECTIVE STUDIES;RISK FACTORS;YOUNG ADULT","111;88;85;72;66;65;42;34;34;28;27;25;19;18;17;15;14;13;13;13","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;LYMPHOID NEOPLASMS;RENAL CELL CARCINOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;GASTRIC CANCER RESEARCH AND TREATMENT;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CHOLESTEROL-LOWERING TREATMENT;DIAGNOSIS AND TREATMENT OF HEART FAILURE;MECHANISMS AND APPLICATIONS OF RNA INTERFERENCE;SHOULDER PATHOLOGY AND TREATMENT OUTCOMES;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS","6;5;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","TREATMENT;CLINICAL ENDPOINT;CARDIAC IMAGING;CARDIAC RESYNCHRONIZATION THERAPY;CARDIOTHORACIC SURGERY;CARDIOVASCULAR RISK ASSESSMENT;SINGLE CENTER;BREAST CANCER;CHOLESTEROL-LOWERING;DISCONTINUATION;DLCO;EGFR INHIBITORS;ETIOLOGY;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;METASTATIC COLORECTAL CANCER;METASTATIC GASTRIC CANCER;MICROSURGICAL RECONSTRUCTION;NEPHROLOGY;PAZOPANIB;PREDICTIVE MARKER","13;8;6;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","HEART FAILURE;PATIENTS TREATED;CANCER PATIENTS;CORONARY ARTERY;BREAST CANCER;CELL CARCINOMA;CHRONIC MYELOID;COLORECTAL CANCER;MYELOID LEUKEMIA;PHASE II;RETROSPECTIVE ANALYSIS;ARTERY BYPASS;BYPASS GRAFTING;CONTROLLED TRIAL;EGFR GENE;EGFR PROMOTER;GENE COPY;II STUDY;LONG-TERM FOLLOW-UP;METASTATIC RENAL;OBSERVATIONAL STUDY;PATIENTS RECEIVING;PROGNOSTIC ROLE;PROMOTER METHYLATION;RECEIVING IRINOTECANCETUXIMAB;RENAL CELL;RISK FACTORS;SIDEDNESS EGFR;UNUSUAL CLINICAL;AMBRA STUDY","6;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2","EGFR GCN;HEART DISEASE;CD CD;CUTOFF VALUES;DETECTION RATE;RISK FACTORS;HR CI;MYOCARDIAL INFARCTION;COLORECTAL CANCER;MULTIVARIATE ANALYSIS;PATIENTS TREATED;CLINICAL PRACTICE;LA DETECTION;RESPONSE RATE;ADVERSE EVENTS;MEDIAN AGE;PATIENTS RECEIVED;SURVIVAL OS;ANTI PL-;FREE SURVIVAL;PATIENTS UNDERWENT;PROMOTER METHYLATION;SURVIVAL PFS;CLINICAL TRIALS;DIABETES MELLITUS;EGFR PROMOTER;HF PATIENTS;LOCOREGIONAL TREATMENT;MECKI SCORE;MEDICAL ONCOLOGY","16;16;14;14;14;14;13;12;11;11;11;10;10;10;9;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7",4,0.02,3.34,7.5,2.5,0,0,0,0,0,0,7.75,0,0,6,0,0,1,2.5,3.5,0,0,0,73.25,73.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,4.28,768.62,8.9,14,0.48,77.66,0,2,7,0,6,0,1,13,0,18,11,0,0,0,0,0,0,28,1,0,29,0,0,0,0,0,0,0,0,0,"United States;Italy;Japan;Denmark;United Kingdom","7;5;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3204 IMMUNOLOGY;4205 NURSING;52 PSYCHOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;5202 BIOLOGICAL PSYCHOLOGY;3213 PAEDIATRICS","28;14;9;5;5;3;3;3;2;2;2;2;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;PATIENT SAFETY;RARE DISEASES;BIOENGINEERING;BREAST CANCER;DIGESTIVE DISEASES;LUNG;AUTOIMMUNE DISEASE;BRAIN DISORDERS;CARDIOVASCULAR;GENETICS;HEART DISEASE;LUNG CANCER;PEDIATRIC;TRANSPLANTATION;AGING;ARTHRITIS","24;14;11;8;8;6;3;3;3;3;2;2;2;2;2;2;2;2;1;1","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;METABOLIC AND ENDOCRINE;SKIN","13;2;2;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)","16;4;2;2;2;1;1;1;1","MYELOMA;BREAST CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;HODGKIN'S DISEASE;NOT SITE-SPECIFIC CANCER;STOMACH CANCER","4;3;3;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","9;3;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,"PUBLIC LIBRARY OF SCIENCE","3","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3202 CLINICAL SCIENCES","6;5;3;3",NA,NA,NA,NA,NA,NA,NA,NA,"CLINICAL MEDICINE AND SCIENCE","3",NA,NA,NA,NA
"AOU_RIUNITIANCONA",2018,175,15.7428571428571,2.56571428571429,0.285714285714286,0.28,0.457142857142857,1.50167224080268,1.28205128205128,1.44117647058824,1.37931034482759,0.6,0,74,49,25,17,0.42,0.28,0.14,0.1,35.46,1.16221474148432,5.54785478547855,0.325714285714286,0.948571428571429,0.426,0.365,0.376,0.372,"GIUSEPPE SANTARPINO;FRANCESCO ONORATI;ANDRÉA PERROTTI;MARISA DE FEO;RICCARDO GHERLI;A RUBINO;FRANCESCO NICOLINI;VITO GIOVANNI RUGGIERI;DANIELE MASELLI;GIUSEPPE GATTI;GIOVANNI MARISCALCO;ANTONIO SALSANO;MAGNUS DALÉN;FAUSTO BIANCARI;GIUSEPPE FAGGIAN;MATTEO SACCOCCI;ROSSANA BERARDI;KARL BOUNADER;STEFANO ROSATO;JUHANI AIRAKSINEN","13;13;13;13;12;12;12;12;12;12;12;12;11;11;11;10;9;9;9;8","GIAN MARCO GIUSEPPETTI;ANTONIO GIULIO GENNARI;EMILIO QUAIA;CORRADO TAGLIATI;CARLO TROMBETTA;GIORGIO BERLOT;ROSSANA BUSSANI;CRISTIANO CALVAGNA;MARIO D’ORIA;MARCO DAMIANO PIPITONE;GIULIO ARGALIA;ANDREA GIOVAGNONI;VIRGILIO CARNIELLI;ROSSANA BERARDI;MARIA ASSUNTA COVA;STEFANO GASPARINI;G. BIANCHI;STEFANO CHIARANDINI;GIUSEPPE SANTARPINO;FRANCESCO ONORATI","1.11;1.08;1.08;0.99;0.81;0.79;0.78;0.72;0.72;0.72;0.7;0.68;0.67;0.66;0.64;0.61;0.6;0.58;0.55;0.55","RICCARDO GHERLI;GIUSEPPE GATTI;ROSSANA BERARDI;STEFANO GASPARINI;VIRGILIO CARNIELLI;GIAN MARCO GIUSEPPETTI;NICOLÒ SCHICCHI;CRISTIANO CALVAGNA;CARLO TROMBETTA;ROSSANA BUSSANI;MARIO D’ORIA;GIORGIO BERLOT;MARCO DAMIANO PIPITONE;STEFANO CHIARANDINI;MARTINA BONIFAZI;RICCARDO GIAMPIERI;MATTEO SANTONI;ANDREA GIOVAGNONI;ANNA RITA SCORTECHINI;MARIANGELA TORNIAI","12;12;9;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4","GIAN MARCO GIUSEPPETTI;ANTONIO GIULIO GENNARI;CARLO TROMBETTA;GIORGIO BERLOT;ROSSANA BUSSANI;CRISTIANO CALVAGNA;MARIO D’ORIA;MARCO DAMIANO PIPITONE;GIULIO ARGALIA;ANDREA GIOVAGNONI;VIRGILIO CARNIELLI;ROSSANA BERARDI;MARIA ASSUNTA COVA;STEFANO GASPARINI;G. BIANCHI;STEFANO CHIARANDINI;STEFANO BUCCI;LUCIO DELL’ATTI;SIMONE SCARCELLA;ANDREA BENEDETTO GALOSI","1.11;1.08;0.81;0.79;0.78;0.72;0.72;0.72;0.7;0.68;0.67;0.66;0.64;0.61;0.6;0.58;0.54;0.53;0.53;0.53","A. VAN GOSSUM;ADRIANA CRIVELLI;AINSLEY MALONE;ANDREW J.S. COATS;DAN LINETZKY WAITZBERG;DAVID C. EVANS;GERTRUDIS ADRIANZA DE BAPTISTA;GORDON L. JENSEN;HEATHER KELLER;IBOLYA NYULASI;JIANCHUN YU;JOHN E. MORLEY;KELLY A. TAPPENDEN;KRIS M. MOGENSEN;LEAH GRAMLICH;LUISITO O. LLIDO;M.A.E. DE VAN DER SCHUEREN;MARÍA CRISTINA GONZÁLEZ;MARÍA ISABEL TOULSON DAVISSON CORREIA;MATTHIAS PIRLICH","4730;4730;4730;4730;4730;4730;4730;4730;4730;4730;4730;4730;4730;4730;4730;4730;4730;4730;4730;4730","ROCCO BARAZZONI;STEFANO GASPARINI;MARIA BEATRICE BILÒ;GIUSEPPE GATTI;ROSSANA BERARDI;MARIANGELA TORNIAI;MARCO MARZIONI;STEFANO CASCINU;MATTEO SANTONI;ROSSANA BUSSANI;DEBORAH BONAZZA;GIAN MARCO GIUSEPPETTI;NICOLÒ SCHICCHI;MARCO CONFALONIERI;PAOLO MANGANOTTI;MICHELA COCCIA;UMBERTO LUCANGELO;ANDREA GIOVAGNONI;GIORGIO BERLOT;FABRIZIO ZANCONATI","4730;333;307;220;214;132;123;111;86;82;71;71;71;70;70;66;66;64;64;61","GIUSEPPE GATTI;ROSSANA BERARDI;GIAN MARCO GIUSEPPETTI;VIRGILIO CARNIELLI;ROSSANA BUSSANI;CARLO TROMBETTA;CRISTIANO CALVAGNA;GIORGIO BERLOT;MARCO DAMIANO PIPITONE;MARIO D’ORIA;NICOLÒ SCHICCHI;STEFANO GASPARINI;ANDREA GIOVAGNONI;ANNA RITA SCORTECHINI;MARIANGELA TORNIAI;MATTEO SANTONI;STEFANO CHIARANDINI;RICCARDO GIAMPIERI;ALICE ROTELLI;ANIELLO PAPPALARDO","11;9;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;ECONOMICS;MATERIALS SCIENCE;MATHEMATICS;PSYCHOLOGY;POLITICAL SCIENCE;SOCIOLOGY;GEOLOGY;HISTORY;PHILOSOPHY","172;29;18;11;10;10;6;5;5;5;4;2;1;1;1","INTERNAL MEDICINE;SURGERY;RADIOLOGY;CARDIOLOGY;PATHOLOGY;GASTROENTEROLOGY;ONCOLOGY;INTENSIVE CARE MEDICINE;IMMUNOLOGY;GENETICS;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;PEDIATRICS;ANESTHESIA;OPTICS;ENDOCRINOLOGY;BIOCHEMISTRY;PALEONTOLOGY;ARTIFICIAL INTELLIGENCE;EMERGENCY MEDICINE;FAMILY MEDICINE;GENERAL SURGERY;PSYCHIATRY","130;66;39;28;27;24;20;17;16;15;14;14;12;10;10;9;8;7;6;6;6;6;6","CANCER;DISEASE;ULTRASOUND;POPULATION;CHEMOTHERAPY;COHORT;CONFIDENCE INTERVAL;LUNG;PROSPECTIVE COHORT STUDY;ARTERY;GENE;ANGIOGRAPHY;STENOSIS;ATRIAL FIBRILLATION;COGNITION;LOGISTIC REGRESSION;LYMPHOMA;MYOCARDIAL INFARCTION;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;ASYMPTOMATIC;DIABETES MELLITUS;IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);LUNG CANCER;MYELOID LEUKEMIA;ODDS RATIO;PERIOPERATIVE;PREGNANCY;THROMBOSIS","29;18;14;13;11;10;10;10;10;9;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5","BREAST CANCER;CONTRAST-ENHANCED ULTRASOUND;METASTASIS;BYPASS GRAFTING;COLORECTAL CANCER;CORONARY ARTERY BYPASS SURGERY;IMATINIB;RITUXIMAB;TYPE 2 DIABETES;ANAPHYLAXIS;AORTIC VALVE REPLACEMENT;CLINICAL ENDPOINT;CONVENTIONAL PCI;HAZARD RATIO;IMAGE QUALITY;NEUTROPENIA;PERCUTANEOUS CORONARY INTERVENTION;PROGRESSION-FREE SURVIVAL;SEPTIC SHOCK;WARFARIN","8;7;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","MAMMOGRAPHY;NILOTINIB;BASIC LIFE SUPPORT;CONNECTIVE TISSUE DISEASE;DASATINIB;GLYCATED HEMOGLOBIN;MECHANICAL INDEX;METASTATIC BREAST CANCER;MILAN CRITERIA;PROTHROMBIN COMPLEX CONCENTRATE;SINGLE-NUCLEOTIDE POLYMORPHISM;ACROMEGALY;ADVANCED LIFE SUPPORT;AMNION;ANAPHYLACTIC REACTIONS;ANDROGEN DEPRIVATION THERAPY;ANTIRETROVIRAL THERAPY;ANTISYNTHETASE SYNDROME;AROMATASE;ATG5;AUTOMATED EXTERNAL DEFIBRILLATOR;BENDAMUSTINE;BIORESORBABLE SCAFFOLD;BLADDER OUTLET OBSTRUCTION;BONE MARROW FAILURE;BONE METASTASIS;BRAIN METASTASIS;BREAKPOINT;BREAST CARCINOMA;BREAST RECONSTRUCTION;CAESAREAN DELIVERY;CAMPESTEROL;CCL2;CETUXIMAB;COLECTOMY;CONTRAST-TO-NOISE RATIO;CORONAVIRUS DISEASE 2019 (COVID-19);CTLA-4;DOCOSAHEXAENOIC ACID;DUP;ENDOVASCULAR ANEURYSM REPAIR;EOTAXIN;FEBRILE NEUTROPENIA;FOCUSED ASSESSMENT WITH SONOGRAPHY FOR TRAUMA;FONDAPARINUX;GERD;GLYCATED HAEMOGLOBIN;GRANULOMATOSIS WITH POLYANGIITIS;HORMONE RECEPTOR;IL-2 RECEPTOR;IMATINIB MESYLATE;INTRAUTERINE GROWTH RESTRICTION;IRINOTECAN;KARYOTYPE;LAMIVUDINE;LDL APHERESIS;LIPOPROTEIN(A);LIRAGLUTIDE;MEDIASTINAL LYMPH NODE;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MICROSCOPIC POLYANGIITIS;MINI–MENTAL STATE EXAMINATION;MODIFIED RANKIN SCALE;MONTREAL COGNITIVE ASSESSMENT;NINTEDANIB;PAZOPANIB;PENICILLIN BINDING PROTEINS;PERSISTENT VEGETATIVE STATE;PHOSPHATIDYLCHOLINE;PLACENTA;PROSTATECTOMY;REGORAFENIB;RENAL HILUM;RIGHT COMMON CAROTID ARTERY;RIVAROXABAN;SAPS II;SPECKLE TRACKING ECHOCARDIOGRAPHY;SPLENIC MARGINAL ZONE LYMPHOMA;THORACIC AORTIC ANEURYSM;THROMBIN TIME;TRASTUZUMAB;TSC1;TSC2;UNITED KINGDOM PROSPECTIVE DIABETES STUDY;VITAMIN K ANTAGONIST","4;4;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;;ADULT;TREATMENT OUTCOME;ITALY;RETROSPECTIVE STUDIES;PROSPECTIVE STUDIES;AGED, 80 AND OVER;CORONARY ARTERY BYPASS;ADOLESCENT;CORONARY ARTERY DISEASE;POSTOPERATIVE COMPLICATIONS;LUNG NEOPLASMS;ULTRASONOGRAPHY;YOUNG ADULT;FOLLOW-UP STUDIES","115;86;82;66;64;55;38;31;28;24;23;22;18;17;14;14;13;13;13;12","EFFICACY AND RESISTANCE IN CML TREATMENT;MANAGEMENT OF VALVULAR HEART DISEASE;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY;DIAGNOSIS AND MANAGEMENT OF IGG4-RELATED DISEASE;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;HEPATOCELLULAR CARCINOMA;MANAGEMENT OF SPLEEN TRAUMA IN POLYTRAUMA PATIENTS;X-RAY IMAGING TECHNIQUES AND APPLICATIONS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CHOLESTEROL-LOWERING TREATMENT;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK","5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","TREATMENT;CONTRAST-ENHANCED ULTRASOUND;BLEEDING RISK;DISCONTINUATION;INTERQUARTILE RANGE;PROSTHETIC VALVES EVALUATION;STROKE (ENGINE);BREAST IMAGING;CLINICAL ENDPOINT;CT IMAGING;DIAGNOSIS;EVEROLIMUS;GRADING (ENGINEERING);IGG4-RELATED DISEASE;LUNG ULTRASOUND;MULTI-ENERGY CT;PANCREATIC NEUROENDOCRINE TUMORS;PHASE CONTRAST IMAGING;PROGRESSION-FREE SURVIVAL;SURGICAL AORTIC-VALVE REPLACEMENT","10;7;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","CORONARY ARTERY;ARTERY BYPASS;BYPASS GRAFTING;CONTRAST-ENHANCED ULTRASOUND;BREAST CANCER;CANCER PATIENTS;CHRONIC MYELOID;MYELOID LEUKEMIA;AORTIC VALVE;ASYMPTOMATIC CAROTID;CCL CCL;COLORECTAL CANCER;LEUKEMIA PATIENTS;LUNG CANCER;PATIENTS UNDERGOING;SEPTIC SHOCK;ACUTE CORONARY;ALLERGIC REACTIONS;ANTISYNTHETASE SYNDROME;ARTERY STENOSIS;ARTIFICIAL NUTRITION;BILIARY CHOLANGITIS;BREAST CT;CAROTID ARTERY;CELL LUNG;CLINICAL NUTRITION;COGNITIVE IMPAIRMENT;COHORT STUDY;COMPARATIVE ANALYSIS;COMPLEX CONCENTRATE","9;8;8;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","SPEAKERS BUREAU;ADVISORY BOARD;ADVISORY COMMITTEES;ENTITYS BOARD;HONORARIA MEMBERSHIP;PATIENTS TREATED;CONFIDENCE INTERVAL;CORONARY ARTERY;INCREASED RISK;ARTERY BYPASS;CONTROL-CONTINUOUS MANDATORY;PATIENTS UNDERGOING;BYPASS GRAFTING;DOUBLE CYCLING;MANDATORY VENTILATION;ELTS SCORE;MEDIAN PFS;COMPUTED TOMOGRAPHY;MINIMALLY INVASIVE;SOKAL SCORE;VOLUME CONTROL-CONTINUOUS;AORTIC VALVE;BOARD SPEAKERS;CLINICAL PRACTICE;CONSULTANCY HONORARIA;HAZARD RATIO;MRI SITES;PATIENTS RECEIVED;SEPTIC SHOCK;SOMATOSTATIN ANALOGUES","25;16;16;16;16;16;15;15;14;12;12;12;11;11;11;10;10;9;9;9;9;8;8;8;8;8;8;8;8;8",4,0.02,16.7,11.75,0,0,0,5,4,0,0,12.5,0,0,7.5,0,0,1,3,5.25,2.5,0,0,61.5,61.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,5.06,1156.46,12.32,15,0.43,93.66,0,0,4,0,14,0,3,14,0,24,11,0,0,0,0,0,0,35,0,0,35,0,0,0,0,0,0,0,0,0,"United States;Germany;Italy;Japan;Switzerland;Spain;United Kingdom","16;4;3;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","32;12;11;5;5;5;3;2;2;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PEDIATRIC;AUTOIMMUNE DISEASE;BRAIN DISORDERS;CARDIOVASCULAR;NEURODEGENERATIVE;PATIENT SAFETY;HEART DISEASE;LUNG;NEUROSCIENCES;PEDIATRIC CANCER;CHILDHOOD LEUKEMIA;DIGESTIVE DISEASES;MULTIPLE SCLEROSIS;PREVENTION;STEM CELL RESEARCH","29;20;12;10;8;7;5;5;5;5;5;4;4;4;4;3;3;3;3;3","CANCER;CARDIOVASCULAR;NEUROLOGICAL;INFECTION;RESPIRATORY;BLOOD;CONGENITAL;INFLAMMATORY AND IMMUNE SYSTEM;SKIN","8;5;3;2;2;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;6.3 MEDICAL DEVICES;7.1 INDIVIDUAL CARE NEEDS","20;2;2;2;1;1;1;1","LEUKEMIA / LEUKAEMIA;MYELOMA;NON-HODGKIN'S LYMPHOMA;ANAL CANCER;BLADDER CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;LUNG CANCER;STOMACH CANCER","6;3;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","11;2;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE","9;2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;3207 MEDICAL MICROBIOLOGY;38 ECONOMICS;3801 APPLIED ECONOMICS;49 MATHEMATICAL SCIENCES","10;5;5;2;1;1;1;1","AGING;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - C;HIV/AIDS;INFECTIOUS DISEASES;KIDNEY DISEASE;LIVER DISEASE","1;1;1;1;1;1;1;1;1;1","CONGENITAL;INFECTION;RENAL AND UROGENITAL","1;1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1","CLINICAL","2","CLINICAL MEDICINE AND SCIENCE","5","LIVER CANCER","1",NA,NA
"AOU_RIUNITIANCONA",2019,182,15.7142857142857,2.52747252747253,0.291208791208791,0.236263736263736,0.395604395604396,1.46496815286624,1.23255813953488,1.34375,1.2,0.675824175824176,1,77,43,19,14,0.42,0.24,0.1,0.08,33.05,1.35934113219911,5.64177215189873,0.357142857142857,0.912087912087912,0.433,0.376,0.421,0.398,"ANDREA GIOVAGNONI;FABRIZIO ZANCONATI;GIUSEPPE GATTI;NICOLÒ SCHICCHI;FABIOLA GIUDICI;GABRIELE GRASSI;ROSSANA BERARDI;GUIDO GINI;VIRGILIO CARNIELLI;MARCO FOGANTE;ALESSANDRA TUCCI;MONICA TANI;DEBORAH BONAZZA;MONICA BALZAROTTI;MARCO CONFALONIERI;MAGNUS DALÉN;FRANCESCA RE;VITO GIOVANNI RUGGIERI;FAUSTO BIANCARI;FRANCESCO MERLI","9;8;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5","ANDREA GIOVAGNONI;ROBERTO COPETTI;NICOLÒ SCHICCHI;MARCO FOGANTE;GIUSEPPE GATTI;GIANCARLO TIRELLI;FABIOLA GIUDICI;FABRIZIO ZANCONATI;GIAN MARCO GIUSEPPETTI;GABRIELE GRASSI;PAOLO MANGANOTTI;CRISTIANO CALVAGNA;MARIO D’ORIA;VIRGILIO CARNIELLI;LUCIO DELL’ATTI;ANDREA BENEDETTO GALOSI;MASSIMO POLITO;GERARDINA LARDIERI;MARCO MOROSIN;LUCA DELL’ANGELA","1.38;1.23;1.02;0.95;0.85;0.74;0.73;0.71;0.62;0.58;0.54;0.54;0.54;0.53;0.53;0.53;0.53;0.5;0.5;0.5","ANDREA GIOVAGNONI;FABRIZIO ZANCONATI;GIUSEPPE GATTI;NICOLÒ SCHICCHI;FABIOLA GIUDICI;GABRIELE GRASSI;ROSSANA BERARDI;GUIDO GINI;VIRGILIO CARNIELLI;MARCO FOGANTE;DEBORAH BONAZZA;MARCO CONFALONIERI;PAOLO MANGANOTTI;MARCO CIPOLLI;GIANCARLO TIRELLI;ALESSANDRO MANGOGNA;MARIA BEATRICE BILÒ;CRISTIANO CALVAGNA;CRISTINA BOTTIN;GIULIA BARBATI","9;8;8;7;7;6;6;6;6;6;5;5;4;4;4;4;3;3;3;3","ANDREA GIOVAGNONI;ROBERTO COPETTI;NICOLÒ SCHICCHI;MARCO FOGANTE;GIUSEPPE GATTI;GIANCARLO TIRELLI;FABIOLA GIUDICI;FABRIZIO ZANCONATI;GIAN MARCO GIUSEPPETTI;GABRIELE GRASSI;PAOLO MANGANOTTI;CRISTIANO CALVAGNA;MARIO D’ORIA;VIRGILIO CARNIELLI;LUCIO DELL’ATTI;MASSIMO POLITO;MARCO MOROSIN;CORRADO TAGLIATI;FEDERICA IEZZI;SARA MATRICARDI","1.38;1.23;1.02;0.95;0.85;0.74;0.73;0.71;0.62;0.58;0.54;0.54;0.54;0.53;0.53;0.53;0.5;0.48;0.45;0.44","A. VAN GOSSUM;MATTHIAS PIRLICH;MAURIZIO MUSCARITOLI;ROCCO BARAZZONI;ADRIANA CRIVELLI;CHARLENE COMPHER;AINSLEY MALONE;ANDREW J.S. COATS;DAN LINETZKY WAITZBERG;DAVID C. EVANS;GERTRUDIS ADRIANZA DE BAPTISTA;GORDON L. JENSEN;HEATHER KELLER;IBOLYA NYULASI;JIANCHUN YU;JOHN E. MORLEY;KELLY A. TAPPENDEN;KRIS M. MOGENSEN;LEAH GRAMLICH;LUISITO O. LLIDO","1189;1148;1148;1148;1146;1146;1105;1105;1105;1105;1105;1105;1105;1105;1105;1105;1105;1105;1105;1105","ROCCO BARAZZONI;VIRGILIO CARNIELLI;MARIA CARLA RE;STEFANO MENZO;MARCO CONFALONIERI;GIUSEPPE GATTI;PAOLA TOMIETTO;FABRIZIO ZANCONATI;TIZIANO BARBUI;SERENA BONIN;FABIOLA GIUDICI;MARINA TAUS;DEBORAH BONAZZA;ROSSANA BERARDI;ALESSANDRO MANGOGNA;ANDREA GIOVAGNONI;MARCO MARINI;PAOLO MANGANOTTI;FABRIZIO FRANCESCHINI;MARIA ASSUNTA COVA","1148;1015;465;442;247;179;163;148;139;137;135;131;129;122;117;109;103;99;82;82","ANDREA GIOVAGNONI;GIUSEPPE GATTI;NICOLÒ SCHICCHI;GUIDO GINI;FABIOLA GIUDICI;FABRIZIO ZANCONATI;VIRGILIO CARNIELLI;MARCO CONFALONIERI;MARCO FOGANTE;ALESSANDRO MANGOGNA;CARLO TROMBETTA;DEBORAH BONAZZA;GABRIELE GRASSI;PAOLO MANGANOTTI;GIANCARLO TIRELLI;MARCO CIPOLLI;ROSSANA BERARDI;MARINA TAUS;ROBERTO COPETTI;ALESSANDRO CAPUCCI","9;8;7;6;6;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;PHYSICS;COMPUTER SCIENCE;ECONOMICS;PSYCHOLOGY;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;PHILOSOPHY","174;41;18;18;15;13;11;11;8;7;5;5;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;RADIOLOGY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;GENETICS;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;ANESTHESIA;PEDIATRICS;CANCER RESEARCH;ENVIRONMENTAL HEALTH;PSYCHIATRY;NUCLEAR MEDICINE;FAMILY MEDICINE;OPTICS;ENDOCRINOLOGY","136;50;34;30;28;28;25;25;20;19;18;13;13;12;11;11;10;9;9;8","CANCER;CHEMOTHERAPY;DISEASE;GENE;HEART FAILURE;COHORT;LUNG;RETROSPECTIVE COHORT STUDY;MYOCARDIAL INFARCTION;POPULATION;CONFIDENCE INTERVAL;MULTIVARIATE ANALYSIS;CLINICAL TRIAL;LYMPHOMA;MAGNETIC RESONANCE IMAGING;PREGNANCY;RADIATION THERAPY;TRANSPLANTATION;AORTA;ARTERY;BLOOD PRESSURE;RANDOMIZED CONTROLLED TRIAL;STEM CELL","29;16;14;13;13;11;10;10;9;9;8;8;7;7;7;7;7;7;6;6;6;6;6","BREAST CANCER;EJECTION FRACTION;COLORECTAL CANCER;DIFFUSE LARGE B-CELL LYMPHOMA;CLINICAL ENDPOINT;INFLAMMATORY BOWEL DISEASE;NEUTROPENIA;RITUXIMAB;CORONARY ANGIOGRAPHY;CORONARY ARTERIES;UNIVARIATE ANALYSIS;GENOTYPE;HAEMATOPOIESIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMAGE QUALITY;PHENOTYPE;SEPTIC SHOCK;ACUTE CARE;ADENOCARCINOMA;AORTIC ANEURYSM;AORTIC REPAIR;ASCENDING AORTA;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BYPASS GRAFTING;CARDIOMYOPATHY;CD8;COPOLYMER;CYCLOPHOSPHAMIDE;DIASTOLE;ESCHERICHIA COLI;FETUS;GERIATRIC ONCOLOGY;GESTATIONAL AGE;HAZARD RATIO;IMATINIB;INTERIM ANALYSIS;INTERSTITIAL LUNG DISEASE;LEFT VENTRICULAR HYPERTROPHY;LENALIDOMIDE;METASTASIS;MICRORNA;MULTICENTER STUDY;MUTATION;NEPHRECTOMY;NEUROPSYCHOLOGY;NEURORADIOLOGY;PAIN CATASTROPHIZING;PANCREATIC CANCER;PARKINSON'S DISEASE;PERFORMANCE STATUS;PERIPROSTHETIC;PHASES OF CLINICAL RESEARCH;PROTOCOL (SCIENCE);REGENERATIVE MEDICINE;RNA;SALVAGE THERAPY;SUPPLEMENTARY MOTOR AREA;THORACIC AORTA;TRANSCRANIAL MAGNETIC STIMULATION;TRIGLYCERIDE;ULCERATIVE COLITIS;VALSARTAN","9;8;7;6;5;5;5;5;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BONE MARROW FAILURE;CARDIAC RESYNCHRONIZATION THERAPY;COLONOSCOPY;RIGHT CORONARY ARTERY;ANTHRACYCLINE;DASATINIB;DOPPLER ECHOCARDIOGRAPHY;EPITHELIAL–MESENCHYMAL TRANSITION;EXOME SEQUENCING;HYPERTRIGLYCERIDEMIA;KLEBSIELLA PNEUMONIAE;POLOXAMER;PROBAND;RIBOSOME;SACUBITRIL;SACUBITRIL, VALSARTAN;TRANSCRANIAL ALTERNATING CURRENT STIMULATION;AKT1;ANAGRELIDE;ANTIRETROVIRAL THERAPY;ANTISYNTHETASE SYNDROME;AORTIC RUPTURE;AUTOIMMUNE THYROIDITIS;AXITINIB;BENIGN PROSTATIC HYPERPLASIA (BPH);BOND STRENGTH;BRAIN-DERIVED NEUROTROPHIC FACTOR;BUSULFAN;CALPROTECTIN;CAPECITABINE;CARDIAC SKELETON;CARFILZOMIB;CATENIN;CENTRAL VENOUS PRESSURE;CHEMOIMMUNOTHERAPY;CHILD ABUSE;CONTINUOUS GLUCOSE MONITORING;CORE BIOPSY;CORONARY ARTERY ANEURYSM;CORONARY CALCIUM SCORE;CORONARY STEAL;DNA METHYLATION;DOCOSAHEXAENOIC ACID;EICOSAPENTAENOIC ACID;ENDOLYMPHATIC HYDROPS;ENDOMYSIUM;FAS LIGAND;FLUDARABINE;GASTRIC BYPASS;HEART FAILURE WITH PRESERVED EJECTION FRACTION;HUMAN VIROME;HYPOTHALAMIC HAMARTOMA;IMMUNOGLOBULIN M;IMMUNOTOXIN;INFLAMMATORY BOWEL DISEASES;INTERFERON ALFA;INTERNATIONAL PROGNOSTIC INDEX;ISCHEMIC CARDIOMYOPATHY;KININOGEN;KRAS;KYNURENINE;LEUKOCYTE ESTERASE;LOSS FUNCTION;LYMPHEDEMA;LYMPHOBLASTIC LYMPHOMA;MALE INFERTILITY;MAMMOGRAPHY;MASSIVE PARALLEL SEQUENCING;MEPOLIZUMAB;METASTATIC BREAST CANCER;MICROSATELLITE;MILAN CRITERIA;MISSENSE MUTATION;MOLECULAR EPIDEMIOLOGY;MORBID OBESITY;MYELOPROLIFERATIVE NEOPLASM;MYOCARDIAL BRIDGE;NEONATAL RESPIRATORY DISTRESS SYNDROME;NILOTINIB;OBINUTUZUMAB;OXALIPLATIN;PENETRANCE;PENILE CURVATURE;POLYGENE;PRIMARY TUMOR;PULSED-FIELD GEL ELECTROPHORESIS;RENAL ARTERY STENOSIS;SANGER SEQUENCING;SEXUAL ABUSE;SEXUAL ASSAULT;SINGLE-NUCLEOTIDE POLYMORPHISM;SURFACTANT THERAPY;SYNOVIAL FLUID;THIOTEPA;THORACIC AORTIC ANEURYSM;TICAGRELOR;TINIDAZOLE;TOTAL MESORECTAL EXCISION;TRACTOGRAPHY;TRIPLE-NEGATIVE BREAST CANCER;TUMOR-INFILTRATING LYMPHOCYTES;UREA BREATH TEST;VARICOCELE;VEDOLIZUMAB;VINCRISTINE","3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;RETROSPECTIVE STUDIES;ITALY;AGED, 80 AND OVER;TREATMENT OUTCOME;POSTOPERATIVE COMPLICATIONS;BREAST NEOPLASMS;NEOPLASMS;FOLLOW-UP STUDIES;LUNG;PROGNOSIS;PROSPECTIVE STUDIES;BIOMARKERS, TUMOR;RISK FACTORS","104;75;72;70;56;49;34;28;26;23;21;18;17;16;14;14;14;13;12;12","LYMPHOID NEOPLASMS;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;EPILEPSY AND SEIZURES;GENETIC BASIS OF NEUTROPENIA DISORDERS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;RENAL CELL CARCINOMA;ACUTE MYELOID LEUKEMIA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF HYPONATREMIA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS AND TREATMENT OF PROSTHETIC JOINT INFECTIONS;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA","6;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","TREATMENT;ANEURYSM SCREENING;CARDIAC IMAGING;CLINICAL ENDPOINT;MULTI-ENERGY CT;CORONARY ARTERIES;CORONARY ARTERY ANOMALIES;DIAGNOSIS;DUAL-ENERGY CT;ECHOCARDIOGRAPHY;GRADING (ENGINEERING);INTERQUARTILE RANGE;SHWACHMAN-DIAMOND SYNDROME;UNIVARIATE ANALYSIS;AORTIC DISSECTION;BONE MARROW FAILURE;CARDIAC RESYNCHRONIZATION THERAPY;CARDIOTHORACIC SURGERY;CARDIOVASCULAR RISK ASSESSMENT;COMPUTED TOMOGRAPHY ANGIOGRAPHY","7;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3","FONDAZIONE ITALIANA;HEART FAILURE;ITALIANA LINFOMI;B-CELL LYMPHOMA;BREAST CANCER;FINAL RESULTS;POSITION PAPER;CANCER PATIENTS;CORONARY ARTERY;EJECTION FRACTION;ELDERLY PATIENTS;INFLAMMATORY BOWEL;PHASE II;REDUCED EJECTION;RETROSPECTIVE STUDY;SHWACHMAN-DIAMOND SYNDROME;ACUTE MYELOID;ADULT PATIENTS;AORTIC ANEURYSM;ARTERY BYPASS;BLOODSTREAM INFECTIONS;BODY RADIOTHERAPY;BOWEL DISEASE;BYPASS GRAFTING;CANCER MITO;CARDIOVASCULAR PREVENTION;COGNITIVE SYMPTOMS;COHORT STUDY;CONSENSUS DOCUMENT;CROSS-OVER TRIAL","6;6;6;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;HONORARIA MEMBERSHIP;RESEARCH FUNDING;MG OAD;CORONARY ARTERY;UNIVERSITY HOSPITAL;HR CI;ADVERSE EVENTS;BONE MARROW;CANCER UNIT;DERMATOLOGY UNIVERSITY;MULTIVARIATE ANALYSIS;SKIN CANCER;TRIESTE TRIESTE;UNIT DEPARTMENT;CONSULTANCY HONORARIA;EXTRACORPOREAL MEMBRANE;COMMITTEES RESEARCH;MEMBRANE OXYGENATION;RISK FACTORS;TRIESTE ITALYSEARCH;ARTERIAL LACTATE;CELGENE HONORARIA;COMMITTEES SPEAKERS;LECTURE FEE;MEDIAN AGE;CARDIAC SURGERY;HEART FAILURE","101;101;38;37;29;19;17;16;15;14;14;14;14;14;14;14;14;13;13;12;12;12;12;11;11;11;11;11;10;10",5,0.03,2.95,5,0,0,0,1,0,0,0,5,0,0,4,1,0,0,1,3,1,0,0,58,58,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,4.29,641.34,13.53,16,0.39,70.41,1,0,10,1,11,0,1,17,0,27,14,0,0,0,0,0,0,40,1,0,40,0,0,1,0,0,0,0,0,0,"United States;Italy;Belgium;Japan;Switzerland","11;6;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3105 GENETICS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3006 FOOD SCIENCES;3207 MEDICAL MICROBIOLOGY;3210 NUTRITION AND DIETETICS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","40;17;14;10;4;4;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;TRANSPLANTATION;LUNG;NEUROSCIENCES;ORPHAN DRUG;PEDIATRIC;STEM CELL RESEARCH;AUTOIMMUNE DISEASE;DIGESTIVE DISEASES;GENETICS;PATIENT SAFETY;PEDIATRIC CANCER;REGENERATIVE MEDICINE;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;AGING;BRAIN DISORDERS","36;24;19;18;13;8;5;5;5;5;5;4;4;4;4;4;4;4;3;3","CANCER;ORAL AND GASTROINTESTINAL;CARDIOVASCULAR;CONGENITAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;RENAL AND UROGENITAL;SKIN","14;3;2;2;2;2;2;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS","26;3;2;2;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;MYELOMA;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LUNG CANCER;BLOOD CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;LIVER CANCER;PANCREATIC CANCER","9;4;4;3;3;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.2 SURVEILLANCE","15;9;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;KARGER PUBLISHERS","18;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;42 HEALTH SCIENCES;51 PHYSICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;37 EARTH SCIENCES;3705 GEOLOGY;4202 EPIDEMIOLOGY;49 MATHEMATICAL SCIENCES;4901 APPLIED MATHEMATICS","21;9;6;2;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;HEMATOLOGY;RARE DISEASES;BIOTECHNOLOGY;CARDIOVASCULAR;LUNG;PREVENTION;AGING;ASTHMA;CANCER;CYSTIC FIBROSIS;DIGESTIVE DISEASES;GENETIC TESTING;GENETICS;INFECTIOUS DISEASES;KIDNEY DISEASE;PANCREATIC CANCER;PEDIATRIC;SEPSIS;VACCINE RELATED","3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","RESPIRATORY;CANCER;CONGENITAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM","2;1;1;1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION","2;1;1","CLINICAL;BIOMEDICAL","4;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","7;3;1","LEUKEMIA / LEUKAEMIA;MYELOMA;LUNG CANCER;PANCREATIC CANCER","3;3;1;1","3 GOOD HEALTH AND WELL BEING","2"
"AOU_RIUNITIANCONA",2020,264,14.5227272727273,3.11742424242424,0.363636363636364,0.306818181818182,0.386363636363636,1.77370689655172,1.35211267605634,1.72340425531915,1.3972602739726,0.674242424242424,0,110,78,28,13,0.42,0.3,0.11,0.05,21.32,0.846007719638877,6.62571103526736,0.306818181818182,0.946969696969697,0.422,0.378,0.374,0.394,"ROSSANA BERARDI;NICOLÒ DE MANZINI;PAOLO MANGANOTTI;FABIOLA GIUDICI;LORENZO FALSETTI;ALEX BUOITE STELLA;MIRKO BAGLIVO;DOMINIKA VEŠELÉNYIOVÁ;MUNIS DÜNDAR;SERCAN KENANOĞLU;ROBERTA SERRANI;JURAJ KRAJČOVIČ;DANJELA KURTI;IRIS ZALAUDEK;MAURIZIO RICCI;CLAUDIO CONFORTI;NICOLA DI MEO;DEBORAH BONAZZA;FABRIZIO ZANCONATI;VALENTINO CHERUBINI","17;11;10;8;8;7;7;7;7;7;7;7;7;7;7;6;6;6;6;6","PAOLO MANGANOTTI;NICOLÒ DE MANZINI;LORENZO FALSETTI;ROSSANA BERARDI;ALEX BUOITE STELLA;FRANCESCO DE FRANCESCO;GABRIELE GRASSI;MARIO GRASSI;IRIS ZALAUDEK;VIRGILIO CARNIELLI;ALAN BILOSLAVO;MICHELE RICCIO;MARINA BORTUL;PAOLA CARUSO;NICOLA DI MEO;CLAUDIO CONFORTI;FABIOLA GIUDICI;CLAUDIO TIRIBELLI;MARCO CONFALONIERI;MILOŠ AJČEVIĆ","1.34;1.33;1.31;1.31;1.01;0.96;0.96;0.96;0.87;0.83;0.78;0.76;0.75;0.73;0.73;0.73;0.72;0.68;0.67;0.64","ROSSANA BERARDI;NICOLÒ DE MANZINI;PAOLO MANGANOTTI;FABIOLA GIUDICI;LORENZO FALSETTI;ALEX BUOITE STELLA;ROBERTA SERRANI;MAURIZIO RICCI;DEBORAH BONAZZA;FABRIZIO ZANCONATI;VALENTINO CHERUBINI;GIOVANNI LIGUORI;VIRGILIO CARNIELLI;ALAN BILOSLAVO;SILVIA RINALDI;MARINA BORTUL;GIUSEPPE GATTI;FRANCESCO DE FRANCESCO;MARCELLO TAVIO;MARTINA BONIFAZI","17;11;10;8;8;7;7;7;6;6;6;6;6;6;6;6;6;6;5;5","PAOLO MANGANOTTI;NICOLÒ DE MANZINI;LORENZO FALSETTI;ROSSANA BERARDI;ALEX BUOITE STELLA;FRANCESCO DE FRANCESCO;GABRIELE GRASSI;VIRGILIO CARNIELLI;ALAN BILOSLAVO;MICHELE RICCIO;MARINA BORTUL;PAOLA CARUSO;FABIOLA GIUDICI;MARCO CONFALONIERI;MILOŠ AJČEVIĆ;GIANLUCA CANTON;LUIGI MURENA;SILVIA RINALDI;GIOVANNA VITICCHI;GABRIELE PAGLIARICCIO","1.34;1.33;1.31;1.31;1.01;0.96;0.96;0.83;0.78;0.76;0.75;0.73;0.72;0.67;0.64;0.6;0.6;0.6;0.6;0.59","DANIELE SANTINI;ALFREDO FALCONE;EMILIANO TAMBURINI;GIUSEPPE APRILE;SARA LONARDI;ALBERTO ZANIBONI;ANGELA BUONADONNA;GIANLUCA TOMASELLO;ROBERTO BORDONARO;ANDREA MAMBRINI;CHIARA CARLOMAGNO;CRISTINA GRANETTO;E. CORGNA;MARIO ROSELLI;MATTEO CLAVAREZZA;SAMANTHA DI DONATO;MARTINA BONIFAZI;FILIPPO GIORGIO DI GIROLAMO;ANTONIO PAOLI;BRUNO GRASSI","606;582;582;564;564;505;505;505;505;488;488;488;488;488;488;488;426;419;418;418","EMILIANO TAMBURINI;FILIPPO GIORGIO DI GIROLAMO;GIANNI BIOLO;NICOLA FIOTTI;VALENTINO CHERUBINI;CARLO TROMBETTA;GIOVANNI LIGUORI;MARCO CONFALONIERI;NICOLA PAVAN;GIANCARLO TIRELLI;MARTINA BONIFAZI;PAOLO MANGANOTTI;BARBARA RUARO;FRANCESCO SALTON;PAOLA CONFALONIERI;ALEX BUOITE STELLA;STELLA BERNARDI;ROSSANA BERARDI;NICOLÒ DE MANZINI;FABRIZIO ZANCONATI","564;419;418;418;376;366;366;344;335;310;294;206;184;184;184;176;175;171;157;153","ROSSANA BERARDI;NICOLÒ DE MANZINI;PAOLO MANGANOTTI;LORENZO FALSETTI;MAURIZIO RICCI;ROBERTA SERRANI;ALEX BUOITE STELLA;FABRIZIO ZANCONATI;GIOVANNI LIGUORI;GIUSEPPE GATTI;VALENTINO CHERUBINI;ALAN BILOSLAVO;DEBORAH BONAZZA;MARINA BORTUL;MICHELE RICCIO;FRANCESCO DE FRANCESCO;MARCO CONFALONIERI;PAOLA CARUSO;SILVIA RINALDI;CARLO TROMBETTA","16;10;10;8;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5","MEDICINE;BIOLOGY;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;PHYSICS;MATHEMATICS;PSYCHOLOGY;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;MATERIALS SCIENCE;GEOLOGY;GEOGRAPHY;HISTORY;PHILOSOPHY","259;58;18;18;17;17;15;15;10;8;7;3;3;2;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;RADIOLOGY;ONCOLOGY;CARDIOLOGY;INTENSIVE CARE MEDICINE;IMMUNOLOGY;GENETICS;GASTROENTEROLOGY;PSYCHIATRY;ENVIRONMENTAL HEALTH;PEDIATRICS;CANCER RESEARCH;VIROLOGY;ANESTHESIA;BIOCHEMISTRY;ENDOCRINOLOGY;FAMILY MEDICINE;NURSING","186;88;57;35;31;30;29;28;27;26;25;24;21;19;16;15;14;13;12;12","DISEASE;CANCER;RETROSPECTIVE COHORT STUDY;POPULATION;GENE;COHORT;CONFIDENCE INTERVAL;OUTBREAK;CHEMOTHERAPY;ULTRASOUND;LUNG;DIABETES MELLITUS;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;MYOCARDIAL INFARCTION;PROSPECTIVE COHORT STUDY;COHORT STUDY;LOGISTIC REGRESSION;PERIOPERATIVE;STENT","50;43;29;24;18;15;14;14;13;12;11;10;10;10;9;9;8;8;8;8","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;HAZARD RATIO;METASTASIS;MUTATION;TYPE 2 DIABETES;ABDOMINAL AORTIC ANEURYSM;BEVACIZUMAB;CONTRAST-ENHANCED ULTRASOUND;EJECTION FRACTION;GESTATIONAL AGE;HEPATITIS C VIRUS;IMMUNOTHERAPY;RITUXIMAB;AORTIC ANEURYSM;AORTIC REPAIR;ARDS;CARDIOGENIC SHOCK;CD34;CHEMOTHERAPY REGIMEN;ELASTOGRAPHY;FIXATION (POPULATION GENETICS);GEMCITABINE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IDIOPATHIC PULMONARY FIBROSIS;KIDNEY TRANSPLANTATION;LIVER FIBROSIS;PANCREATIC CANCER;PHENOTYPE;PROGRESSIVE DISEASE;PULMONARY FIBROSIS;SEPTIC SHOCK;TYPE 1 DIABETES;UNIVARIATE ANALYSIS;VASCULAR ENDOTHELIAL GROWTH FACTOR;VASCULITIS","34;14;14;13;8;7;7;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);LYMPHEDEMA;ENDOVASCULAR ANEURYSM REPAIR;PROBAND;IRINOTECAN;MISSENSE MUTATION;OXALIPLATIN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;BRONCHOPULMONARY DYSPLASIA;CETUXIMAB;DASATINIB;IMATINIB MESYLATE;KETOACIDOSIS;LYMPHANGIOGENESIS;METASTATIC BREAST CANCER;NEUROPILIN 1;NILOTINIB;NIVOLUMAB;PORTAL VENOUS PRESSURE;PROSTATECTOMY;TRANSIENT ELASTOGRAPHY","33;7;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;COVID-19;RETROSPECTIVE STUDIES;COLORECTAL NEOPLASMS;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;TREATMENT OUTCOME;ADOLESCENT;CORONAVIRUS INFECTIONS;PNEUMONIA, VIRAL;SARS-COV-2;RISK FACTORS;YOUNG ADULT","152;111;79;75;56;51;44;44;36;26;20;19;17;16;15;15;15;15;13;13","CORONAVIRUS DISEASE 2019;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;LYMPHANGIOGENESIS IN CANCER METASTASIS AND DISEASE;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PANCREATIC CANCER RESEARCH AND TREATMENT;ATRIAL FIBRILLATION;CANCER IMMUNOTHERAPY;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;OLFACTORY DYSFUNCTION IN HEALTH AND DISEASE;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;PROVISION AND ASSESSMENT OF NUTRITION SUPPORT THERAPY;RENAL CELL CARCINOMA;ACUTE MYELOID LEUKEMIA","8;8;7;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;2","PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;ENDOVASCULAR REPAIR;METASTATIC COLORECTAL CANCER;TREATMENT;INTERQUARTILE RANGE;LYMPHEDEMA;PROBAND;STROKE (ENGINE);ATRIAL FIBRILLATION;CARDIAC IMAGING;CONTRAST-ENHANCED ULTRASOUND;DIABETES;ENDOVASCULAR ANEURYSM REPAIR;EXTRACORPOREAL MEMBRANE OXYGENATION;FRACTURE CLASSIFICATION;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;PERIOPERATIVE;POSITIVE END-EXPIRATORY PRESSURE","16;13;9;7;7;7;6;6;5;5;4;4;4;4;4;4;4;4;4;4","COLORECTAL CANCER;COVID- PANDEMIC;CANCER PATIENTS;COHORT STUDY;BREAST CANCER;EXTRACORPOREAL MEMBRANE;ILL PATIENTS;MEMBRANE OXYGENATION;METASTATIC COLORECTAL;PATIENTS TREATED;PROSPECTIVE STUDY;TYPE DIABETES;ADULT PATIENTS;AORTIC REPAIR;ATRIAL FIBRILLATION;CELL CARCINOMA;CONTROLLED TRIAL;CRITICALLY ILL;ENDOVASCULAR AORTIC;LIVER FIBROSIS;PATIENTS ADMITTED;PATIENTS UNDERGOING;SINGLE CENTER;STEM CELL;STEM CELLS;BARIATRIC SURGERY;BLOOD PRESSURE;CANDIDATE GENE;CARDIOGENIC SHOCK;CHECKPOINT INHIBITOR","8;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","SPEAKERS BUREAU;ADVISORY COMMITTEES;ENTITYS BOARD;ACUTE RESPIRATORY;RESEARCH FUNDING;TRIESTE ITALYSEARCH;COMMITTEES SPEAKERS;CONSULTANCY HONORARIA;MAGGIORE HOSPITAL;HR CI;PATIENTS TREATED;RESPIRATORY SYNDROME;SEVERE ACUTE;SYNDROME CORONAVIRUS;CORONAVIRUS DISEASE;DISEASE COVID-;TRIESTE TRIESTE;ADVERSE EVENTS;PATIENTS UNDERGOING;TRIESTE UNIVERSITY;DERMATOLOGY MAGGIORE;MD DEPARTMENT;DISEASE PROGRESSION;STENT GRAFT;COVID- PANDEMIC;HONORARIA MEMBERSHIP;COLORECTAL CANCER;CONSULTANCY MEMBERSHIP;STATISTICALLY SIGNIFICANT;HOSPITAL TRIESTE","59;45;45;31;28;28;27;27;26;25;23;22;22;20;19;18;18;17;17;17;16;16;15;15;14;14;13;13;13;12",17,0.06,1.25,2,1,0,0,0,0,1,1,3,0,0,2,0,0,1,3.75,2,2.25,0,0,29,29,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,3,778.71,9.09,21,0.54,84.69,0,0,11,0,9,0,2,17,0,25,13,0,0,0,0,0,0,36,3,0,38,1,0,0,0,0,0,0,0,0,"Italy;United States;Germany;Netherlands;Switzerland;France;United Kingdom;Austria;Belgium;Czechia;Denmark;Japan;Poland;Spain;Sweden","11;9;5;5;4;3;2;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4207 SPORTS SCIENCE AND EXERCISE;46 INFORMATION AND COMPUTING SCIENCES","38;17;9;7;6;4;4;4;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;LUNG;PATIENT SAFETY;INFECTIOUS DISEASES;PREVENTION;CARDIOVASCULAR;AGING;HEART DISEASE;BRAIN DISORDERS;PEDIATRIC;ACUTE RESPIRATORY DISTRESS SYNDROME;AUTOIMMUNE DISEASE;DIGESTIVE DISEASES;NEUROSCIENCES;PNEUMONIA;PNEUMONIA & INFLUENZA","36;20;14;14;11;9;9;7;7;6;5;5;4;4;3;3;3;3;3;3","CANCER;CARDIOVASCULAR;RESPIRATORY;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;STROKE;EYE;MENTAL HEALTH;SKIN","9;4;3;2;2;2;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;6.7 PHYSICAL;7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES","23;4;4;2;2;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;BLOOD CANCER;MYELOMA;CERVICAL CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;LUNG CANCER;OVARIAN CANCER;PANCREATIC CANCER","7;3;3;2;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.2 SURVEILLANCE","11;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,"FRONTIERS;KARGER PUBLISHERS","2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;42 HEALTH SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","7;3;2;1;1;1;1","BIOMEDICAL IMAGING;CARDIOVASCULAR;CLINICAL RESEARCH;HEMATOLOGY;LUNG;NEUROSCIENCES;NUTRITION;OBESITY","2;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;NEUROLOGICAL","1;1;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;6.1 PHARMACEUTICALS","2;1;1","BIOMEDICAL;CLINICAL","1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","3;1",NA,NA,"3 GOOD HEALTH AND WELL BEING","1"
"AOU_RIUNITIANCONA",2021,298,17.6442953020134,3.01342281879195,0.332214765100671,0.322147651006711,0.36241610738255,1.8765690376569,1.35616438356164,1.74545454545455,1.33333333333333,0.691275167785235,1,131,66,32,19,0.44,0.22,0.11,0.06,13.23,0.857819559861031,6.8170478170478,0.26510067114094,0.966442953020134,0.504,0.486,0.478,0.475,"PAOLO MANGANOTTI;ALESSANDRO DINOTO;ARIANNA SARTORI;ROSSANA BERARDI;MARCO CONFALONIERI;GUIDO GINI;MARTA CHELI;FABIOLA GIUDICI;FABIO MONICA;STEFANO GASPARINI;FULVIO PASQUIN;ALESSIO BRATINA;ANTONIO DELLO RUSSO;ANNALISA ARCARI;ELISA BARATELLA;MARTINA BONIFAZI;VITTORIO RUGGERO ZILIOLI;ALBERTO FABBRI;ANTONIO BOSCO;BARBARA RUARO","27;16;13;13;12;12;12;10;10;10;9;9;9;9;8;8;8;8;8;8","PAOLO MANGANOTTI;ALESSANDRO DINOTO;ARIANNA SARTORI;MARTA CHELI;MASSIMILIANO PETRELLI;STEFANO GASPARINI;FULVIO PASQUIN;ALESSIO BRATINA;MARTINA BONIFAZI;ANTONIO BOSCO;FABIOLA GIUDICI;FRANCESCO DE FRANCESCO;MARCO FOGANTE;ROSSANA BERARDI;ANDREA GIOVAGNONI;MARIA ASSUNTA COVA;MARCO CONFALONIERI;GABRIELE PAGLIARICCIO;FRANCESCO BIADUZZINI;LINA ZUCCATOSTA","3.48;2.21;2.12;1.66;1.33;1.15;1.12;1.12;1.03;1;0.91;0.9;0.87;0.82;0.78;0.77;0.77;0.75;0.75;0.74","PAOLO MANGANOTTI;ALESSANDRO DINOTO;ARIANNA SARTORI;ROSSANA BERARDI;MARCO CONFALONIERI;GUIDO GINI;MARTA CHELI;FABIOLA GIUDICI;FABIO MONICA;STEFANO GASPARINI;FULVIO PASQUIN;ALESSIO BRATINA;ANTONIO DELLO RUSSO;ELISA BARATELLA;MARTINA BONIFAZI;ANTONIO BOSCO;BARBARA RUARO;MARIA ASSUNTA COVA;LINA ZUCCATOSTA;FEDERICA PECCI","27;16;13;13;12;12;12;10;10;10;9;9;9;8;8;8;8;8;7;7","PAOLO MANGANOTTI;ALESSANDRO DINOTO;ARIANNA SARTORI;MARTA CHELI;MASSIMILIANO PETRELLI;STEFANO GASPARINI;FULVIO PASQUIN;ALESSIO BRATINA;MARTINA BONIFAZI;ANTONIO BOSCO;FABIOLA GIUDICI;FRANCESCO DE FRANCESCO;MARCO FOGANTE;ROSSANA BERARDI;ANDREA GIOVAGNONI;MARIA ASSUNTA COVA;MARCO CONFALONIERI;GABRIELE PAGLIARICCIO;FRANCESCO BIADUZZINI;LINA ZUCCATOSTA","3.48;2.21;2.12;1.66;1.33;1.15;1.12;1.12;1.03;1;0.91;0.9;0.87;0.82;0.78;0.77;0.77;0.75;0.75;0.74","DAVOR MILIČIĆ;JOHN KANAKAKIS;MIKA LAINE;ALDO P. MAGGIONI;ABDRAKHMANOV AYAN;ADAM TIMMIS;ADRIANO MURRONE;AGNIESZKA PAWLAK;ALEKSANDRA TORBICA;ALEN DŽUBUR;ALEX MCCONNACHIE;ALEXANDER ALADASHVILI;ALEXANDRIA PATRIANAKOS;ALEŠ LINHART;ANDREAS M. ZEIHER;ARIEL COHEN;ARIK WOLAK;AUREL DEMIRAJ;BARAK ZAFRIR;BARBARA IGNATIUK","658;658;657;632;624;624;624;624;624;624;624;624;624;624;624;624;624;624;624;624","BARBARA IGNATIUK;MARCO CONFALONIERI;ELISA BARATELLA;MARIA ASSUNTA COVA;VIRGILIO CARNIELLI;BARBARA RUARO;FRANCESCO SALTON;FABIOLA GIUDICI;LUCA CANTINI;SILVIA VARANO;ROSSANA BERARDI;PAOLO FRATICELLI;PAOLA CONFALONIERI;GUIDO GINI;ROCCO BARAZZONI;CRISTINA MARROCCHIO;FABIO MONICA;DANIELE CASTELLANI;PAOLO MANGANOTTI;RITA CHIARI","624;267;213;213;197;194;183;174;136;134;127;126;114;112;106;104;97;93;93;90","PAOLO MANGANOTTI;ALESSANDRO DINOTO;ARIANNA SARTORI;MARCO CONFALONIERI;GUIDO GINI;MARTA CHELI;FABIO MONICA;ROSSANA BERARDI;ALESSIO BRATINA;FULVIO PASQUIN;ANTONIO BOSCO;MARIA ASSUNTA COVA;ELISA BARATELLA;ANDREA GIOVAGNONI;BARBARA RUARO;FABIOLA GIUDICI;LUCA CANTINI;ANTONIO DELLO RUSSO;VIRGILIO CARNIELLI;ALESSANDRO BITTONI","26;15;13;12;11;11;10;9;9;9;8;8;8;7;7;6;6;6;6;5","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;ECONOMICS;POLITICAL SCIENCE;PSYCHOLOGY;MATHEMATICS;SOCIOLOGY;HISTORY;MATERIALS SCIENCE;PHILOSOPHY;BUSINESS;ART;GEOLOGY","296;54;28;22;15;15;11;11;11;10;9;3;3;3;2;1;1","INTERNAL MEDICINE;SURGERY;RADIOLOGY;PATHOLOGY;CARDIOLOGY;GASTROENTEROLOGY;ONCOLOGY;PSYCHIATRY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PEDIATRICS;INTENSIVE CARE MEDICINE;VIROLOGY;ANESTHESIA;GENETICS;BIOCHEMISTRY;EMERGENCY MEDICINE;NUCLEAR MEDICINE;PHYSICAL THERAPY;ENDOCRINOLOGY;OPTICS","242;82;57;56;47;38;38;35;34;29;27;26;22;20;19;18;18;18;15;13;13","DISEASE;CANCER;POPULATION;RETROSPECTIVE COHORT STUDY;COHORT;CONFIDENCE INTERVAL;OUTBREAK;LUNG;GENE;HEART FAILURE;PNEUMONIA;LYMPHOMA;CHEMOTHERAPY;CLINICAL TRIAL;INCIDENCE (GEOMETRY);MAGNETIC RESONANCE IMAGING;MYOCARDIAL INFARCTION;LOGISTIC REGRESSION;MULTIPLE SCLEROSIS;ATRIAL FIBRILLATION;INTENSIVE CARE UNIT;LUNG CANCER;NEUROLOGY;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL","78;50;32;27;24;24;21;19;15;15;14;13;12;12;12;12;11;10;10;9;9;9;9;9;9","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;BREAST CANCER;COLORECTAL CANCER;CLINICAL ENDPOINT;EJECTION FRACTION;HAZARD RATIO;ADENOCARCINOMA;DIFFUSE LARGE B-CELL LYMPHOMA;IMMUNOTHERAPY;HIGH-RESOLUTION COMPUTED TOMOGRAPHY;INTERSTITIAL LUNG DISEASE;NEURORADIOLOGY;UNIVARIATE ANALYSIS;CARDIOGENIC SHOCK;GESTATIONAL AGE;HODGKIN LYMPHOMA;ISCHEMIC STROKE;PERCUTANEOUS CORONARY INTERVENTION;TELEMEDICINE;VASCULITIS","55;20;14;13;12;11;10;7;7;7;6;6;5;5;4;4;4;4;4;4;4","CORONAVIRUS DISEASE 2019 (COVID-19);CARDIAC RESYNCHRONIZATION THERAPY;IRINOTECAN;OXALIPLATIN;PEMBROLIZUMAB;ANTHRACYCLINE;BRENTUXIMAB VEDOTIN;DASATINIB;DUCTAL CARCINOMA;KRAS;MAMMOGRAPHY;NEONATAL RESPIRATORY DISTRESS SYNDROME;SURFACTANT THERAPY;TELEHEALTH;AUTOIMMUNE ENCEPHALITIS;BENDAMUSTINE;DNA MISMATCH REPAIR;GRANULOMATOSIS WITH POLYANGIITIS;GROUND-GLASS OPACITY;INTERNATIONAL PROGNOSTIC INDEX;INTRA-AORTIC BALLOON PUMPING;LIMBIC ENCEPHALITIS;LYMPHEDEMA;MICROSATELLITE;MISSENSE MUTATION;NILOTINIB;PROBAND;RIVAROXABAN;USUAL INTERSTITIAL PNEUMONIA","55;6;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;MALE;FEMALE;COVID-19;RETROSPECTIVE STUDIES;AGED;MIDDLE AGED;ITALY;TREATMENT OUTCOME;ADULT;SARS-COV-2;AGED, 80 AND OVER;RISK FACTORS;RESPIRATORY DISTRESS SYNDROME, NEWBORN;PANDEMICS;POSTOPERATIVE COMPLICATIONS;PROSPECTIVE STUDIES;HEART FAILURE;ATRIAL FIBRILLATION","150;148;60;58;53;50;41;37;36;29;27;23;20;16;14;13;13;13;12;11","IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;CORONAVIRUS DISEASE 2019;LYMPHOID NEOPLASMS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;CANCER IMMUNOTHERAPY;EFFICACY AND RESISTANCE IN CML TREATMENT;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;APPLICATIONS OF DEEP LEARNING IN MEDICAL IMAGING;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS","15;12;8;7;6;6;6;5;5;5;4;4;4;3;3;3;3;3;3;3","PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;SINGLE CENTER;TREATMENT;CLINICAL CHARACTERISTICS;INTERQUARTILE RANGE;STROKE (ENGINE);ARRHYTHMIAS;HIGH-RESOLUTION COMPUTED TOMOGRAPHY;ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;BIOMARKERS FOR IMMUNOTHERAPY;CLINICAL PRACTICE;LUNG ULTRASOUND;NEURORADIOLOGY;UNIVARIATE ANALYSIS;CARDIAC RESYNCHRONIZATION THERAPY;CARDIAC SUPPORT DEVICE;CARDIAC ULTRASOUND;EMERGENCY DEPARTMENT VISITS","24;19;12;9;9;8;7;7;6;6;5;5;5;5;5;5;4;4;4;4","COVID- PANDEMIC;MULTIPLE SCLEROSIS;FONDAZIONE ITALIANA;ITALIANA LINFOMI;PATIENTS TREATED;PATIENTS UNDERGOING;HEART FAILURE;LUNG CANCER;MULTICENTER STUDY;SARS-COV- INFECTION;CELL LUNG;COMPUTED TOMOGRAPHY;INTERSTITIAL LUNG;LINFOMI FIL;LUNG ULTRASOUND;POSITION PAPER;RESPIRATORY DISTRESS;VENTRICULAR ARRHYTHMIAS;CELL CARCINOMA;CLINICAL PRACTICE;COHORT STUDY;COVID- PATIENTS;DISTRESS SYNDROME;ELDERLY PROJECT;INTERNAL MEDICINE;MACHINE LEARNING;NON-SMALL CELL;NSCLC PATIENTS;RETROSPECTIVE COHORT;SARS-COV- PANDEMIC","10;9;8;8;8;8;7;7;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;PERSONAL FEES;PATIENTS TREATED;HR CI;COVID- PATIENTS;PATIENTS UNDERGOING;COVID- PNEUMONIA;MEDIAN AGE;SARS-COV- INFECTION;ACCOMODATIONS EXPENSES;CONSULTANCY HONORARIA;TRAVEL ACCOMODATIONS;RESEARCH FUNDING;STATISTICALLY SIGNIFICANT;CLINICAL PRACTICE;INTENSIVE CARE;CARE UNIT;COVID- PANDEMIC;MEDIAN FOLLOW-UP;CONFIDENCE INTERVAL;DOSE INTENSITY;HAZARD RATIO;INCREASED RISK;COMMITTEES SPEAKERS;HEART FAILURE;SIGNIFICANT DIFFERENCE;SURVIVAL OS;CONSECUTIVE PATIENTS","91;91;64;39;32;27;26;25;22;20;20;19;19;19;18;18;17;17;16;16;16;15;15;15;15;14;14;14;14;13",19,0.06,10.25,12,2.5,2,0,1.75,0,0,1,14,1,0,12,0,0,3.5,9,7,6.5,0,0,36,36,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,3.67,621.1,9.91,22,0.51,82.65,0,0,8,0,15,0,4,16,0,28,14,0,0,0,0,0,0,42,1,0,42,1,0,0,0,0,0,0,0,0,"United States;Italy;Germany;Netherlands;United Kingdom;France;Japan;Switzerland","8;6;2;2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3213 PAEDIATRICS;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3208 MEDICAL PHYSIOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","43;22;12;7;3;2;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;LUNG;PEDIATRIC;PREVENTION;AUTOIMMUNE DISEASE;CARDIOVASCULAR;HEART DISEASE;BRAIN DISORDERS;BREAST CANCER;DIGESTIVE DISEASES;INFECTIOUS DISEASES;ORPHAN DRUG;TRANSPLANTATION;ARTHRITIS;BIOENGINEERING","42;28;16;16;10;9;6;5;5;4;4;4;3;3;3;3;3;3;2;2","CANCER;CARDIOVASCULAR;CONGENITAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL;RESPIRATORY;NEUROLOGICAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;SKIN;STROKE","13;3;2;2;2;2;2;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;7.3 MANAGEMENT AND DECISION MAKING","24;5;3;3;2;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;MYELOMA;COLON AND RECTAL CANCER;GASTROINTESTINAL TRACT;HEAD AND NECK CANCER;HODGKIN'S DISEASE;LARYNGEAL CANCER;LIVER CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;SARCOMA","4;4;3;3;1;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","9;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"ZENODO;FRONTIERS;MENDELEY DATA","6;5;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;44 HUMAN SOCIETY;3211 ONCOLOGY AND CARCINOGENESIS","22;12;2;2;1","CLINICAL RESEARCH;PATIENT SAFETY;BRAIN DISORDERS;EPILEPSY;LUNG;NEURODEGENERATIVE;NEUROSCIENCES;PEDIATRIC;AUTOIMMUNE DISEASE;CARDIOVASCULAR;CYSTIC FIBROSIS;DIABETES;HEART DISEASE;NUTRITION;PREVENTION;PSORIASIS;RARE DISEASES;CANCER;INFECTIOUS DISEASES;PNEUMONIA","6;5;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1","CARDIOVASCULAR;CONGENITAL;METABOLIC AND ENDOCRINE;NEUROLOGICAL;SKIN;CANCER","2;2;2;2;2;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","4;2;1","CLINICAL;BIOMEDICAL","7;2","CLINICAL MEDICINE AND SCIENCE","9","BREAST CANCER;COLON AND RECTAL CANCER","1;1",NA,NA
"AOU_RIUNITIANCONA",2022,306,19.4640522875817,2.73856209150327,0.235294117647059,0.235294117647059,0.294117647058824,1.70325203252033,1.26315789473684,1.44,1.32352941176471,0.738562091503268,4,100,79,36,18,0.33,0.26,0.12,0.06,7.87,0.881899622943223,6.08665681930083,0.356209150326797,0.96078431372549,0.533,0.397,0.396,0.392,"DANIELE CASTELLANI;MARCO CONFALONIERI;GIANLUCA MORONCINI;BARBARA RUARO;LORENZO FALSETTI;FEDERICO GUERRA;EMILIANO TAMBURINI;GIOVANNI LIGUORI;CARLO TROMBETTA;FRANCESCO SALTON;VINCENZO ZACCONE;GIOVANNA VITICCHI;DAVIDE STOLFO;ANTONIO DELLO RUSSO;FEDERICO MEI;NICOLÒ DE MANZINI;ANTONIO GIGANTE;GIANFRANCO SINAGRA;JACOPO SABBATINELLI;MARCO FOGANTE","13;12;11;11;10;9;9;9;9;9;8;8;8;8;7;7;7;7;7;7","MARCO FOGANTE;CATERINA ANTONAGLIA;BARBARA RUARO;NICOLÒ DE MANZINI;DANIELE CASTELLANI;GIANLUCA MORONCINI;FRANCESCO MESSINA;LUCA BURRONI;ANTONIO GIGANTE;LORENZO FALSETTI;MARINA BORTUL;MARCO CONFALONIERI;STEFANO GASPARINI;FEDERICO MEI;LINA ZUCCATOSTA;CARLO TROMBETTA;GIOVANNA VITICCHI;FRANCESCO SALTON;MICHELA CASELLA;GIOVANNI LIGUORI","2.76;1.28;1.1;1.09;1.07;1;1;1;0.96;0.88;0.86;0.84;0.84;0.82;0.81;0.8;0.77;0.77;0.73;0.73","DANIELE CASTELLANI;MARCO CONFALONIERI;GIANLUCA MORONCINI;BARBARA RUARO;LORENZO FALSETTI;FEDERICO GUERRA;EMILIANO TAMBURINI;GIOVANNI LIGUORI;CARLO TROMBETTA;FRANCESCO SALTON;VINCENZO ZACCONE;GIOVANNA VITICCHI;DAVIDE STOLFO;ANTONIO DELLO RUSSO;FEDERICO MEI;NICOLÒ DE MANZINI;ANTONIO GIGANTE;GIANFRANCO SINAGRA;JACOPO SABBATINELLI;MARCO FOGANTE","13;12;11;11;10;9;9;9;9;9;8;8;8;8;7;7;7;7;7;7","MARCO FOGANTE;CATERINA ANTONAGLIA;BARBARA RUARO;NICOLÒ DE MANZINI;DANIELE CASTELLANI;GIANLUCA MORONCINI;FRANCESCO MESSINA;LUCA BURRONI;ANTONIO GIGANTE;LORENZO FALSETTI;MARINA BORTUL;MARCO CONFALONIERI;STEFANO GASPARINI;FEDERICO MEI;LINA ZUCCATOSTA;CARLO TROMBETTA;GIOVANNA VITICCHI;FRANCESCO SALTON;MICHELA CASELLA;GIOVANNI LIGUORI","2.76;1.28;1.1;1.09;1.07;1;1;1;0.96;0.88;0.86;0.84;0.84;0.82;0.81;0.8;0.77;0.77;0.73;0.73","EMILIANO TAMBURINI;GIANLUCA MASI;SARA LONARDI;LORENZO ANTONUZZO;F TURRINI;PIERGIUSEPPE AGOSTONI;ALESSANDRA BOCCACCINO;ALESSANDRO PASSARDI;CARLOTTA ANTONIOTTI;CHIARA CREMOLINI;DANIELE ROSSINI;FRANCESCA BERGAMO;MIRELLA GIORDANO;VERONICA CONCA;BEATRICE BORELLI;ENRICO AMMIRATI;FEDERICA MARMORINO;FEDERICA MORANO;FILIPPO PIETRANTONIO;GABRIELLA FONTANINI","324;277;277;243;191;183;177;177;177;177;177;177;177;177;176;176;176;176;176;176","EMILIANO TAMBURINI;MARCO MARINI;MARIA VITTORIA MATASSINI;MARCO CONFALONIERI;DANIELE CASTELLANI;BARBARA RUARO;ELISA BARATELLA;PAOLA CONFALONIERI;FRANCESCO SALTON;RITA CHIARI;BARBARA IGNATIUK;LINDA NICOLARDI;JACOPO SABBATINELLI;ROCCO BARAZZONI;GIANLUCA MORONCINI;CARLO TROMBETTA;GIOVANNI LIGUORI;LORENZO FALSETTI;CATERINA ANTONAGLIA;VINCENZO ZACCONE","314;175;174;135;116;108;100;84;82;81;73;67;65;62;61;60;60;60;55;49","DANIELE CASTELLANI;LORENZO FALSETTI;MARCO CONFALONIERI;CARLO TROMBETTA;GIOVANNI LIGUORI;EMILIANO TAMBURINI;GIANLUCA MORONCINI;VINCENZO ZACCONE;MARCO FOGANTE;MICHELE RIZZO;FEDERICO MEI;FRANCESCO SALTON;BARBARA RUARO;ELISA BARATELLA;NICOLA PAVAN;ANTONIO DELLO RUSSO;FEDERICO GUERRA;MARTINA BONIFAZI;GIANFRANCO SINAGRA;NICOLÒ SCHICCHI","12;10;10;9;9;8;8;8;7;7;7;6;6;6;6;6;6;6;5;5","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;PSYCHOLOGY;ENGINEERING;MATHEMATICS;MATERIALS SCIENCE;POLITICAL SCIENCE;ECONOMICS;SOCIOLOGY;PHILOSOPHY;GEOGRAPHY;GEOLOGY;ART;BUSINESS","297;52;30;21;20;16;14;12;7;7;6;6;5;2;2;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;CARDIOLOGY;RADIOLOGY;ONCOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;GASTROENTEROLOGY;IMMUNOLOGY;PEDIATRICS;GENETICS;BIOCHEMISTRY;NURSING;PSYCHIATRY;PALEONTOLOGY;OPTICS;EMERGENCY MEDICINE;ENDOCRINOLOGY;FAMILY MEDICINE;UROLOGY","238;91;52;50;42;35;33;29;26;25;25;21;19;18;18;17;15;14;14;14;14","DISEASE;CANCER;RETROSPECTIVE COHORT STUDY;POPULATION;COHORT;GENE;HEART FAILURE;PNEUMONIA;OUTBREAK;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);CHEMOTHERAPY;MYOCARDIAL INFARCTION;OBSERVATIONAL STUDY;PROSPECTIVE COHORT STUDY;BLOOD PRESSURE;CLINICAL TRIAL;LOGISTIC REGRESSION;OBESITY;RANDOMIZED CONTROLLED TRIAL","54;48;36;33;25;19;17;16;15;14;14;13;13;13;13;11;11;10;10;10","INFECTIOUS DISEASE (MEDICAL SPECIALTY);COLORECTAL CANCER;2019-20 CORONAVIRUS OUTBREAK;BREAST CANCER;EJECTION FRACTION;IMMUNOTHERAPY;CLINICAL ENDPOINT;BEVACIZUMAB;HAZARD RATIO;NEUTROPENIA;CARDIOMYOPATHY;CONVENTIONAL PCI;CRYOABLATION;GENOTYPE;GESTATIONAL AGE;MUTATION;NEPHRECTOMY;PERCUTANEOUS CORONARY INTERVENTION;PHASES OF CLINICAL RESEARCH;PROSTATE CANCER;RITUXIMAB;SORAFENIB;TOLERABILITY","39;13;12;11;7;7;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","CORONAVIRUS DISEASE 2019 (COVID-19);IRINOTECAN;LENVATINIB;OXALIPLATIN;KRAS;MAMMOGRAPHY;NIVOLUMAB;ANTHRACYCLINE;CERVICAL INTRAEPITHELIAL NEOPLASIA;CHEMOIMMUNOTHERAPY;DASATINIB;FEBRILE NEUTROPENIA;INTRAVENTRICULAR HEMORRHAGE;NILOTINIB;PEMBROLIZUMAB;PROSTATECTOMY;SINGLE-NUCLEOTIDE POLYMORPHISM;TIMI;UROTHELIAL CARCINOMA;ACINETOBACTER BAUMANNII;ACINIC CELL CARCINOMA;ADIPOKINE;ADIPONECTIN;AJCC STAGING SYSTEM;ANAPHYLACTIC REACTIONS;ANGIOTENSIN RECEPTOR BLOCKERS;ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA;ATHERECTOMY;ATRIAL TACHYCARDIA;ATROPHIC GASTRITIS;ATRX;AXITINIB;BASIC LIFE SUPPORT;BENDAMUSTINE;BONE MARROW FAILURE;BRADYCARDIA;BREAST RECONSTRUCTION;BROTH MICRODILUTION;CALCITONIN GENE-RELATED PEPTIDE;CAPECITABINE;CARDIAC RESYNCHRONIZATION THERAPY;CATHINONE;CD38;CENTRAL SENSITIZATION;CENTRAL VENOUS PRESSURE;CERVICAL SCREENING;CILIARY NEUROTROPHIC FACTOR;CLAUDICATION;COLONOSCOPY;CONGENITAL NEUTROPENIA;CORONARY STENT;CYCLIN D1;DIFFUSE ALVEOLAR DAMAGE;DNA METHYLATION;DNA MISMATCH REPAIR;ENDOVASCULAR ANEURYSM REPAIR;ETHOSUXIMIDE;EVANS SYNDROME;EXOME SEQUENCING;FAS RECEPTOR;FERTILITY PRESERVATION;FILGRASTIM;FOLINIC ACID;FOURNIER GANGRENE;GENE SIGNATURE;GENOME INSTABILITY;GENOTYPING;GLUCOSE HOMEOSTASIS;GROWTH HORMONE DEFICIENCY;HEART FAILURE WITH PRESERVED EJECTION FRACTION;HORMONE RECEPTOR;HUMAN GROWTH HORMONE;IBRUTINIB;IL-2 RECEPTOR;IMIPENEM;INDOCYANINE GREEN ANGIOGRAPHY;INGUINAL CANAL;INTERMITTENT CLAUDICATION;INTRA-AORTIC BALLOON PUMPING;IPILIMUMAB;IVACAFTOR;LOWER URINARY TRACT SYMPTOMS;LYMPHEDEMA;MACULA DENSA;MASTECTOMY;MEASLES VACCINE;MEDIASTINAL LYMPH NODE;MISSENSE MUTATION;MODIFIED RANKIN SCALE;NATIONAL CHOLESTEROL EDUCATION PROGRAM;NEOADJUVANT THERAPY;NINTEDANIB;ORTHOSTATIC INTOLERANCE;OXCARBAZEPINE;P2Y12;PARADOXICAL EMBOLISM;PAZOPANIB;PEDIATRIC STROKE;PERIVENTRICULAR LEUKOMALACIA;PITTSBURGH SLEEP QUALITY INDEX;PRENATAL DIAGNOSIS;PRESSURE OVERLOAD;PRIMARY TUMOR;PROBAND;PROSTATE-SPECIFIC ANTIGEN;PULSED-FIELD GEL ELECTROPHORESIS;RADIOIMMUNOTHERAPY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RETINOL BINDING PROTEIN;RIBOSOME;RIGHT-TO-LEFT SHUNT;RIVAROXABAN;RNA SPLICING;ROCK2;SODIUM CHANNEL BLOCKER;SPIRILLACEAE;STEATOHEPATITIS;SURFACTANT THERAPY;SYSTEMIC THERAPY;TAXANE;TELOMERASE REVERSE TRANSCRIPTASE;TIROFIBAN;TNM STAGING SYSTEM;TOTAL MESORECTAL EXCISION;TRANSCRIPTOME;TRANSLABYRINTHINE APPROACH;TRASTUZUMAB;UNDERWEIGHT;UTERINE ARTERY;VENETOCLAX;ZIDOVUDINE","39;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;RETROSPECTIVE STUDIES;COVID-19;FEMALE;MALE;TREATMENT OUTCOME;ADULT;AGED;COLORECTAL NEOPLASMS;MIDDLE AGED;ITALY;BREAST NEOPLASMS;SARS-COV-2;KIDNEY NEOPLASMS;CHILD;AORTIC VALVE;PROGNOSIS;PROSPECTIVE STUDIES;AGED, 80 AND OVER","164;141;58;50;43;35;30;28;27;26;22;21;20;18;17;16;15;13;13;12","CORONAVIRUS DISEASE 2019;RENAL CELL CARCINOMA;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;HEPATOCELLULAR CARCINOMA;MANAGEMENT OF VALVULAR HEART DISEASE;PREVALENCE AND MANAGEMENT OF KIDNEY STONES;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;APPLICATIONS OF DEEP LEARNING IN MEDICAL IMAGING;DIAGNOSIS AND TREATMENT OF HEART FAILURE;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;SLEEP-DISORDERED BREATHING AND HEALTH OUTCOMES;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ATRIAL FIBRILLATION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND TREATMENT OF MENINGIOMAS","14;8;7;6;6;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3","TREATMENT;PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;CARDIAC IMAGING;STROKE (ENGINE);TRANSCATHETER AORTIC-VALVE REPLACEMENT;CLINICAL ENDPOINT;PROSTHETIC VALVES EVALUATION;GROUP B;METASTATIC COLORECTAL CANCER;REGIMEN;RENAL SCARRING;ATEZOLIZUMAB;CONCOMITANT;CONCORDANCE;CRYOABLATION;GUIDELINE;HEPATOCELLULAR CARCINOMA;INTERQUARTILE RANGE;LENVATINIB","13;10;9;7;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4","COLORECTAL CANCER;COVID- PATIENTS;MULTICENTER STUDY;HEART FAILURE;HEPATOCELLULAR CARCINOMA;COVID- PNEUMONIA;ELDERLY PATIENTS;METASTATIC COLORECTAL;OBSERVATIONAL STUDY;PATIENTS UNDERGOING;POSITION PAPER;AORTIC VALVE;ARTERIAL HYPERTENSION;INTRARENAL SURGERY;ITALIAN SOCIETY;PULMONARY ARTERIAL;PULMONARY EMBOLISM;RETROGRADE INTRARENAL;BREAST CANCER;CELL CARCINOMA;COVID- VACCINATION;MYOCARDIAL INFARCTION;OBSTRUCTIVE SLEEP;RENAL MASSES;RETROSPECTIVE STUDY;SLEEP APNEA;ACUTE HEART;ACUTE MYOCARDITIS;APNEA SYNDROME;ATRIAL FIBRILLATION","8;8;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3","PATIENTS TREATED;COVID- PATIENTS;BREAST CANCER;IN-HOSPITAL MORTALITY;COVID- PNEUMONIA;IN-HOSPITAL DEATH;EJECTION FRACTION;ELDERLY PATIENTS;RISK FACTORS;CORONAVIRUS DISEASE;HEART FAILURE;HR CI;MEDIAN FOLLOW-UP;INCLUSION CRITERIA;MEDIAN AGE;MONTHS CI;NEWLY DIAGNOSED;PATIENTS ADMITTED;RETROSPECTIVE STUDY;SIGNIFICANT DIFFERENCE;CLINICAL CHARACTERISTICS;PATIENTS UNDERGOING;COLORECTAL CANCER;DISEASE COVID-;MONTHS NA;RENAL FUNCTION;SIGNIFICANT DIFFERENCES;ACE EXPRESSION;AORTIC VALVE;CFTR MODULATOR","32;27;20;20;19;17;16;16;16;15;15;15;15;13;13;13;13;13;13;13;12;12;11;11;11;11;11;10;10;10",30,0.1,8.7,7.25,1,2.5,0,26.5,0,1,0,8.75,1,1,6.5,0,0,2.5,4,4.75,3,0,0,19.75,19.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,3.75,1212.43,8.77,21,0.52,121.82,2,2,6,1,13,0,1,15,0,29,11,0,0,0,0,0,0,40,0,0,40,0,0,0,0,0,0,0,0,0,"United States;Italy;Germany;Japan;United Kingdom","9;8;4;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3204 IMMUNOLOGY;3208 MEDICAL PHYSIOLOGY;4203 HEALTH SERVICES AND SYSTEMS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3009 VETERINARY SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4206 PUBLIC HEALTH","40;21;15;5;4;2;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;LUNG;HEMATOLOGY;PATIENT SAFETY;DIGESTIVE DISEASES;LUNG CANCER;PREVENTION;AGING;AUTOIMMUNE DISEASE;ASSISTIVE TECHNOLOGY;BIOENGINEERING;BIOMEDICAL IMAGING;BREAST CANCER;CARDIOVASCULAR;CYSTIC FIBROSIS;LYMPHOMA;NEUROSCIENCES","37;28;20;18;13;8;8;5;5;5;4;4;3;3;3;3;3;3;3;3","CANCER;RESPIRATORY;CARDIOVASCULAR;CONGENITAL;GENERIC HEALTH RELEVANCE;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL;BLOOD;NEUROLOGICAL;STROKE","17;4;3;2;2;2;2;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.4 SURVEILLANCE AND DISTRIBUTION;4.4 POPULATION SCREENING;5.2 CELLULAR AND GENE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;6.4 SURGERY","25;6;4;3;2;1;1;1;1;1;1","LUNG CANCER;MYELOMA;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;LIVER CANCER;BLOOD CANCER;COLON AND RECTAL CANCER;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;STOMACH CANCER","7;5;3;3;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","14;3;2;2;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,"FRONTIERS;ZENODO;KARGER PUBLISHERS","10;8;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;36 CREATIVE ARTS AND WRITING;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3212 OPHTHALMOLOGY AND OPTOMETRY","28;11;8;4;2;2;1;1;1","CLINICAL RESEARCH;RARE DISEASES;PEDIATRIC;AUTOIMMUNE DISEASE;HEMATOLOGY;GENETICS;PATIENT SAFETY;CANCER;CARDIOVASCULAR;HEART DISEASE;AGING;BRAIN DISORDERS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIABETES;LUNG;NEUROSCIENCES;PREVENTION;STROKE","11;9;8;7;7;6;3;2;2;2;1;1;1;1;1;1;1;1","INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;STROKE","7;3;2;2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","4;2;2;1;1","BIOMEDICAL;CLINICAL;HEALTH SERVICES & SYSTEMS","6;4;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","13;2","LUNG CANCER;MYELOMA","1;1","3 GOOD HEALTH AND WELL BEING","1"
"AOU_RIUNITIANCONA",2023,262,18.9312977099237,2.65648854961832,0.229007633587786,0.217557251908397,0.248091603053435,1.47974413646055,1.25,1.29545454545455,1.27450980392157,0.687022900763359,0,119,41,26,19,0.45,0.16,0.1,0.07,3.68,0.83858031578746,5.64891153311718,0.32824427480916,0.946564885496183,0.491,0.432,0.401,0.416,"GIANFRANCO SINAGRA;PAOLO COMPAGNUCCI;MARCO ZUIN;MICHELA CASELLA;ANTONIO DELLO RUSSO;LINA ZUCCATOSTA;MARCO CONFALONIERI;ALAN BILOSLAVO;CLAUDIO BILATO;MARCO MARINI;FEDERICO MEI;ELISA BARATELLA;NICOLÒ DE MANZINI;LUIGI MURENA;BARBARA RUARO;MARTINA BONIFAZI;ROSSANA BERARDI;DANIELE GENERALI;FABRIZIO ZANCONATI;GUIDO GINI","16;9;9;9;9;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6","MARCO ZUIN;GIANFRANCO SINAGRA;CLAUDIO BILATO;LUIGI MURENA;FABIO MONICA;LINA ZUCCATOSTA;GIANLUCA RIGATELLI;MARCO DI EUSANIO;ATTILIO OLIVIERI;ELISA BARATELLA;FEDERICO MEI;MICHELE RICCIO;LAURA CORVATTA;MASSIMO OFFIDANI;MICHELA CASELLA;A SAPAROV;F DE FRANCESCO;MARTINA BONIFAZI;MARIA PAOLA MARTELLI;GIANLUCA RIGATELLI","1.44;1.31;1.3;1.14;0.89;0.88;0.83;0.78;0.78;0.77;0.76;0.75;0.73;0.73;0.68;0.67;0.67;0.65;0.64;0.61","GIANFRANCO SINAGRA;PAOLO COMPAGNUCCI;MARCO ZUIN;MICHELA CASELLA;ANTONIO DELLO RUSSO;LINA ZUCCATOSTA;MARCO CONFALONIERI;ALAN BILOSLAVO;CLAUDIO BILATO;MARCO MARINI;FEDERICO MEI;ELISA BARATELLA;NICOLÒ DE MANZINI;LUIGI MURENA;BARBARA RUARO;MARTINA BONIFAZI;ROSSANA BERARDI;DANIELE GENERALI;FABRIZIO ZANCONATI;GUIDO GINI","16;9;9;9;9;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6","MARCO ZUIN;GIANFRANCO SINAGRA;CLAUDIO BILATO;LUIGI MURENA;FABIO MONICA;LINA ZUCCATOSTA;GIANLUCA RIGATELLI;MARCO DI EUSANIO;ATTILIO OLIVIERI;ELISA BARATELLA;FEDERICO MEI;MICHELE RICCIO;MASSIMO OFFIDANI;MICHELA CASELLA;F DE FRANCESCO;MARTINA BONIFAZI;GIANLUCA RIGATELLI;LORENZO BRUNETTI;DANIELE CASTELLANI;BARBARA RUARO","1.44;1.31;1.3;1.14;0.89;0.88;0.83;0.78;0.78;0.77;0.76;0.75;0.73;0.68;0.67;0.65;0.61;0.58;0.58;0.58","SARA LONARDI;EMILIANO TAMBURINI;ANDREA CASADEI‐GARDINI;CATERINA VIVALDI;MARA PERSANO;MARGHERITA RIMINI;MARIO SCARTOZZI;STEFANO CASCINU;MARIA BEATRICE BILÒ;ANTONIO DELLO RUSSO;ALESSANDRO PASTORINO;ANDREA PRETTA;ANNA DIANA;BRUNO DANIELE;CHIARA PIRRONE;DANIELE LAVACCHI;ELEONORA GUSMAROLI;ENRICO CALIMAN;ERIKA MARTINELLI;FEDERICO NICHETTI","106;97;77;77;77;77;77;77;55;51;50;50;50;50;50;50;50;50;50;50","EMILIANO TAMBURINI;MARIA BEATRICE BILÒ;MATTEO RAMUNDO;GIANLUCA RIGATELLI;ALAN BILOSLAVO;MARTINA API;MARCO CONFALONIERI;MARTINA DUCA;FABIO MONICA;ELISA BARATELLA;PAOLO FRATICELLI;STELLA BERNARDI;BARBARA RUARO;LEONARDO ANTONICELLI;ANDREA BENEDETTO GALOSI;ANTONIO DELLO RUSSO;DEBORAH BONAZZA;FRANCESCA MALLAMACI;FRANCESCO BIANCO;FRANCESCO FEDELE","97;55;50;43;40;32;30;28;23;22;21;20;18;18;17;17;17;17;17;16","GIANFRANCO SINAGRA;GIANLUCA RIGATELLI;ALAN BILOSLAVO;LINA ZUCCATOSTA;MARCO MARINI;ELISA BARATELLA;MARIA VITTORIA MATASSINI;FABIO MONICA;MARCO CONFALONIERI;ATTILIO OLIVIERI;LUIGI MURENA;STEFANO GASPARINI;FEDERICO MEI;ANDREA BENEDETTO GALOSI;DANIELE GENERALI;FABRIZIO ZANCONATI;FRANCESCA GONNELLI;G PONGETTI;GUIDO GINI;ILARIA BATTISTONI","11;9;8;7;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;SOCIOLOGY;CHEMISTRY;PSYCHOLOGY;ECONOMICS;ENGINEERING;MATHEMATICS;MATERIALS SCIENCE;POLITICAL SCIENCE;GEOGRAPHY;BUSINESS;GEOLOGY;PHILOSOPHY;ENVIRONMENTAL SCIENCE;ART","255;57;26;22;16;12;11;10;10;10;8;8;5;4;4;4;2;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;RADIOLOGY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;PEDIATRICS;INTENSIVE CARE MEDICINE;EMERGENCY MEDICINE;ENDOCRINOLOGY;DEMOGRAPHY;PHYSICAL THERAPY;PSYCHIATRY;OPTICS;BIOCHEMISTRY;CANCER RESEARCH;NURSING","203;79;47;46;45;38;33;28;26;25;23;22;18;15;14;14;14;13;12;10;10","CANCER;POPULATION;RETROSPECTIVE COHORT STUDY;HEART FAILURE;DISEASE;COHORT;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;LUNG;MYOCARDIAL INFARCTION;INCIDENCE (GEOMETRY);PROSPECTIVE COHORT STUDY;ATRIAL FIBRILLATION;EPIDEMIOLOGY;BACTERIA;COHORT STUDY;OBSERVATIONAL STUDY;TRANSPLANTATION;LYMPHOMA;MORTALITY RATE;PROPORTIONAL HAZARDS MODEL","48;38;25;24;23;21;21;19;19;18;14;12;12;11;11;9;9;9;9;8;8;8","BREAST CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);EJECTION FRACTION;COLORECTAL CANCER;HAZARD RATIO;IMMUNOTHERAPY;RITUXIMAB;BLADDER CANCER;IDIOPATHIC PULMONARY FIBROSIS;CARDIOGENIC SHOCK;CATHETER ABLATION;CHRONIC LYMPHOCYTIC LEUKEMIA;CLINICAL ENDPOINT;INTERSTITIAL LUNG DISEASE;PROSTATE CANCER;TYPE 2 DIABETES;ADENOCARCINOMA;BEVACIZUMAB;CARDIOMYOPATHY;GENOTYPE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;ISCHEMIC STROKE;LUNG FUNCTION;PROSTATE;SPINAL CORD INJURY;TOLERABILITY","16;11;10;9;8;7;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","CORONAVIRUS DISEASE 2019 (COVID-19);VENETOCLAX;DIFFUSING CAPACITY;NIVOLUMAB;COLONOSCOPY;IGHV@;KARYOTYPE;MASTECTOMY;NEOADJUVANT THERAPY;NINTEDANIB;POLY ADP RIBOSE POLYMERASE;BREAST RECONSTRUCTION;CEFTAZIDIME;DISEASE MANAGEMENT;DNA METHYLATION;IVACAFTOR;LYMPHOVASCULAR INVASION;MAMMOGRAPHY;MEROPENEM;METASTATIC BREAST CANCER;OBINUTUZUMAB;PEMBROLIZUMAB;PROSTATECTOMY;USUAL INTERSTITIAL PNEUMONIA;VINCRISTINE","11;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;ITALY;FEMALE;RETROSPECTIVE STUDIES;MALE;BREAST NEOPLASMS;PROSPECTIVE STUDIES;AGED;POSTOPERATIVE COMPLICATIONS;ANTI-BACTERIAL AGENTS;ADULT;ASTHMA;COVID-19;TREATMENT OUTCOME;HEART FAILURE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LUNG DISEASES, INTERSTITIAL;CHILD;LUNG","138;120;35;33;32;23;19;19;17;17;16;15;14;14;13;12;11;11;9;9","IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF HEART FAILURE;ACUTE MYELOID LEUKEMIA;ATRIAL FIBRILLATION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;MOLECULAR MECHANISMS OF AMYLOIDOSIS;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;WOUND HEALING AND REGENERATION;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CORONAVIRUS DISEASE 2019;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEALTH EFFECTS OF AIR POLLUTION;IMPACT OF CLIMATE CHANGE ON HUMAN HEALTH;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;LYMPHOID NEOPLASMS;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS","7;6;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","TREATMENT;PANDEMIC;CLINICAL ENDPOINT;STROKE (ENGINE);INFARCTION TREATMENT;VENETOCLAX;BLADDER CANCER;CARDIAC IMAGING;DIABETES;DIAGNOSIS;ENDOSCOPIC ULTRASOUND;IDIOPATHIC PULMONARY FIBROSIS;INTERNATIONAL MYELOMA WORKING GROUP;METASTATIC COLORECTAL CANCER;NEOADJUVANT THERAPY;REFRACTORY (PLANETARY SCIENCE);TOLERABILITY;ACUTE MYELOID LEUKEMIA;AML;ATEZOLIZUMAB","13;9;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3","HEART FAILURE;RETROSPECTIVE STUDY;BREAST CANCER;COHORT STUDY;LUNG DISEASE;PATIENTS TREATED;PULMONARY FIBROSIS;CELL LUNG;COLORECTAL CANCER;CORD INJURY;CYSTIC FIBROSIS;FONDAZIONE ITALIANA;INTERSTITIAL LUNG;ITALIANA LINFOMI;LEFT VENTRICULAR;LUNG CANCER;METASTATIC COLORECTAL;MULTICENTER STUDY;MULTIPLE MYELOMA;NON-SMALL CELL;RISK FACTORS;SINGLE CENTRE;SPINAL CORD;ACUTE MYELOID;ADVANCED NON-SMALL;BLADDER CANCER;BREAST CENTRES;CANCER PATIENTS;CARDIOGENIC SHOCK;CATHETER ABLATION","8;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3","HEART FAILURE;HR CI;RISK FACTORS;STATISTICALLY SIGNIFICANT;EJECTION FRACTION;MEDIAN AGE;PROXIMAL INTERPHALANGEAL;PATIENTS TREATED;INHOSPITAL MORTALITY;CONSECUTIVE PATIENTS;INTERPHALANGEAL JOINT;MEDIAN FOLLOW-UP;PATIENTS RECEIVED;PATIENTS UNDERGOING;RETROSPECTIVE STUDY;ACTIVE SURVEILLANCE;BREAST CANCER;MULTIVARIATE ANALYSIS;SURVIVAL OS;CYSTIC FIBROSIS;DONOR SITE;GLOBAL HEART;PREVIOUS INFECTIONS;PRIMARY OUTCOME;SIGNIFICANT DIFFERENCES;SIGNIFICANTLY LOWER;TYPE DIABETES;CARDIAC EVENTS;COHORT STUDY;COVID- PANDEMIC","22;22;19;19;18;18;18;17;16;14;14;14;14;14;14;13;13;12;12;11;11;11;11;11;11;11;11;10;10;10",12,0.05,7.34,3,0,1,0,1,0,1,0,4.5,0,0,2.25,0,0,3,16,2,6.5,0,0,9.5,9.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,3.25,799.2,3.78,4,0.25,98.81,0,0,3,1,6,0,1,5,0,13,3,0,0,0,0,0,0,16,0,0,16,0,0,0,0,0,0,0,0,0,"United States;Denmark;Germany","7;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY;3213 PAEDIATRICS;42 HEALTH SCIENCES","15;8;3;2;2;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;AUTOIMMUNE DISEASE;CARDIOVASCULAR;HEART DISEASE;RARE DISEASES;TRANSPLANTATION;DIGESTIVE DISEASES;HEMATOLOGY;NEURODEGENERATIVE;NEUROSCIENCES;PEDIATRIC;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;AGING;ARTHRITIS;BIOMEDICAL IMAGING","16;13;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1","CANCER;CARDIOVASCULAR;SKIN;METABOLIC AND ENDOCRINE;EYE;INFLAMMATORY AND IMMUNE SYSTEM;REPRODUCTIVE HEALTH AND CHILDBIRTH","5;4;3;2;1;1;1","6.1 PHARMACEUTICALS;3.3 NUTRITION AND CHEMOPREVENTION;5.3 MEDICAL DEVICES;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES","12;1;1;1;1","MYELOMA;COLON AND RECTAL CANCER;LIVER CANCER;LUNG CANCER","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","5;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"ZENODO;PUBLIC LIBRARY OF SCIENCE;FRONTIERS;KARGER PUBLISHERS","6;4;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;44 HUMAN SOCIETY;46 INFORMATION AND COMPUTING SCIENCES;3103 ECOLOGY;3105 GENETICS;4203 HEALTH SERVICES AND SYSTEMS;4601 APPLIED COMPUTING","15;8;4;2;2;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;AUTOIMMUNE DISEASE;CANCER;DIABETES;DIGESTIVE DISEASES;PANCREATIC CANCER;RARE DISEASES;BRAIN DISORDERS;COMPARATIVE EFFECTIVENESS RESEARCH;HEART DISEASE;IMMUNIZATION;PREVENTION;VACCINE RELATED","6;4;3;2;2;2;2;2;2;1;1;1;1;1;1","CARDIOVASCULAR;METABOLIC AND ENDOCRINE;NEUROLOGICAL;INFECTION","3;2;2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.4 VACCINES;6.4 SURGERY","2;1;1","CLINICAL;HEALTH SERVICES & SYSTEMS","6;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","8;1;1","LEUKEMIA / LEUKAEMIA;PANCREATIC CANCER;HODGKIN'S DISEASE;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","2;2;1;1;1","3 GOOD HEALTH AND WELL BEING","1"
"AOU_RIUNITIANCONA",2024,202,22.5742574257426,2.48514851485149,0.178217821782178,0.217821782178218,0.227722772277228,1.39944134078212,0.972972972972973,1.18918918918919,1.04545454545455,0.594059405940594,0,83,46,12,13,0.41,0.23,0.06,0.06,0.96,1.00490895424931,4.75765178123432,0.430693069306931,0.96039603960396,0.411,0.357,0.39,0.368,"SARA LONARDI;EMILIANO TAMBURINI;BARBARA RUARO;GIACOMO EMMI;GIANFRANCO SINAGRA;PAOLO COMPAGNUCCI;LORENZO ANTONUZZO;FABIO MONICA;MICHELA CASELLA;ANTONIO DELLO RUSSO;MICHAEL HUGHES;ALESSIO GASPERETTI;MARCO CONFALONIERI;GIANLUCA MASI;DANIELE CASTELLANI;STEFANO TAMBERI;NICOLÒ SCHICCHI;PAOLO MANGANOTTI;LUIGI DI BIASE;GIUSEPPE LOPALCO","10;9;9;9;8;8;7;7;7;7;6;6;6;6;6;5;5;5;5;5","MARCO ZUIN;FABIO MONICA;DEBORAH BONAZZA;GIANLUCA RIGATELLI;CLAUDIO BILATO;BARBARA RUARO;SANDRO DONATO;GIANFRANCO SINAGRA;PAOLO MANGANOTTI;GIANLUCA RIGATELLI;NICOLÒ SCHICCHI;MARTINA BONIFAZI;FRANCESCA GONNELLI;MARCO CONFALONIERI;GIACOMO EMMI;MICHAEL HUGHES;PAOLA CONFALONIERI;FRANCESCO SALTON;ANTONIO GIGANTE;C. SIMETH","1.08;0.94;0.87;0.84;0.82;0.71;0.68;0.65;0.58;0.57;0.48;0.46;0.46;0.45;0.45;0.42;0.42;0.42;0.41;0.39","EMILIANO TAMBURINI;BARBARA RUARO;GIACOMO EMMI;GIANFRANCO SINAGRA;PAOLO COMPAGNUCCI;FABIO MONICA;MICHELA CASELLA;ANTONIO DELLO RUSSO;MARCO CONFALONIERI;DANIELE CASTELLANI;NICOLÒ SCHICCHI;PAOLO MANGANOTTI;LUIGI DI BIASE;DEBORAH BONAZZA;VALENTINO CHERUBINI;PAOLA CONFALONIERI;FRANCESCO SALTON;FRANCESCO BIANCO;ANETA ALEKSOVA;I. TOMA","9;9;9;8;8;7;7;7;6;6;5;5;5;5;5;5;5;4;4;4","FABIO MONICA;DEBORAH BONAZZA;GIANLUCA RIGATELLI;BARBARA RUARO;GIANFRANCO SINAGRA;PAOLO MANGANOTTI;GIANLUCA RIGATELLI;NICOLÒ SCHICCHI;MARTINA BONIFAZI;MARCO CONFALONIERI;GIACOMO EMMI;PAOLA CONFALONIERI;FRANCESCO SALTON;C. SIMETH;STELLA BERNARDI;SONIA MORÈ;VALENTINO CHERUBINI;ALEX BUOITE STELLA;FABRIZIO ZANCONATI;ANDREA CLARICI","0.94;0.87;0.84;0.71;0.65;0.58;0.57;0.48;0.46;0.45;0.45;0.42;0.42;0.39;0.38;0.36;0.36;0.35;0.35;0.34","ANTONIO DELLO RUSSO;MICHELA CASELLA;PAOLO COMPAGNUCCI;LUIGI DI BIASE;AMIN AL‐AHMAD;ANDREA NATALE;CAROLA GIANNI;DOMENICO G. DELLA ROCCA;GIAN–BATTISTA CHIERCHIA;JOHN BURKHARDT;PREM GEETA TORLAPATI;SANGHAMITRA MOHANTY;VINCENZO MIRCO LA FAZIA;ALEXANDRE PINEL;ALFONSO J. CRUZ‐JENTOFT;BRUNO PEREIRA;CHRISTELLE GUILLET;DORIS EGLSEER;ELIZABETH BENZ;EVA TOPINKOVÁ","36;36;33;30;26;26;26;26;26;26;26;26;26;22;22;22;22;22;22;22","ANTONIO DELLO RUSSO;PAOLO COMPAGNUCCI;ROCCO BARAZZONI;BARBARA RUARO;MARCO CONFALONIERI;MICHELA CASELLA;FRANCESCO SALTON;PAOLA CONFALONIERI;LUCREZIA MONDINI;NICOLÒ RECCARDINI;ANDREA SALOTTI;BEATRICE DA RE;SALVATORE FABIO NICOLOSI;STEFANO KETTE;EMILIANO TAMBURINI;DANIELE CASTELLANI;DEBORAH BONAZZA;F. MARTELLANI;FABRIZIO ZANCONATI;MICHELE BERTOLOTTO","32;31;22;15;15;15;14;14;13;13;11;11;11;11;10;9;9;7;7;6","GIACOMO EMMI;EMILIANO TAMBURINI;BARBARA RUARO;PAOLO COMPAGNUCCI;DANIELE CASTELLANI;MICHELA CASELLA;ANTONIO DELLO RUSSO;DEBORAH BONAZZA;NICOLÒ SCHICCHI;ALAN BILOSLAVO;FRANCESCO SALTON;VALENTINO CHERUBINI;MARCO CONFALONIERI;ANTONELLA POCOGNOLI;ELISA NICOLINI;FRANCESCO BIANCO;GUIDO GINI;I. TOMA;MICHELE BERTOLOTTO;PAOLA CONFALONIERI","9;9;7;7;6;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;CHEMISTRY;ENGINEERING;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY;MATHEMATICS;PHILOSOPHY;MATERIALS SCIENCE;ART;ECONOMICS;GEOGRAPHY;HISTORY;GEOLOGY","197;41;19;17;12;9;8;8;8;5;5;4;2;2;2;2;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;INTENSIVE CARE MEDICINE;ONCOLOGY;PATHOLOGY;RADIOLOGY;PEDIATRICS;GASTROENTEROLOGY;IMMUNOLOGY;GENETICS;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;PHYSICAL THERAPY;PALEONTOLOGY;PSYCHIATRY;GERONTOLOGY;BIOCHEMISTRY;CANCER RESEARCH;FAMILY MEDICINE;GENERAL SURGERY","151;52;38;28;28;28;22;19;18;18;17;16;15;12;11;11;10;9;9;9;9","CANCER;DISEASE;COHORT;POPULATION;DIABETES MELLITUS;CHEMOTHERAPY;RETROSPECTIVE COHORT STUDY;HEART FAILURE;RANDOMIZED CONTROLLED TRIAL;CLINICAL TRIAL;GENE;LUNG;PROSPECTIVE COHORT STUDY;ADVERSE EFFECT;OBSERVATIONAL STUDY;IMMUNE SYSTEM;MYOCARDIAL INFARCTION;ANTIBIOTICS;ANTIBODY;BODY MASS INDEX;CONFIDENCE INTERVAL;DISCONTINUATION;HISTOLOGY;OBESITY;PREGNANCY","36;35;16;15;14;13;13;12;12;9;9;9;9;8;8;7;7;6;6;6;6;6;6;6;6","COLORECTAL CANCER;IMMUNOTHERAPY;BREAST CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);CARDIOMYOPATHY;IDIOPATHIC PULMONARY FIBROSIS;TYPE 1 DIABETES;BEVACIZUMAB;CLINICAL ENDPOINT;HAZARD RATIO;MULTICENTER STUDY;2019-20 CORONAVIRUS OUTBREAK;CATHETER ABLATION;GEMCITABINE;INTERSTITIAL LUNG DISEASE;NEURORADIOLOGY;PARKINSON'S DISEASE;PHENOTYPE;SYSTEMIC LUPUS ERYTHEMATOSUS;TOLERABILITY;VITAMIN D DEFICIENCY","11;10;8;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);NIVOLUMAB;IMMUNE CHECKPOINT;IRINOTECAN;BILIARY TRACT CANCER;BREAST RECONSTRUCTION;BRONCHOPULMONARY DYSPLASIA;COLONOSCOPY;FRACTIONAL FLOW RESERVE;HYPOVITAMINOSIS;INSULIN DELIVERY;MAMMOGRAPHY;MASTECTOMY;NINTEDANIB;PEMBROLIZUMAB;USTEKINUMAB;VANCOMYCIN;VEDOLIZUMAB;ABDOMINAL OBESITY;ABLATION OF ATRIAL FIBRILLATION;AL AMYLOIDOSIS;APREMILAST;ARTIFICIAL PANCREAS;BIOMARKER DISCOVERY;BRAIN-DERIVED NEUROTROPHIC FACTOR;BREAST SURGERY;CARDIAC SKELETON;CD40;CETUXIMAB;CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS;CLASSIFICATION OF OBESITY;COGNITIVE DECLINE;CONTINUOUS GLUCOSE MONITORING;DASATINIB;DEEP BRAIN STIMULATION;DEUBIQUITINATING ENZYME;DIFFUSING CAPACITY;DISEASE MANAGEMENT;DISSOLUTION TESTING;DNA METHYLATION;DNA MISMATCH REPAIR;ENDOMYSIUM;ENTEROCOCCUS FAECALIS;GASTRIC BYPASS;GESTATIONAL DIABETES;GLUTATHIONE DISULFIDE;GLUTATHIONE SYNTHETASE;HEMATOPOIETIC CELL;HYPOTHALAMIC HAMARTOMA;IBRUTINIB;IMPELLA;INFLAMMATORY BOWEL DISEASES;INTERLEUKIN 23;INTRAVENOUS IRON;INTRAVENTRICULAR HEMORRHAGE;IPILIMUMAB;IRON STATUS;IRON SUPPLEMENTATION;KRAS;LENVATINIB;MALE BREAST CANCER;MALE INFERTILITY;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MOTOR SYMPTOMS;MULTILOCUS SEQUENCE TYPING;NASAL DORSUM;NILOTINIB;OXALIPLATIN;PERIVENTRICULAR LEUKOMALACIA;PIRFENIDONE;PODOCYTE;PRENATAL DIAGNOSIS;PROSTATECTOMY;PULSE WAVE ANALYSIS;RECEPTOR ANTAGONIST;REPRESSOR;RETINOPATHY OF PREMATURITY;SEED DORMANCY;SEROTONERGIC;STAPHYLOCOCCUS EPIDERMIDIS;SURFACTANT THERAPY;TELEREHABILITATION;TRANSCRIPTOME;UNDERWEIGHT;UROTHELIAL CARCINOMA;VACCINIA;VARICOCELE;VATS LOBECTOMY;WATCHFUL WAITING","6;5;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ITALY;AGED, 80 AND OVER;CHILD;ADOLESCENT;PROGNOSIS;YOUNG ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;FOLLOW-UP STUDIES;POSTOPERATIVE COMPLICATIONS;PROSPECTIVE STUDIES;QUALITY OF LIFE","124;77;51;47;36;33;30;22;16;14;13;9;8;8;7;6;6;6;6;6","IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;ACUTE MYELOID LEUKEMIA;MANAGEMENT OF VALVULAR HEART DISEASE;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;PREVALENCE AND MANAGEMENT OF KIDNEY STONES;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES;CHOLANGIOCARCINOMA;DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;EPIDEMIOLOGY AND MANAGEMENT OF OCULAR INFLAMMATORY DISEASES;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;X-RAY IMAGING TECHNIQUES AND APPLICATIONS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASES","6;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2","TREATMENT;DIABETES;CARDIAC IMAGING;DIAGNOSIS;HISTOLOGY;CONTINUOUS GLUCOSE MONITORING;DISCONTINUATION;ACUTE MYELOID LEUKEMIA;BIOMARKERS FOR IMMUNOTHERAPY;CARDIOVASCULAR RISK ASSESSMENT;IDIOPATHIC PULMONARY FIBROSIS;METASTATIC COLORECTAL CANCER;REFRACTORY (PLANETARY SCIENCE);TRANSCATHETER AORTIC-VALVE REPLACEMENT;2019-20 CORONAVIRUS OUTBREAK;ANGIOLOGY;AORTIC ROOT REPLACEMENT;ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;ATEZOLIZUMAB;BILIARY TRACT CANCER","10;8;6;6;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3","OBSERVATIONAL STUDY;AORTIC VALVE;COHORT STUDY;COLORECTAL CANCER;IDIOPATHIC PULMONARY;MAGNETIC RESONANCE;MULTICENTER STUDY;MYELOID LEUKEMIA;TYPE DIABETES;ACUTE MYELOID;BREAST CANCER;DIABETES MELLITUS;HEART FAILURE;METASTATIC COLORECTAL;MULTICENTRE STUDY;PULMONARY FIBROSIS;SYSTEMIC SCLEROSIS;AIDA NETWORK;ARTERY DISEASE;ATRIAL FIBRILLATION;BEHÇETS DISEASE;BILIARY TRACT;CLINICAL OUTCOMES;INTERNATIONAL AIDA;INTRARENAL SURGERY;ITALIAN STUDY;PULSED-FIELD ABLATION;RETROGRADE INTRARENAL;TRACT CANCER;TREATMENT PREFERENCES","7;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","HR CI;SEVERE CAD;RISK FACTORS;SIGNIFICANT DIFFERENCES;CLINICAL REMISSION;ADVERSE EVENTS;CELIAC DISEASE;MMLMATH CT;MMLMATH XMLNSMMLHTTPWWWWORGMATHMATHML;MMLMIΜMMLMI MMLMATH;MU MMLMATH;PATIENTS TREATED;STRONGLY AGREED;XMLNSMMLHTTPWWWWORGMATHMATHML MMLMIΜMMLMI;OBSERVATIONAL STUDY;SAFETY PROFILE;ALL-CAUSE MORTALITY;ARTERY DISEASE;BED REST;CLINICAL PRACTICE;CLINICAL TRIALS;CONSECUTIVE PATIENTS;FEMALE PATIENTS;HF SCORE;IMMUNOSUPPRESSIVE THERAPY;MALE INFERTILITY;MEDIAN AGE;PHC MU;PULSE WAVE;SEVERE INFECTIONS","18;15;14;11;10;9;8;8;8;8;8;8;8;8;7;7;6;6;6;6;6;6;6;6;6;6;6;6;6;6",1,0,22.45,32,0,0,0,0,0,0,0,44,0,0,32,0,0,4,4,22,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,2,98,0.61,1,0.5,5,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","2;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BIOENGINEERING;BIOMEDICAL IMAGING;CANCER;INFECTIOUS DISEASES;LUNG;LUNG CANCER;PREVENTION","2;2;1;1;1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS","1","LUNG CANCER","1","4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"TAYLOR & FRANCIS GROUP","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","2;1","CLINICAL RESEARCH;DIGESTIVE DISEASES;INFLAMMATORY BOWEL DISEASE;NUTRITION;PATIENT SAFETY","1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS","1","CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","1",NA,NA,NA,NA
